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PROLOOG
Isn’t it ironic…
8 december 2016. Het moet ergens begin van de avond geweest zijn. Ik ontwaakte na de 
heroperatie, maar de verlichting van het plafond zag er anders uit dan twee dagen eerder 
op de recovery. ‘Je ligt op de Intensive Care’ hoorde ik zeggen. De IC! Wat was er gebeurd? 
Enerzijds was ik geschrokken, maar anderzijds was ik blij op een afdeling te liggen waar er écht 
op je wordt gelet (mijn vertrouwen in de reguliere afdeling had een aardige deuk opgelopen).
Hoe wakkerder ik werd, hoe meer ik me bewust werd van de situatie. Ik kon amper bewegen 
want mijn armen waren gefixeerd, en ik kon niet praten want ik had een tube in mijn keel. Ik 
kreeg te horen dat de tube diende om mijn bedreigde ademweg veilig te stellen de komende 
dagen. ‘Logische keuze’, dacht ik. Gelukkig kon ik al gauw duidelijk maken dat ik die tube écht 
niet eigenhandig zou verwijderen, en kregen mijn handen weer hun bewegingsvrijheid terug. 
Ik kreeg een letterbord, waarmee ik kon communiceren. De eerste vraag die ik stelde bracht 
mijn vrouw en de verpleging meteen in verlegenheid. ‘T-R-I-G-G-E-R I-K Z-E-L-F?’ Een tikje 
beroepsgedeformeerd, maar kennelijk zat de ABC-systematiek er zó ingebakken dat ik 
deze vraag reflexmatig stelde. En het geeft aan dat als je op de IC aan de beademing 
ligt, je de regie over je eigen lichaam even kwijt bent. En die wilde ik zo snel mogelijk terug. 
Weten of je zelfstandig ademt, is daarvan de eerste stap. De daarop volgende vragen 
hadden allemaal betrekking op mijn eigen vitale functies en medicatie.
In hoofdstuk 6 laten we zien dat endotracheaal uitzuigen de meest voorkomende pijnlijke/
stressvolle handeling op de kinder-IC is. Of dit pijnlijk was of niet? Mijn antwoord is ‘nee’. 
Ik heb het een aantal keer per dag aan den lijve ondervonden, maar ik vond er geen pijn 
aan te pas komen. Het was wel des te stressvoller… 
10 december 2016. Na anderhalve dag genoten te hebben van een snufje propofol, een 
heerlijk narcosemiddel, vond de verpleging me kalm genoeg om het zonder te proberen. 
Hoewel ik aan de buitenkant kalm bleef, vond mijn lichaam de situatie toch niet zo kalm 
wat zich uitte in torenhoge bloeddrukken (tot 210 systolisch). Daarop besloot de intensivist 
me een ander kalmerend en bloeddrukverlagend middel te geven: clonidine. Hoera! Clo-
nidine! Daar doe ik onderzoek naar! Isn’t it ironic… Enerzijds voelde ik me bevoorrecht om 
als onderzoeker zelf aan de medicatie te raken waar ik mijn baan en dus uiteindelijk dit 
proefschrift aan te danken had, anderzijds voelde het als ironie ten top. 
Desalniettemin, deze 5 dagen hebben me minstens zoveel geleerd als 3,5 jaar promotie en 
kan ik daar met minstens zoveel dankbaarheid op terugkijken als op het promotietraject! 
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GENERAL INTRODUCTION
In The Netherlands, around 5000 children with the age of 1 day to 18 years old, are admitted 
to a PICU annually. Half of these patients are being mechanically ventilated at least once 
during their PICU stay.1 During mechanical ventilation, it is essential to provide patients with 
adequate analgesia and sedation in order to provide maximal comfort by reducing anxiety, 
pain and distress. Also, adequate sedation provides more optimal ventilator conditions by 
improving patient-ventilator synchronicity and avoidance of unwanted adverse events such 
as autoextubations.2 Pharmacologic treatment is key to provide adequate analgesia and 
sedation, however, this is currently far from ideal. The available agents have an identifiable 
side effect profile and children still suffer from iatrogenic withdrawal syndrome (IWS) or pedi-
atric delirium (PD)3 with a prevalence of 17-57% for IWS4 and 5-47% for PD.5-9 Apart from 
pharmacological interventions, non-pharmacologic measures such as noise reduction, parental 
presence, pacifiers and oral sucrose solution administration support sedation and analgesia.
Unlicensed drug use in children
The major issue in the pharmacologic treatment of children in general is the lack of available 
evidence. Even more so for the critically ill child, as 80-90% of patients in a PICU or NICU receive 
off-label drug therapy.10 To overcome this problem, the European Medicines Agency (EMA) and 
the US Food and Drug Administration (FDA) have prioritized pediatric pharmacological research 
efforts with financial and regulatory measures, such as the Best Pharmaceuticals for Children’s 
Act in 2004 by the FDA11 and the introduction of the Pediatric Regulation in 2007 by the EMA 
including financial support from the Seventh Framework Programme.12 In the pediatric ICU, 
off-label drug use has the highest rate along with the NICU.10,13 The PICU has its own challenges 
for researchers: it is a very heterogeneous group of patients with regard to age, co-morbidities 
and diseases, and patient numbers for individual diagnoses are low.14
Pain management
It has long been believed that neonates do not feel pain. Even major cardiac surgery 
procedures were performed in neonates without analgesia. Since 1987, when Anand and 
colleagues found a huge stress response in these non-anesthesized patients,15 a paradigm 
shift took place and opioids obtained a key position in neonatal pain management. How-
ever, two new questions arose: 1. do these agents cause harm to the developing brain with 
adverse outcomes in the long term?16 and 2. what is the optimal dose of these opioids in 
neonates? We do unfortunately not have clear answers yet, but nevertheless some import-
ant steps have been made towards optimal dosing. Population pharmacokinetics allow us 
to predict the optimal dose for an individual patient based on a Bayesian approach to 
population-wide obtained data. This allows for sparse sampling and provides insight in the 
maturation process of drug metabolism during early life.
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Also, some alternatives for opioids have been proposed. IV paracetamol proved an effec-
tive alternative to IV morphine for very young children after major surgery.17 This led to 
the development and implementation of a new postoperative pain protocol in our PICU. 
However, this transition from opioids to IV paracetamol might herald a new paradigm shift 
and we wondered whether this implementation would be successful and lead to the same 
outcome as in the RCT. 
Sedation management
In the PICU, benzodiazepines are the first-choice agents for sedation18,19 with midazolam 
used most frequently in The Netherlands. Although midazolam has certain advantages, like 
anxiolysis, anterograde amnesia and muscle relaxation,20 it is far from ideal. Disadvantages 
are that it may result in tolerance, iatrogenic withdrawal syndrome, and an increased risk 
of delirium.21 Therefore, in adults, a shift has taken place towards analgosedation with an 
opioid as first-choice agent.22 Non-benzodiazepine agents like propofol or α2-receptor 
agonists are preferred above benzodiazepines in adults. However, there is no evidence 
for the use of other agents in children although they are being used off-label increasingly. 
Over the last years, increased use of dexmedetomidine is advocated as the new magic 
bullet but convincing evidence of its superiority is still lacking. One of the aims of this thesis 
is therefore to investigate whether other agents than benzodiazepines are suitable for the 
sedation of patients in the PICU.
The big interplay
A major challenge in pediatric drug research is the lack of gold standard end points.23 This 
holds especially true for pain and sedation research, because young children are unable 
to speak about their pain or discomfort, at least in a way that physicians and caregivers 
understand it. Therefore, we rely on behavioral indicators to estimate their level of pain 
and discomfort.24 However, these indicators have their limitations as patients can be too ill 
to show behavior indicating pain.25 Moreover, delirium and withdrawal symptoms resem-
ble signs of pain, although these phenomena require a different treatment strategy.26 It 
is therefore necessary to find discriminating items between pain, discomfort, withdrawal 
and delirium and to identify other factors contributing to ‘pain-like’ behavior. For instance, 
drugs with anticholinergic activity may precipitate the development of an anticholinergic 
toxidrome, a combination of manifestations classically taught as ‘dry as a bone, blind as a 
bat, red as a beet, hot as a hare and mad as a hatter’. Restlessness, tachycardia, ataxia, 
picking movements and agitation are other symptoms of the toxidrome, which are similar 
to delirium and withdrawal symptoms. We investigated the anticholinergic burden, i.e. a 
sum of anticholinergic acting drugs, in patients diagnosed with pediatric delirium and/or 
iatrogenic withdrawal syndrome. 
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AIMS AND OUTLINE
In this thesis, we aim for providing answers on three key research questions:
• What is the anticholinergic burden in patients diagnosed with pediatric delirium, iat-
rogenic withdrawal syndrome or both?
• Is there a role for non-benzodiazepine agents for the sedation of patients in the PICU?
• Does the implementation of IV paracetamol in daily clinical practice as primary anal-
gesic for infants achieve comparable results as in a RCT? 
In part I of this thesis we describe the current pharmacological treatment for pain and 
sedation management in the pediatric and neonatal intensive care unit, as well as cur-
rent sedation research. Chapter 2 describes the pharmacokinetic and pharmacodynamic 
properties of the most commonly used sedatives on the PICU, with the aim of identifying 
pediatric-specific knowledge gaps. Chapter 3 describes the evidence for the current treat-
ment of pain in neonates and infants, along with challenging aspects of pain research in 
this population.
In part II we look further into these challenging aspects. Chapter 4 describes the clinical 
study protocol of a multi-center, double-blind randomized controlled trial of clonidine versus 
midazolam for the sedation of mechanically ventilated children. In this trial, we faced sev-
eral new challenges which we addressed. Chapter 5 describes the so-called anticholinergic 
burden in patients with delirium and withdrawal symptoms.
Part III takes the journey further from trial to clinical practice. In chapter 6, we counted 
procedural pain and distress in the PICU in order to explore the extent of this problem. 
Chapter 7 illustrates the successful implementation of a new pain management protocol for 
postoperative infants. 
In chapter 8, our research findings are discussed in the broader perspective along with 
recommendations for future research. Chapter 9 summarizes the most important findings 
of this thesis. 
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Pharmacological sedation management 
in the paediatric intensive care unit
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ABSTRACT
Objective: This review addresses sedation management on paediatric intensive care units 
and possible gaps in the knowledge of optimal sedation strategies. We present an overview 
of the commonly used sedatives and their pharmacokinetic and pharmacodynamic consider-
ations in children, as well as the ongoing studies in this field. Also, sedation guidelines and 
current sedation strategies and assessment methods are addressed.
Key findings: This review shows that evidence and pharmacokinetic data are scarce, but 
fortunately, there is an active research scene with promising new PK and PD data of seda-
tives in children using new study designs with application of advanced laboratory methods 
and modelling. The lack of evidence is increasingly being recognized by authorities and 
legislative offices such as the US Food and Drug Administration (FDA) and European Med-
icines Agency (EMA).
Conclusion: The population in question is very heterogeneous and this overview can aid 
clinicians and researchers in moving from practice-based sedation management towards 
more evidence- or model-based practice. Still, paediatric sedation management can be 
improved in other ways than pharmacology only, so future research should aim on sedation 
assessment and implementation strategies of protocolized sedation as well.
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INTRODUCTION
Sedation management is a crucial element of paediatric critical care medicine, aiming at 
reducing children’s anxiety, distress and oxygen demand. Adequate sedation improves 
patient–ventilator synchrony and prevents autoextubation in ventilated children.1 Moreover, 
it allows tolerance to diagnostic or therapeutic procedures. However, sedation induced by 
pharmacological agents often leads to adverse events including prolonged mechanical 
ventilation, tolerance, withdrawal syndrome and even paediatric delirium. Dosing regimens 
are not always based on PK data or paediatric pharmacological research findings, and 
even today, more than 80% of drugs used in the paediatric intensive care unit (PICU) are 
off-label or unlicensed.2 Still, the European Medicines Agency (EMA) and the US Food and 
Drug Administration (FDA) have prioritized paediatric pharmacological research efforts to 
achieve more evidence-based pharmacotherapy.3
To date, there is no consensus on sedation management for children.4,5 This review provides 
an overview of evidence for the commonly used drugs in paediatric sedation management 
and inventories ongoing and future research. Table 1 presents an overview of prospective 
observational studies and randomized controlled trials performed so far.
Sedation Assessment
A ‘gold standard’ tool to assess the sedation state of children on intensive care units has 
not yet been identified.6 Assessment is difficult because signs such as motor restlessness, 
agitation and increased muscle tone that may point at undersedation are also signs of 
pain. It is generally accepted that preverbal children are not able to express their pain or 
discomfort in a way caregivers understand or interpret as such. Furthermore, children may 
suffer from separation anxiety and fear for strangers and thus show behaviour indicating 
undersedation.
Roughly, two types of sedation assessment scales are available6,7: those that score a number 
of behavioural indicators of distress and those that consist of one item describing the level 
of consciousness. Examples of the latter type validated for children are the University of 
Michigan Sedation Scale (UMSS)8 and the State Behavioral Scale (SBS).9 The UMSS assesses 
level of consciousness from 0 (awake and alert) to 4 (unarousable). The SBS has six levels 
from -3 (unresponsive) to +2 (agitated). Another one-item scale, the Ramsay scale, has been 
used mainly for adults and is not applicable to preverbal children as it includes an item 
‘responds to commands only’.10,11 To date, the Richmond Agitation–Sedation Scale (RASS)12 
is more often used in adults, but it has not been validated for children as this includes the 
item ‘overtly combative or violent; immediate danger to staff’.
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Table 1. An overview of performed pharmacological studies in paediatric intensive care sedation.
Study Sample size
and age
Design Outcome
Booker et al.149 N=50, 
6 months-9 years
Observational cohort study 
(midazolam bolus 200 mcg/
kg followed by CI 120-360 
mcg/kg/h)
Adequate sedation, no major 
adverse events
Shelly et al.150 N=50, 
0-18 years
Prospective observational 
cohort study of midazolam CI
Adequate sedation, delayed 
awakening especially in renal 
failure patients
Macnab et al. 151 N=23, 
6 months-6 years
Prospective observational 
cohort study of a midazolam 
loading dose after 
cardiothoracic surgery
Termination of study after 
severe hypotension, other 
participants showed no 
hemodynamic changes
De Wildt et al.62 N=21, 
0-17 years
Observational cohort PK-
PD study with protocolized 
sedation strategy: start dose 
midazolam 0.1 mg/kg bolus, 
followed by 100 mcg/kg/h
No clear PK-PD relationship, 
adequate sedation reached 
with protocol
No report on toxicity
Rigby-Jones et al.152 N=26, 
0-10 years
Observational cohort PK 
study, remifentanil and 
midazolam 
Adequate sedation, 1 patient 
showed hypotension
Ambrose et al.153 N=30, 
0-10 years
Three-step: IV clonidine: 
low-dose vs. high-dose 
(variable dose together with 
midazolam), 3rd group fixed 
dose
No adverse effects on 
hemodynamics, sufficient 
sedation in combination with 
midazolam
Arenas-Lopez et al.83 N=24, 
0-5 years
Prospective cohort study, 
oral clonidine as additive to 
morphine/lorazepam
Opioid- and benzodiazepine 
sparing, safe and effective
Wolf et al.81 N=129, 
0-15 years
Double-blind, randomized 
controlled trial of IV clonidine 
vs. midazolam
No difference in effectivity, 
underpowered due to 
recruitment problems
Hünseler et al.82 N=219, 
0-2 years
Double-blind, randomized 
controlled trial of IV clonidine 
vs. midazolam
Opioid- and benzodiazepine-
sparing in neonatal age 
group
Duffett et al.84 N=50, 
0-18 years
Double-blind, randomized 
controlled trial of oral 
clonidine vs. placebo in 
addition to physician-driven 
sedation
No significant difference 
in effectivity, study with 
clonidine clinically feasible
Su et al.154 N=36, 
1-24 months 
Open-label dose-response 
study of dexmedetomidine
Reduction of supplementary 
sedatives, no cardiovascular 
adverse effects
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Table 1. Continued.
Study Sample size
and age
Design Outcome
Hosokawa et al.155 N=141, 
0-15 years
Observational cohort 
study: dexmedetomidine vs. 
chlorpromazine, midazolam 
or fentanyl in cardiac surgery 
patients
Comparable efficacy, more 
haemodynamic adverse 
effects in dexmedetomidine 
group
Aydogan et al.88 N=32, 
12-17 years
Double-blind, randomized 
controlled trial of IV 
dexmedetomidine vs. 
midazolam in adolescents 
after scoliosis surgery
Decreased pain score, 
fentanyl consumption and 
delirium in dexmedetomidine 
group, more bradycardia in 
dexmedetomidine group
Diaz et al.156 N=10, 
0-8 years
Observational PK study 
of dexmedetomidine for 
postoperative sedation
Hypotension in most cardiac 
surgery patients
Tobias et al.89 N=30, 
0-8 years
Randomized controlled 
trial: IV low-dose or high-
dose, dexmedetomidine vs. 
midazolam
Equivalent sedation across 
3 groups, lower heart rate 
in dexmedetomidine group: 
1 patient removed from the 
study after bradycardia
Svensson et al.157 N=174, 
0-16 years
Prospective observational 
cohort study: propofol CI in 
the PICU
No occurrence of PRIS in 
cohort group
Rigby-Jones et al.158 N=21, 
0-12 years
Observational PK study of 
propofol CI
Adequate sedation in 17 of 
20 scored patients, 1 case of 
hypotension and metabolic 
acidosis
Hartvig et al.159 N=10, 
8-30 months
Observational PK study of 
ketamine CI after cardiac 
surgery
Adequate sedation, no 
adverse effects observed
Parkinson et al.107 N=44, 
0-15 years
Randomized controlled trial 
of midazolam IV vs. chloral 
hydrate and promethazine 
PO
More optimal sedation in 
chloral hydrate/promethazine 
group, 1 patient with indication 
of delirium in chloral hydrate/
promethazine group
Abbreviations: CI: continuous infusion; EEG: electroencephalogram; IV: intravenous; PO: oral; PICU: Paediatric 
Intensive Care Unit; PK: Pharmacokinetic; PK-PD: Pharmacokinetic-Pharmacodynamic; PRIS: PRopofol Infusion 
Syndrome;
An example of a scale that includes several behavioural indicators of distress is the COM-
FORT behavioural (COMFORT- B) scale.10 The COMFORT-B scale can be used both in 
ventilated and spontaneously breathing patients and has proven to be valid for both 
pain and sedation assessment. In addition, the scale is able to detect treatment-related 
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changes in pain or distress intensity and therefore can reliably guide pain and sedation 
management.13 Still, the COMFORT-B scale cannot be applied in patients with fluctuations in 
neurological status, pre-existing neurological disorders or patients receiving neuromuscular 
blocking agents. A limitation of behavioural assessment tools in general is the difficulty to 
discriminate between pain, discomfort, withdrawal symptoms or delirium. For example, the 
Face, Legs, Activity, Cry and Consolability (FLACC) scale, one of the most widely used pain 
assessment scales, was found wanting in its capacity to discriminate pain and distress.14 
For a decade, the Bispectral Index Monitor (BIS) was considered promising for objective 
assessment of sedation. Studies comparing BIS to the COMFORT (or COMFORT-B) scale15–22 
showed correlations ranging from weak15 to excellent when grouped in a BIS range of 
41–60.17 This wide variation can be partially explained by different study conditions, as 
the weak correlation was found in patients undergoing endotracheal suctioning, and the 
high correlation was found during continuous sedation. Depending on the clinical indication, 
BIS can potentially be used, although it has not proven valid for children under the age of 
1 year old as the EEG algorithm has not been validated in infants.23
Prolonged administration of sedatives may lead to drug tolerance and physical depen-
dency, leading to iatrogenic withdrawal syndrome after abrupt discontinuation or (too 
rapidly) tapering down of these drugs. The symptoms of this syndrome overlap with signs 
of undersedation. The Withdrawal Assessment Tool-1 (WAT-1) and the Sophia Observa-
tion withdrawal Symptoms score (SOS) are the most valid and reliable tools to identify 
withdrawal in the PICU.24,25 Furthermore, a position statement from the European Society 
for Paediatric and Neonatal Intensive Care (ESPNIC) provides clinical recommendations for 
sedation and withdrawal syndrome assessment in the paediatric age group.26
Sedation Guidelines
Sedation management in adults has shifted from full unconscious sedation to a more easily 
arousable state.27 In this approach, the use of sedation guidelines and protocols was asso-
ciated with reduced ICU and hospital length of stay (LOS) as well as reduced duration 
of mechanical ventilation (MV).28 In paediatrics, however, a systematic review published 
in 201329 showed that some studies also found a reduced ICU LOS and duration of MV 
in protocolized sedation arms, but concluded that the overall evidence for protocolized 
sedation remained relatively poor due to the low quality of studies. Children’s cognition 
and behaviour clearly require a different strategy. 
One year later, Curley et al.30 reported on the largest multicentre RCT comparing protoco-
lized sedation with physician-driven usual care in a mixed PICU population. The protocolized 
sedation management had not resulted, however, in shorter MV duration or ICU and hospital 
LOS. Heterogeneity in outcome measures and pharmacological agents makes it difficult to 
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obtain sufficient evidence for the usefulness of sedation guidelines in paediatric intensive 
care. A systematic review of Vet et al.31 concluded that optimal sedation is achieved in only 
around 60% of sedation assessments and that oversedation is more common than under-
sedation. Oversedation often was not adequately managed by tapering off medication, 
indicating that healthcare professionals may be tolerating oversedation. This attitude may 
diminish the effect of protocolized sedation in trials. It would seem that ‘protocolized’ does 
not automatically mean ‘uniformity’ or ‘one size fits all’.32 In adults, the method of daily 
sedation interruption (DSI) seemed promising in reducing ICU LOS and MV duration,33,34 
but conclusive evidence has not yet been found.35,36 A multicentre RCT comparing protoco-
lized sedation and DSI plus protocolized sedation in the PICU showed no beneficial effects 
of DSI,37 in contrast to two other RCTs in children.38,39 Vet et al. compared to protocolized 
sedation management instead of physician-based sedation management, which may imply 
a positive effect of the protocolized sedation in the control arm.
Although an optimal level of sedation often cannot be achieved without pharmacological 
treatment it is also important to consider environmental factors and non-pharmacological 
interventions. Light and noise, for example, can be disturbing, and care should be taken 
to let the children wear ear plugs, ask staff to speak softly and prevent ongoing alarm 
sounds, etc. Non-pharmacological interventions to reduce stress, such as live or recorded 
music, have been primarily studied in adult critical care.40 A meta-analysis including three 
RCTs of music therapy offered to paediatric surgical patients (0–18 years), although not 
in the intensive care setting, reported significant reduction in pain, anxiety and distress.41 It 
would be worthwhile to study non-pharmacological interventions in the PICU setting.
Pharmacological Aspects
Several overviews of commonly used sedatives have already been published.42–44 Still, the 
dosing regimens greatly differ. This is not surprising, as most of these sedatives are prescribed 
off-label.2 Figure 1 illustrates the mechanisms of actions of the different sedatives. Table 2 pro-
vides PK and PD properties of the most common sedatives including proposed dosing strategies.
Low-volume blood collection techniques such as dry blood spot sampling45 in combination 
with new analysis techniques such as LC-MS/MS, for which less blood is needed, could help 
establish optimal paediatric dosing strategies by enhancing pharmacokinetic research. 
Moreover, comparative effectiveness studies and population PK-PD studies using oppor-
tunistic and sparse sampling could further facilitate paediatric drug research.46 However, 
many internal and external factors can alter the PK and PD of sedative drugs. The internal 
factors include critical illness itself, which has been correlated with altered PK parameters 
of midazolam47,48 and other drugs,49 decreased cardiac output, changes in liver and kidney 
function and altered distribution, for example, in children with burns.50 
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External factors include renal replacement therapy,51 ECMO52,53 and hypothermia.52,54 
Increasingly, physiology-based pharmacokinetic (PBPK) studies will offer the opportunity 
to integrate physiological and pathophysiological changes over time in the drug dosing 
schedules. Furthermore, weight-based infusion concentrations are often inaccurate. In a 
prospective study, 65% of opiate concentrations in a PICU and NICU differed >10% from 
the prescribed concentration.55 This confounder should be taken into account in PK-PD stud-
ies, and it should be considered to measure the actual administered infusion concentration. 
Not only PK but also PD may be affected by critical illness. An adult study56 found a signif-
icant correlation between disease severity and level of sedation, independent of propofol 
clearance. It is plausible that this holds also for children.
Table 2. Sedative PK/PD properties.
Elimination half life Metabolism Recommended dose Advantages Caveats
Benzodiazepines
Midazolam 3-4 hours CYP3A4/3A5, glucuronidation of 
phase I metabolite
IV: Bolus of 0.1-0.2 mg/kg, 
followed by 0.1-0.6 mg/kg/h CI
Fast-acting Accumulation in 
hepatic/renal failure
Lorazepam 10-20 hours Glucuronidation IV: 0.02-0.1 mg/kg q4-8h 
or 0.025 mg/kg/h CI
Metabolism independent of 
liver and kidney function
Propylene glycol toxicity
Alpha-2-adrenergic receptor agonists
Clonidine 7-17 hours 60% kidney excretion, 
metabolism by CYP2D6
IV: Bolus of 2 mcg/kg, 
followed by 0.1-2 mcg/kg/h CI
Preserves respiratory drive 
and has analgesic properties
Bradycardia and
rebound hypertension
Dexmedetomidine 2-4 hours CYP2A6 and 
glucuronidation
IV: 0.2-2.5 mcg/kg/h CI Short half-life Rebound hypertension
Other sedatives
Propofol 30-60 minutes CYP2B6/2C9, 
glucuronidation
3-15 mg/kg/h Fast-acting, short half-life Associated with PRIS at higher 
doses or prolonged use
Ketamine 2-3 hours CYP3A4/2B6/2A9 IV: Bolus of 1 mg/kg 
followed by 16 mcg/kg/min 
(1 mg/kg/h) CI
Preserves respiratory drive 
and has analgesic properties
Hypertension, raised 
intracranial pressure
Chloral hydrate 8-35 hours (TCE) Glucuronidation PO or RC: 25-75 mg/kg q4-6h Does not interfere 
with EEG results
No IV solution available
Barbiturates
Pentobarbital 15-50 hours Hepatic microsomal 
enzyme system
IV: 0.5-5 mg/kg/h Decreases intracranial pressure, 
profound sedation
Not suitable for hemodynamically 
unstable patients
Thiopental 6-15 hours Oxidation (CYP2C19) and 
hydroxylation
IV: Bolus of 4-6 mg/kg 
followed by 5 mg/kg/h 
up to a maximum of 10 mg/kg/h
Decreases intracranial pressure, 
profound sedation
Not suitable for hemodynamically 
unstable patients
Abbreviations: CI: continuous infusion; EEG: electroencephalogram; IV: intravenous; PO: oral; RC; rectal; 
TCE: trichloroethanol. 
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Pharmacological Agents
Benzodiazepines
Benzodiazepines are the drug class of first choice, often in combination with opioids. An 
exception must be made, however, for the premature population as a study showed that 
midazolam was associated with a higher incidence of intraventricular haemorrhage grade 
III or IV and periventricular leucomalacia compared to morphine.57 Benzodiazepines have 
been used for sedation of mechanically ventilated children for many years. The exact 
mechanism of action is not yet clear, although it is known that all agents from this class 
share the same site of action. Binding to this site increases the frequency at which the 
chloride channel is opened by ɣ-amino butyric acid (GABA), thereby making the neuron 
more sensitive to GABA. The more chloride is allowed to enter the target neuron, the more 
it is hyperpolarized, resulting in a decrease in firing rate of this target neuron. This in turn 
leads to the pharmacological effects of benzodiazepines: sedation, anxiolysis and muscle 
Table 2. Sedative PK/PD properties.
Elimination half life Metabolism Recommended dose Advantages Caveats
Benzodiazepines
Midazolam 3-4 hours CYP3A4/3A5, glucuronidation of 
phase I metabolite
IV: Bolus of 0.1-0.2 mg/kg, 
followed by 0.1-0.6 mg/kg/h CI
Fast-acting Accumulation in 
hepatic/renal failure
Lorazepam 10-20 hours Glucuronidation IV: 0.02-0.1 mg/kg q4-8h 
or 0.025 mg/kg/h CI
Metabolism independent of 
liver and kidney function
Propylene glycol toxicity
Alpha-2-adrenergic receptor agonists
Clonidine 7-17 hours 60% kidney excretion, 
metabolism by CYP2D6
IV: Bolus of 2 mcg/kg, 
followed by 0.1-2 mcg/kg/h CI
Preserves respiratory drive 
and has analgesic properties
Bradycardia and
rebound hypertension
Dexmedetomidine 2-4 hours CYP2A6 and 
glucuronidation
IV: 0.2-2.5 mcg/kg/h CI Short half-life Rebound hypertension
Other sedatives
Propofol 30-60 minutes CYP2B6/2C9, 
glucuronidation
3-15 mg/kg/h Fast-acting, short half-life Associated with PRIS at higher 
doses or prolonged use
Ketamine 2-3 hours CYP3A4/2B6/2A9 IV: Bolus of 1 mg/kg 
followed by 16 mcg/kg/min 
(1 mg/kg/h) CI
Preserves respiratory drive 
and has analgesic properties
Hypertension, raised 
intracranial pressure
Chloral hydrate 8-35 hours (TCE) Glucuronidation PO or RC: 25-75 mg/kg q4-6h Does not interfere 
with EEG results
No IV solution available
Barbiturates
Pentobarbital 15-50 hours Hepatic microsomal 
enzyme system
IV: 0.5-5 mg/kg/h Decreases intracranial pressure, 
profound sedation
Not suitable for hemodynamically 
unstable patients
Thiopental 6-15 hours Oxidation (CYP2C19) and 
hydroxylation
IV: Bolus of 4-6 mg/kg 
followed by 5 mg/kg/h 
up to a maximum of 10 mg/kg/h
Decreases intracranial pressure, 
profound sedation
Not suitable for hemodynamically 
unstable patients
Abbreviations: CI: continuous infusion; EEG: electroencephalogram; IV: intravenous; PO: oral; RC; rectal; 
TCE: trichloroethanol. 
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relaxation.58 This inhibitory effect of the GABA system is developing during the first weeks 
of life; therefore, GABA-ergic agents may be less effective in prematurely born and term 
born neonates and may even lead to paradoxical reactions such as increased agitation 
and convulsions.59
Figure 1. An overview of the sites of action of the most commonly used sedatives in the pediatric intensive care unit. 
GABA-receptor Alpha-2 adrenergic receptor 
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Midazolam Clonidine Dexmedetomidine Lorazepam 
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Midazolam
Midazolam is recommended in UK PICU guidelines as first-choice sedative in most critically 
ill children. With onset of action occurring within 1–5 min after infusion, its effects last for 
30–120 min after a single infusion, and even up to 48 h after one week of continuous 
infusion.60 Besides sedation and anxiolysis, midazolam also provides anterograde amne-
sia, thus minimizing children’s recall of unpleasant experiences after a PICU admission.61 
Midazolam is mainly metabolized to the equipotent metabolite 1-OH-midazolam and then 
glucuronidated to the renally excreted 1-OH-MDZ-glucuronide.
Although a clear PK-PD relationship was not found in a prospective study in 21 PICU 
patients, effective sedation was achieved within the recommended range.62 Midazolam 
dosing can be effectively and simply titrated based on level of sedation. However, as 
80% of conjugated 1-OH-midazolam is eliminated renally, accumulation of the metabolites 
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may lead to prolonged sedation in children with renal failure.63 Furthermore, the sedation 
strategy for a patient with severe sepsis should take into account that critical illness reduces 
midazolam clearance independently of serum creatinine levels and could increase seda-
tion depth. Critical illness thus leads to a great variability in midazolam clearance, as was 
confirmed in a systematic review.64 It should be clear that this variability greatly affects 
correct dosing. Ongoing midazolam trials in paediatric long-term sedation or pharmacology 
are listed in Table 3.
Lorazepam
The longer acting benzodiazepine lorazepam is used much less than midazolam in the PICU 
but has been included in the Best Pharmaceuticals for Children Act (BPCA) Priority List.30,65 
Its IV formulation contains propylene glycol (PG), which at toxic amounts can lead to lactic 
acidosis.43,66 Note should be taken that the PG metabolism is immature in preterm and term 
neonates.67,68 It is recommended to carefully monitor the osmol gap.69 Data on a PK-PD 
relationship of lorazepam for sedation are lacking. Pharmacokinetics are well-described 
in children with seizures and status epilepticus70–72 and a PBPK model underscores the low 
elimination rate in neonates and the higher elimination rate in children around 2 years 
of age.73 Still, a clear evidence-based dosing regimen for critically ill children is not yet 
available (see Table 3 for ongoing paediatric lorazepam studies). 
Alpha-2-adrenergic receptor agonists 
If benzodiazepines fail to achieve adequate sedation, adjuncts such as the α2-receptor 
agonists clonidine and dexmedetomidine can be used, which nevertheless are not labelled 
for this indication. Α2-receptor agonists reduce sympathetic outflow74 by stimulating pre-
synaptic α2-adrenergic receptors, thereby reducing the noradrenaline release into the 
synapse. This provides sedation without respiratory depression. Because of its analgesic 
properties, clonidine is often given as spinal anaesthesia adjunct after surgical procedures.75 
Dexmedetomidine could reduce MV duration and ICU LOS76 when compared to standard 
sedation practices, but there is still limited experience with this sedative. In critically ill chil-
dren, both clonidine and dexmedetomidine exert effects on the cardiovascular system, the 
latter theoretically to a lesser extent, as this is a more α2-selective agonist. However, both 
seem to be well-tolerated and the cardiovascular side effects are well-manageable.77–79
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Table 3. An overview of current trials with sedative agents in children.
Trial register number Short title Sedative agent Type of study Study population Comparator 
(if applicable)
Co-medication
EudraCT 
2014-003269-46
PedMicMida Midazolam Microdosing PK study Children on midazolam(0-6 years) N/A None
NCT02302391 Morpheus Midazolam PK analysis MV children (1 month-18 years) N/A Fentanyl
NCT00109395 Lorazepam Sedation for Critically Ill Children Lorazepam Double-blind RCT MV children (0-18 years) Midazolam None
NTR5112 PK of Lorazepam Oral Liquid in PICU Patients Midazolam PK analysis of new oral 
formulation
Children on benzodiazepine 
weaning (2 weeks-12 years)
N/A None
NCT02509273 CloSed Clonidine RCT, PK-PD analysis MV children (0-18 years) Midazolam Morphine
NCT02252848 N/A Clonidine Phase I trial Neonates with HIE treated with 
hypothermia
N/A None
NCT02249039 N/A Clonidine Dose-finding study (phase I-II) MV infants N/A None
NCT01091818 Dexmedetomidine Versus Midazolam for Intensive Care 
Sedation of Children
Dexmedetomidine Double-blind RCT MV children (2-18 years) Midazolam None
NCT02296073 The Efficacy and the Safety of Dexmedetomidine 
Sedation on the Pediatric Intensive Unit(PICU) Patients.
Dexmedetomidine Open-label RCT MV children (1-16 years) Midazolam Fentanyl
NCT00875550 Study Evaluating Safety and Efficacy of 
Dexmedetomidine (DEX) in Intubated and Mechanically 
Ventilated Pediatric Intensive Care Unit (PICU) Subjects
Dexmedetomidine Double-blind RCT MV children (1-16 years) Low dose vs. high 
dose
Fentanyl, 
morphine, 
midazolam
NCT02375243 Use of Dexmedetomidine in Children Undergoing Cardiac 
Surgery
Dexmedetomidine Open-label RCT Children undergoing cardiac 
surgery (1 month-2 years)
Half-dose co-
medication plus 
DEX vs. full-dose 
co-medication
Midazolam and 
morphine
ACTRN12615001304527 Cardiac Baby SPICE Dexmedetomidine Double-blind RCT Children undergoing cardiac 
surgery (>6 years)
Midazolam None
ACTRN12614000225617 Baby SPICE Dexmedetomidine Open-label RCT MV children (0-16 years) Standard sedation 
care
None
NCT02529202 Dexmedetomidine Pharmacokinetics in Neonates During 
Therapeutic Hypothermia
Dexmedetomidine PK analysis Neonates with HIE treated with 
hypothermia
N/A None
NCT01266252 NEODEX Dexmedetomidine PK analysis MV neonates N/A None
NCT02544854 Pharmacokinetic/Pharmacodynamic Model of Propofol in 
Children
Propofol PK-PD analysis Children (1-12 years) undergoing 
surgery
N/A None
NCT01621373 NEOPROP Propofol PK-PD analysis Neonates undergoing INSURE N/A None
NCT02040909 NEOPROP2 Propofol Dose-finding study Neonates undergoing intubation N/A None
ACTRN12611000451909 The pharmacokinetics and pharmacodynamics of propofol 
infusion in obese children
Propofol PK-PD analysis Obese children (5-15 years) N/A None
NCT00618397 Pharmacokinetics of Low Dose Ketamine Infusion Ketamine Phase I trials with PK-analysis MV children (3-18 years) N/A None
EudraCT 2008-003293-18 Pharmacokinetics of ketamine in infants Ketamine PK analysis Infants undergoing anesthesia N/A None
NCT trials are found on www.clinicaltrials.gov, EudraCT trials on www.clinicaltrialsregister.eu, ACTRN trials on 
www.anzctr.org.au and NTR trials on www.trialregister.nl. PK=pharmacokinetics; MV=mechanically ventilated; 
RCT=randomized controlled trial; HIE=Hypoxic-ischemic encephalopathy
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Table 3. An overview of current trials with sedative agents in children.
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Dexmedetomidine Double-blind RCT MV children (1-16 years) Low dose vs. high 
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Dexmedetomidine PK analysis Neonates with HIE treated with 
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Propofol PK-PD analysis Children (1-12 years) undergoing 
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NCT01621373 NEOPROP Propofol PK-PD analysis Neonates undergoing INSURE N/A None
NCT02040909 NEOPROP2 Propofol Dose-finding study Neonates undergoing intubation N/A None
ACTRN12611000451909 The pharmacokinetics and pharmacodynamics of propofol 
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Propofol PK-PD analysis Obese children (5-15 years) N/A None
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Clonidine
Clonidine has a relatively long half-life,80 and therefore, it is recommended to give a loading 
dose before a continuous infusion. Only one published trial in children, the SLEEPS study, did 
use a loading dose81; whereas in other trials, a loading dose was not applied.82–84 This practice 
could lead to a later onset of action of clonidine.80
The SLEEPS study compared clonidine to midazolam and found no significant difference in 
efficacy. The study was underpowered, however, as recruitment appeared problematic, and 
true non-inferiority of clonidine therefore was not shown. Genuine PK-PD research has not 
been performed, but adequate sedation could be reached with a plasma level of 0.9–2.5 
ng/ml.83 PK-PD simulations80 have shown that this level is reached in the majority of patients 
receiving 1 mcg/kg per h, but without the use of a bolus dose, it will take up to at least 24 
h to reach this level. Dosing recommendations are still not evidence-based, but evidence is 
gained from an ongoing RCT (the CloSed trial: NCT02509273 on clinicaltrials.gov).
Dexmedetomidine
Dexmedetomidine seems to reduce cardiovascular complications after cardiac surgery.85 A 
beneficial effect was found in a meta-analysis86 of haemodynamic outcomes in children after 
surgery for congenital heart disease. Three RCTs on dexmedetomidine in children87–89 showed 
a decrease in MV duration and an opioid-sparing effect. Many of the children in these trials 
had bradycardia, but this had no effect on blood pressure. Optimal dosing of dexmede-
tomidine is unknown. Its clearance is immature during the first 2 years of life, then increases 
to above adult level when expressed per kg bodyweight and returns to adult levels after 5 
years of age.90 The half-life in preterm neonates is twice that in term neonates.91 A PK-PD 
model has been established only for children after cardiac surgery.92 A target plasma level of 
0.6 mcg/l is regarded effective in adults,93 but a target plasma level for children is unknown. 
Simulation of doses used in trials based on a pooled population PK analysis90 estimates the 
target plasma level to lie between 0.4 and 0.8 mcg/l, but this needs to be confirmed in a 
larger patient group. Moreover, experience with dexmedetomidine in children is relatively 
scarce so knowledge on safety is also lacking. Nevertheless, several paediatric studies on 
dexmedetomidine are underway (see Table 3). 
Other sedative agents 
Propofol
Propofol is a very rapid-acting and versatile sedative. It is included in the revised priority list 
of the EMA,94 for procedural sedation in the neonatal age group. While often used as sedative 
in adult ICUs,95 its long-term use in children is contraindicated as it may lead to a propofol 
infusion syndrome (PRIS), a metabolic disorder with severe metabolic acidosis, hyperkalaemia, 
hyperlipidemia, rhabdomyolysis and organ failure, associated with an increased risk of mor-
tality.60 A fatty acid oxidation disturbance may be the underlying aetiology. Risk factors are 
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doses >4 mg/kg per h with a duration of >48 h, but short-term high doses can be dangerous, 
too. Other risk factors include a young age, critical illness, high fat and low carbohydrate 
intake, inborn errors of mitochondrial fatty acid oxidation and concomitant catecholamine 
infusion or steroid therapy.96 Wang et al.97 pooled seven paediatric pharmacokinetic studies 
and evaluated the allometric exponent of 0.75, which is often used to estimate the clearance 
in individuals of different age. The models gave a clear insight into the PK of propofol in 
all age groups. Propofol PD is less well-studied. One study found a PK-PD relation98 with a 
wide variability in the PD end point, for which reason the authors advise dose titration. Four 
propofol PK-PD trials are being performed (Table 3).
Ketamine
Ketamine is a NMDA receptor-blocking agent, which provides dissociative anaesthesia99 
‘disconnecting’ the thalamocortical and limbic systems, that is disconnecting the CNS from 
outside stimuli.100 Ketamine preserves the respiratory drive and the blood pressure and is 
thus suitable for use in haemodynamically unstable patients.101 It stimulates the release of 
endogenous catecholamines, producing dose-dependent tachycardia and hypertension. This 
mechanism is also used in refractory bronchospastic events.102 Ketamine is contraindicated 
for patients with a raised intracranial pressure as ketamine may further increase the pres-
sure by intracerebral vasodilation. The blocking of the NMDA receptor may prevent opioid 
tolerance; therefore, ketamine often serves as an adjunct to sedatives and opioid analgesics, 
with an opioid-sparing effect.43,103 Ketamine is available as the racemic mixture of R(-) and 
S(+) ketamine, but the S(+) enantiomer is twice as potent as racemic ketamine and has fewer 
side effects.104 Some European countries have consequently replaced the racemic mixture with 
S(+) ketamine (esketamine). A PD profile of ketamine has been established in children in an 
emergency department setting where short-term sedation and analgesia were required for 
brief painful procedures.105 The profile shows that a target serum concentration of 1 mg/l 
provides moderate sedation and that a concentration of 1.5 mg/l provides deep sedation. 
However, optimal dosing should still be confirmed by a well-designed RCT with adequate 
long-term sedation as end point (for ongoing PK studies, see Table 3). 
Chloral hydrate
Chloral hydrate (CH) is a prodrug, rapidly converted by acetaldehyde dehydrogenase to the 
active metabolite trichloroethanol (TCE), which is either glucuronidated to an inactive metab-
olite, or oxidized to trichloroacetic acid (TCA) and then excreted by the kidneys.106 One trial 
showed better sedation using chloral hydrate with promethazine compared to midazolam 
intravenously in critically ill children who tolerated nasogastric feeding.107 However, enteral 
sedatives are not recommended primarily in this population as the enteral absorption is unpre-
dictable.108 Plasma levels of CH could be detected after hours in neonates, while in healthy 
adults, the half-life is very short.109 A correlation was also found between CH plasma levels 
and sedation scores, although TCE is the presumed active metabolite. As it is unclear which 
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of the compounds, CH or TCE, provides sedation, pharmacokinetic data are difficult to inter-
pret, and thus, an evidence-based dosing recommendation is lacking.110 Moreover, neonates 
may be vulnerable to toxic levels of TCE and TCA because these metabolites have a longer 
half-life at neonatal age.111 Chloral hydrate has been associated with a higher incidence 
of bradycardiac events in prematurely born neonates, which implies that cardiorespiratory 
monitoring is needed.112 Future research should be aimed at the efficacy and safety of CH in 
long-term sedation, preferably by establishing a good PK-PD profile in different age groups. 
No trials involving CH have been registered yet.
Barbiturates
Pentobarbital
Pentobarbital (pentobarbitone) can provide profound sedation when other first-line thera-
pies fail. Doses are titrated based upon a clear pharmacodynamic end point, that is burst 
suppression on the EEG. However, BIS monitoring, which is easier to perform, could be a valid 
alternative to EEG monitoring in this indication.113 BIS monitoring is validated only for children 
older than 1 year and also has its limitations when used in critical care. For example, BIS is 
usually recorded on one side of the brain, while asymmetrical intracranial pathology may be 
present.114 As the cerebral oxygen demand is reduced, the cerebral blood flow is reduced 
as well and consequently the intracranial pressure will fall.115 Pentobarbital is a relatively 
short-acting barbiturate.116 It is a very efficient sedative, but has been associated with adverse 
effects117 such as hypotension (as it is a direct negative inotrope), oversedation, choreo-athe-
toid neuromuscular phenomena and withdrawal. The drug may suppress the immune system, 
which effect could be relevant to critically ill children with multiple accesses to the blood 
stream.118 Its PK and PD have been well-established in adults, but data in children are limited. 
A population PK study in children after open heart surgery suggested that younger infants 
would need a relatively higher dose based on body weight due to increased clearance.92 
However, in this study, no link was made to a PD end point, so it remains unclear whether 
dosages should be adapted as there is a clear clinical titration end point.
Thiopental
Thiopental (thiopentone) is an ultra-short-acting barbiturate with an onset of action of 20–40 
s after intravenous infusion.119 It is widely used as an anaesthesia induction agent. Like pen-
tobarbital, thiopental is a suitable agent for patients with raised intracranial pressure. PK 
and PD studies have been rarely performed in children, and most of them date from the 
1980s.120–123 Despite a reported double clearance compared to adults,121 doses do not 
need to be doubled.119 Thiopental dose requirement varies among individuals, and titration 
to the burst suppression EEG pattern should take place, along with careful therapeutic drug 
monitoring.124,125 Effective plasma levels vary between 15 and 35 mg/l (see Table 2 for a 
proposed dosing strategy).
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DISCUSSION
This review shows an increasing interest in research on PICU sedation pharmacotherapy. 
Still, there is a lack of well-designed studies and consequently many practices are not yet 
evidence based. This type of research is complicated by different methods of sedation 
assessment, different pharmacokinetics in different age and weight categories, patient 
heterogeneity with multiple factors influencing the pharmacokinetics and also by ethical and 
practical considerations. For ethical reasons, drug studies cannot be performed in healthy 
children, which implies that illness severity will always be a confounding factor. On the other 
hand, for PICU practice, we only need information on critically ill children, and there should 
be always dealt with different severities of illness.
Traditional RCTs come with limitations as well. Results often apply only to a selective study 
population based on strict inclusion and exclusion criteria for the sake of internal validity. 
External validity is compromised, however, thus, pragmatic RCTs or cohort studies and 
well-designed titration studies with an objective and clear PD end point should complement 
classical RCT designs.126 Moreover, using a classical RCT design with placebo as comparator 
is unethical in sedation research as then the control group may suffer profound anxiety and 
agitation. When it comes to safety, children should be followed for decades after drug 
exposure as long-term effects are important end points as well.127
PK-PD modelling might overcome several practical issues in paediatric drug research. While 
in the standard two-stage approach, individual values play a central role in determining PK 
parameters, and therefore, large patient samples are needed; the nonlinear mixed-effects 
models (NONMEM) approach provides a Bayesian-based prediction of PK parameters 
using population data.128 This approach resulted in a new dosing regimen for morphine 
in infants129 with much lower dosing than generally recommended so far, suggesting that 
neonates have been universally overdosed.
Improvements may also be made in the field of quantifying pharmacodynamics. A study 
in which the item response theory was applied to the COMFORT scale and the Premature 
Infant Pain Profile (PIPP) score made clear that the behavioural items corresponded better 
with pain and discomfort than did the physiological items.130 A previous study has already 
made clear that the physiological items in the COMFORT scale have no added value,10 but 
the item response theory with its more advanced statistical techniques allows calculating 
the probability of pain for each item. Thus, when using assessment scales consisting of more 
than one item, it would be worthwhile to collect data on each of the items rather than the 
total score only.
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Another form of in silico experiments are PBPK models73,131 representing a multicompartment 
model applicable to multiple drugs. Pharmacodynamics can be linked to such models by 
adding biophase concentrations, but only a few full PBPK-PD models have been developed 
so far for the administration of midazolam, theophylline, lorazepam and propofol to chil-
dren.73,132,133 The validity of these models should be evaluated further. As sedatives act on 
the CNS, evaluation requires obtaining brain tissue concentrations, which is not possible in 
routine critical care. Experimental strategies include calculations based on mass balance 
principles using the net flux of drugs (obtained from arterial and venous concentration 
differences)134 or microdialysis.135 Both strategies are invasive and therefore subject to 
practical objections and ethical considerations.
FUTURE PERSPECTIVES
Apart from optimal dosing strategies, new products may also improve pharmacological 
sedation management. A promising example is the ultra-rapid-acting benzodiazepine 
remimazolam,136 which has a pharmacokinetic profile comparable to that of remifentanil, 
allowing for fast titration. It has only been studied in adults so far. 
Monotherapy with remifentanil was found effective for long-term ICU sedation in adults.137 
In a paediatric study, remifentanil was as effective as fentanyl for sedation and analgesia 
and allowed for earlier extubation.138 However, its use carries the risk of opioid-induced 
hyperalgesia (OIH) that is a phenomenon seen after opioid administration,139 notably on 
account of its short half-life and fast onset of action.140,141 It has been suggested that 
ketamine or clonidine as adjuvants could prevent the OIH,142 but these agents may have 
unwanted side effects. Gradual remifentanil withdrawal has been suggested as well, but 
OIH was still observed after cold pressure testing in one study.143 Moreover, chronic pain 
may develop after (prolonged) surgery,144 so more data on these issues are warranted 
before it is regularly used in children.
In adult intensive care, volatile agents such as sevoflurane, desflurane and isoflurane have 
a favourable pharmacological profile with short elimination half-lives and low toxicity 
and could be suitable for long-term sedation.145 These agents have not been studied in 
children so far. There is some concern that they may have adverse long-term neurological 
effects,146–148 so more conclusive studies on the long-term effects of these agents are needed 
before efficacy trials may be performed.
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CONCLUSION
A variety of sedatives are used in the paediatric intensive care unit, but evidence and 
pharmacokinetic data are still scarce. Fortunately, there is an active research scene which 
yields promising new PK and PD data using new study designs combined with advanced 
laboratory methods and modelling. However, pharmacology is not the only way that can 
lead to improved paediatric sedation management. We recommend that future research 
focuses also on sedation assessment and implementation strategies of protocolized sedation.
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ABSTRACT
Introduction: Pharmacologic pain management in newborns and infants is often based on 
limited scientific data. To close the knowledge gap, drug-related research in this popula-
tion is increasingly supported by the authorities, but remains very challenging. This review 
summarizes the challenges of analgesic studies in newborns and infants on morphine and 
paracetamol (acetaminophen).
Areas covered: Aspects such as the definition and multimodal character of pain are 
reflected to newborn infants. Specific problems addressed include defining pharmacody-
namic end points, performing clinical trials in this population and assessing developmental 
changes in both pharmacokinetics and pharmacodynamics.
Expert commentary: Neonatal and infant pain management research faces two major 
challenges: lack of clear biomarkers and very heterogeneous pharmacokinetics and phar-
macodynamics of analgesics. There is a clear call for integral research addressing the 
multimodality of pain in this population and further developing population pharmacokinetic 
models towards physiology-based models.
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INTRODUCTION
Only a few years ago, doses of commonly used drugs such as morphine and paracetamol 
(acetaminophen) in newborns and infants were based on extrapolated data from adults or 
older children. Sufficient knowledge about the efficacy, appropriate dosing, and safety of 
these drugs derived from properly designed studies has been lacking for years. However, 
dose validation and the beginning of formulation of evidence-based guidelines for these 
drugs have now been based on a number of clinical trials, population PK/PD studies, and 
research on pain assessment and long-term outcomes.1-4 To understand the challenges in 
designing and conducting clinical investigations with analgesic medications in newborns and 
infants, it is important to learn from the previous successes and failures in this area. This 
review will describe and discuss the challenges of analgesic research in this population on 
different levels. We first discuss the pain definition and next address the issue of adequate 
pain assessment. With paracetamol and morphine as model drugs, we provide an overview 
of clinical trials so far, discuss the clinical pharmacology of these drugs as well as their short- 
and long-term effects. Special attention will be paid to premature neonates, as research 
in this population is even more challenging.
Pain
Definition of pain and its multimodality
The International Association for the Study of Pain (IASP) has provided the following defi-
nition of pain: ‘an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage.’ They further state that ‘pain 
is always subjective. Each individual learns the application of the word through experiences 
related to injury in early life.’ However, as this is not applicable to neonates and infants,5 
they revised this statement and added: ‘The inability to communicate verbally does not 
negate the possibility that an individual is experiencing pain and is in need of appropriate 
pain-relieving treatment.’
This definition aims to cover the multimodality of pain, as pain is more than nociception 
and/or perception of (possible) noxious stimuli alone. Loeser proposed a pain model which 
includes four components: nociception, pain, suffering, and pain behavior (see Figure 1).6 
Nociception refers to the detection of tissue damage by transducers connected to Aδ and 
C nerve fibers. The IASP defines this as ‘the neural process of encoding noxious stimuli.’ 
Pain occurs at the moment of perception, once the signal from the peripheral nerve system 
reaches the central nervous system (CNS). Pain can also occur without input from the periph-
eral nerve system, for example after CNS damage. Pain usually leads to suffering as 
described by Cassel7: a ‘consequence of a physical or psychological threat to the integrity 
of the human being,’ which has similarity with ‘actual or potential tissue damage.’ The fourth 
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component is pain behavior, which includes the whole spectrum from small moans in acute 
short-term pain to frequent doctor visits in cases of chronic pain. This behavior can be inter-
preted by others as having pain. Loeser’s model makes clear that pain is a biopsychosocial 
phenomenon, not merely a biological one.
Figure 1. Depiction of pain multimodality according to Loeser. 
Pain behavior 
Suffering 
Pain 
Nociception 
Adapted with permission from: Loeser JD. Pain and suffering. Clin J Pain 2000; 16(2 Suppl): p. S2-6.
Types of pain
In neonatal and infant critical care, four different types of pain need to be distinguished:
• Procedural pain, acute pain caused by a short-term procedure such as venipuncture, 
heel lancing, or chest drain insertion/removal.
• Postoperative pain, defined as the pain experienced in the first 24–48 h after surgery.
• ‘Prolonged’ pain, a term increasingly used for pain with a duration >72 h and specif-
ically for the neonatal population.8,9
• Chronic pain, defined as pain persisting beyond the expected tissue healing time. 
However, expected healing times are not clearly delineated. Thus, chronic pain was
• assumed to persist for time periods varying from 1 to 6 months,10 but in general practice 
a duration >3 months is being used.
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These types of pain are important when implementing pain assessment tools both in research 
and clinical practice. It is important to know for what type of pain a tool is validated.
Pain assessment and PD markers
Behavioral assessment tools
Taking the definition of pain into account, it follows that pain can be only reliably assessed 
by self-report. In preverbal infants, this is not possible and then we have to rely on the 
interpretation of pain behavior.
A great variety of pain assessment tools has been developed over the past decades and 
to date, more than 40 different tools are available just for pain assessment in neonates 
and infants.11 Table 1 lists the validated observational pain assessment tools for the use 
in preverbal children, including their indication and age category for which it has been 
validated. These are recommended by several international guidelines.12,13
Table 1. Validated pain assessment tools according to age and their indication.
Pain assessment tool Indication Age category Type of tool
Premature Infant Pain Profile 
(PIPP)15-17 
Procedural and 
postoperative pain
Premature infants 
>24 weeks GA
Behavioral, contextual, 
physiologic parameters
Revised premature Infant Pain 
Profile (PIPP-Revised)18,19 
Procedural pain Premature infants 
>28 weeks GA
Behavioral and 
physiologic parameters
Neonatal Pain, Agitation and 
Sedation Scale(N-PASS)20 
Procedural and 
prolonged pain
Sedation level
Premature infants 
>23 weeks GA
Behavioral and 
physiologic parameters
COMFORTneo scale21 Prolonged pain
Sedation level
Premature infants 
>24 weeks
Behavioral parameters
COMFORT scale22,23 Postoperative pain
Sedation level
Children 0-18 years Behavioral and 
physiologic parameters
COMFORT behavior scale24 Postoperative pain
Sedation level
Children 0-3 years
Children 0-18 years
Behavioral parameters
Faces, Legs, Arms, Cry, 
Consolability (FLACC) scale25,26
Postoperative pain Children 2 months-
7 years
Behavioral parameters
Multidimensional Assessment of  
Pain Scale (MAPS)27 
Postoperative pain Infants 0-31 months Behavioral and 
physiologic parameters
GA: Gestational age
Physiology-based pharmacodynamic markers
As behavioral assessment tools are subjective to a certain degree, research efforts have 
been directed at identifying objective pharmacodynamic markers for the estimation of 
pain. Changes in vital signs, such as heart rate and blood pressure, do not serve as a link 
of pain neurobiology to pain behavior, as these autonomous responses to pain may be 
absent after a noxious stimulus.23 Therefore, physiology-based markers such as near-infra-
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red spectroscopy (NIRS), heart rate variability (HRV), skin conductance or pupillary reflex 
dilatation (PRD) have been studied but are not yet sufficiently validated. An overview is 
given in Table 2.
Table 2. Potential pharmacodynamic markers in neonates and infants.
Potential outcome measures Advantages Limitations
NIRS28,29 Non-invasive, continuously 
monitoring
Measures only cortical response; 
aEEG30 Continuous monitoring Not validated for pain in children 
<2 years
Skin conductance31-34 Non-invasive, continuously 
monitoring
Sympathetic activity may be 
caused by anxiety and/or distress 
as well
SSEP35,36 Non-invasive, continuously 
monitoring (when repetitive stimuli 
are being given)
Only reflects sensory response, not 
validated in infants
Pupillary reflex dilatation37,38 Promising bedside application in 
older children
Sympathetic activity may be 
caused by anxiety and/or distress, 
practical difficulties in infants
HRV (including ANI)39-51 Non-invasive, continuously 
monitoring
Sympathetic activity may be 
caused by anxiety and/or distress
fMRI52,53 Good overlap between findings in 
infants and adults, insight in pain 
beyond the sensory cortex
Not suitable for clinical application
Salivary cortisol levels Non-invasive collection of sample Delay in laboratory results
Plasma cortisol levels54-56 Suitable for both short- and long-
term pain 
Delay in laboratory results, 
sampling restricted in neonates
Plasma adrenalin levels54, 57 Delay in laboratory results, 
sampling restricted in neonates, 
less sensitive than noradrenalin
Plasma noradrenalin levels54, 57 Significantly reduced by 
analgesics
Delay in laboratory results, 
sampling restricted in neonates
Limitations of current pain assessment methods
On a critical note, the currently available pain assessment tools have a number of limita-
tions. First, they cannot satisfactorily distinguish pain from anxiety, stress, or other emotional 
states.57 Second, application of a particular tool in different contexts and circumstances, 
such as severity of illness and diagnosis, can be problematic. For example, lethargy, stiff 
limbs, minimal movement, and grunting all predict severity of illness,58 but may significantly 
affect the total score. Third, they may be subject to a certain degree of subjectivity from the 
observer, who may or may not know how the child usually reacts to pain and may interpret 
certain behavior such as less movement as reflecting being comfortable, when in fact the 
child holds still because of pain. 
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Physiology-based assessment methods such as NIRS, skin conductance, and HRV also have 
their limitations. Overall, they measure either the sympathetic nervous system activity or 
a cortical brain response to a stimulus. Sympathetic activity may reflect pain, but is also 
associated with stress, anxiety, and delirium. Also, vasopressor agents may influence sym-
pathetic tone. A cortical brain response to a stimulus may be indicative of nociception, but 
does not tell us directly whether a stimulus is perceived as painful. For example, in a study 
using NIRS,27 cortical brain responses were not altered by the administration of oral sucrose 
solution, whereas observational pain scores decreased significantly.
Practical aspects of performing such measurements also impede the use of physiological 
tools. As an example, pupillometry can only be done in subjects with eyes opened. Infants 
are unable to collaborate and measuring the pupil diameter could become another stressful 
event. Last, amplitude-integrated electroencephalography (aEEG) measurement has been 
used for research purposes but has not yet been shown a useful marker for pain and anal-
gesia in newborns and young infants.59–62
Item Response Theory
Pain assessment tools include several behavioral and/or physiological items. However, the 
items may not be indicative of pain to the same extent. Item Response Theory, an advanced 
statistical technique, could give insight in the informativeness of each separate item: the 
highest grade of intensity in one item may be more indicative of pain than the highest 
grade of another item. A recent study applied this technique to both the COMFORT scale 
and the Premature Infant Pain Profile (PIPP) in term and preterm neonates.63 The behavioral 
items corresponded best with pain; physiological items did less. A similar pattern was pre-
viously reported,21 and now advanced statistics show that high ratings of some behavioral 
items corresponded better with high pain levels than other items. This should be taken into 
account when using such a scale in new clinical trials, or when developing new observational 
assessment tools.
Despite numerous efforts to quantify pain, finding the optimal PD marker in infant pain 
studies remains a challenge.64 We still have to rely on surrogate end points in neonatal 
and infant pain research. Beecher posed the problem of scientists’ and clinicians’ wishes to 
express subjective outcomes in objective measures research already 50 years ago and this 
problem has not yet been mitigated in infant and neonatal pain research.65,66
Clinical trials
Clinical trials to evaluate dosing, efficacy, and safety of paracetamol and morphine in 
infants and newborns have been performed rather unconventionally compared to the sci-
entifically desired drug development process known from newly introduced drugs. Both 
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drugs are not new at all and were both given to newborns and young infants long before 
the first trials were performed. Several research groups started to evaluate the efficacy of 
analgesia during surgery67 and ventilation68 in the early 1990s. The first pharmacokinetic 
studies were also published.69 Figure 2 presents a schematic overview of steps toward 
evidence-based pharmacotherapy (the desired way is illustrated by the black boxes) and 
illustrates that clinical research with morphine and paracetamol has followed the opposite 
way so far (as the white boxes indicate). The gray boxes indicate factors that influence 
the white and black boxes. These factors require further research to optimize analgesic 
research in neonates and infants.
Figure 2. Schematic diagram of clinical research with morphine and paracetamol (white boxes) in practice. 
Clinically used 
analgesics 
(Morphine / 
Paracetamol) 
New potential 
analgesics 
Dose 
finding 
RCT 
Pain 
assessment 
validation 
Pop 
PK/PD 
Dose 
validation 
RCTs 
Pharmaco 
genetics 
Pop 
PK/PD Drug 
models 
Search for PD 
markers 
Follow-up 
Black boxes represent new drugs to be studied. Dose finding and population PK/PD modelling with both internal and 
external validation into clinical practice will be possible. RCT: randomized controlled trial; pop PK/PD: population 
pharmacokinetics/pharmacodynamics; PCM: paracetamol.
Before those trials, it was generally believed that neonates were not capable of experienc-
ing pain, therefore neonatal surgery often was performed without any analgesia.70 Anand 
et al.53 showed significantly lower hormonal stress responses in an analgesia group of oper-
ated newborns and better neurological outcome compared to placebo-treated neonates.
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These findings raised public and scientific interest in neonatal and infant pain research.71 
Consequently, several analgesic trials were performed since. These trials compared for 
instance the short-term outcomes of continuous and intermittent postoperative morphine in 
newborns and infants,72 postoperative rectal paracetamol vs. morphine,73 and routine mor-
phine with placebo during endotracheal ventilation in preterm newborns.74 See Tables 3a 
and 3b for the randomized controlled trials (RCTs) performed. Studies involving neonatal 
abstinence syndrome or without analgesic end point (for example endotracheal intubation 
facilitation) were excluded. 
In the earlier trials, dosing regimens were based on scarce neonatal pharmacokinetic 
data.69,89 Later trials used dosages based on population PK/PD models derived from these 
early trials.1,3 Besides optimizing dosing regimens in clinical practice, this evidence-based 
dosing improved the quality of analgesic clinical trials. In the Ceelie et al. trial3 for exam-
ple, a fairer comparison between paracetamol and morphine could be made, as morphine 
plasma levels across all ages were the same. In the Van der Marel et al. trial,73 which found 
no beneficial effect of paracetamol, the analgesic effect of paracetamol could have been 
masked by relatively high morphine plasma levels as their study population was very young.
Pharmacokinetics/pharmacodynamics
One of the major challenges in neonatal and infant drug research is the rapidly changing 
pharmacology in this age group. Due to the rapid developmental changes in both the phar-
macokinetics and the pharmacodynamics of a drug, a very heterogeneous population exists. 
These developmental changes will to a large extent determine the safety and efficacy of 
the studied drugs. Below, we will discuss the PK and PD of morphine and paracetamol as 
model drugs, to illustrate the importance of the changes throughout the first phase of life.
Morphine pharmacokinetics
Morphine metabolism
Drug metabolizing enzymes are classified by the reactions they catalyze: phase I reactions 
including oxidation, reduction, or hydrolysis and phase II reactions including glucuroni-
dation, sulfation, methylation, or acetylation. Traditionally, phase I enzymes such as the 
cytochrome P450 system have received more attention in pharmacological research than 
phase II enzymes such as the uridine diphosphate glucuronosyltransferase (UGT) isoen-
zymes.90 Morphine is glucuronidated by the UGT isoenzyme 2B7 into two active metabolites, 
morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G).91
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Table 3a. Randomized controlled trials with morphine in the young pediatric population.
Authors Year Sample 
size
RCT study design Outcome Major limitation(s)
Barker et al.76 1995 27 Low vs. high loading 
dose diamorphine
Adequate analgesia 
in both groups, 
high loading 
dose produced 
greater respiratory 
depression
Pain was not the 
primary end point 
and assessed by 
hormonal stress 
response
Wood et al.77 1998 88 Morphine vs. 
diamorphine in 
ventilated preterm 
neonates
Reduced stress 
response in both 
groups, more 
hypotension in 
morphine group
High morphine dose: 
200 mcg/kg in 2 
hours and 25 mcg/
kg.hr in preterm 
neonates
Pain assessed by 
hormonal stress 
response, no placebo 
control group
Anand et al.78 1999 67 Morphine vs. 
midazolam vs. 
placebo in ventilated 
preterm neonates 
(NOPAIN pilot trial)
Morphine and 
midazolam reduced 
PIPP scores, only 
morphine improved 
neurological outcome
High midazolam 
loading dose and 
high morphine 
maintenance doses
Lynn et al.79 2000 83 Morphine continuous 
targeting predefined 
plasma level vs. 
intermittent bolus in 
infants postsurgery
Continuous morphine 
provided better 
analgesia, morphine 
dosing was higher
Power calculation 
performed on 
ventilatory end point
Van Dijk et al. 73 2002 181 Morphine continuous 
vs. intermittent 
postsurgery aged 
0-3 year
No difference in pain 
scores or morphine 
consumption
No power calculation 
performed
Simons et al.75 2003 150 Morphine continuous 
vs. placebo in 
ventilated preterm 
neonates
No beneficial 
effect on pain, less 
IVH in morphine 
group, comparable 
composite outcome
Rescue morphine 
not based on pain 
assessments
Anand et al.80 2004 898 Morphine continuous 
vs. placebo in 
ventilated preterm 
neonates (NEOPAIN 
trial)
No beneficial 
effect on neurologic 
outcome measures
High morphine dose, 
no baseline for 
primary composite 
outcome
Carbajal et al.81 2005 42 Morphine boluses 
vs. placebo for 
procedural pain
No adequate 
analgesia in 
morphine group
Continuous morphine 
used for procedure
Taddio et al.82 2006 132 Morphine vs. placebo 
vs. tetracaine for 
central catheter 
insertion in 
premature neonates
Beneficial effect of 
both morphine and 
tetracaine
Morphine infusion 
allowed during 
intervention
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Table 3b. Randomized controlled trials with paracetamol in the young pediatric population.
Authors Year Sample 
size
RCT study design Outcome Major limitation(s)
Howard et al.83 1994 44 Paracetamol 
vs. placebo 
in neonates 
undergoing 
circumcision
Minimal effect of 
paracetamol 
Sweet solutions 
(both PCM and 
placebo) may have 
biased the results
Crying time as pain 
end point
Shah et al.84 1998 75 Paracetamol vs. 
placebo 90 minutes 
before heel lance
No effect of 
paracetamol
No validated pain 
assessment tool
Van der Marel et al.74 2007 54 Morphine vs. rectal 
paracetamol in 
postsurgery infants
No effect of 
paracetamol
High continuous 
morphine doses 
could have 
masked a clean 
paracetamol effect
Van Lingen et al.85 2001 122 Rectal paracetamol 
vs. placebo after 
vacuum extraction
No analgesic effect 
of paracetamol
No validated 
pain assessment 
tool, rectal 
administration 
unreliable in 
neonates
Bonetto et al. 2008 76 Oral glucose vs. 
oral paracetamol 
vs. topical EMLA vs. 
placebo
No effect of 
paracetamol
No comment on 
inter-observer 
variability of pain 
assessment tools
Badiee et al.86 2009 72 Oral paracetamol 
vs. placebo 90 
minutes before heel 
lance
No effect of 
paracetamol
Time of 
administration 
could possibly be 
too early: no clear 
PK data on start of 
study
Manjunatha et al.87 2009 18 Oral paracetamol 
vs. oral morphine 
vs. placebo 60 
minutes before ROP 
screening
No significant 
effect of morphine 
or paracetamol
Underpowered 
(calculated sample 
size was n=63)
Tinner et al.88 2013 123 Rectal paracetamol 
vs. placebo after 
forceps or vacuum 
extraction delivery
No effect of 
paracetamol
Only 2 doses of 
paracetamol: no 
steady-state
Seifi et al.89 2013 120 Oral 
acetaminophen 
vs. oral sucrose vs. 
placebo
No effect of 
paracetamol
Paracetamol 
administered 30 
minutes before ROP 
screening
Ceelie et al.3 2013 71 Morphine vs. IV 
paracetamol in 
postsurgery infants
Significant 
reduction of 
morphine 
consumption
Single-center study
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Maturation of morphine metabolism
Maturation of glucuronidation significantly influences the clearance of morphine in neonates, 
and most of the maturation process takes place in the first few months. A first indication 
came from the work of Lynn et al.92 in a group of post-cardiac surgery newborns and 
infants. Morphine clearance (expressed per kg bodyweight) was reduced in the first month 
of life but then increased to above adult levels. This pattern has been confirmed by two 
models derived from nonlinear mixed-effects modeling93 and clinical research, respectively. 
Bouwmeester et al.94 described that neonates in the first week of life required less mor-
phine and had higher morphine plasma concentrations than thereafter, at the same mg/
kg dosing regimen. These findings led to the development of a pharmacokinetic model for 
children up to the age of 3 years, including preterm neonates.2 This model shows that the 
morphine glucuronidation capacity and the clearance of the glucuronides are influenced by 
bodyweight in a nonlinear manner (bodyweight-based power equation with an exponen-
tial scaling factor of 1.44). Furthermore, before the postnatal age of 10 days, clearance 
and glucuronidation capacity was approximately 50% lower than thereafter. The resulting 
new model-based dosing advice recommended significantly lower doses, particularly for 
the youngest neonates, than the generally recommended 10–40 mcg/kg/h.1 It is thought 
therefore that neonates, especially aged <10 days, frequently may have been overdosed 
worldwide because of their low glucuronidation capacity. Figure 3 illustrates the plasma 
levels of morphine, M3G and M6G with the old vs. the new dosing regimen.
Model-based dosing
As this increase in clearance at day 10 after birth may be considered an arbitrary cut-off, 
Wang et al. further evaluated morphine pharmacokinetics and, using a wider population, 
developed a bodyweight-dependent exponent (BDE) model. The BDE model predicted 
clearance across the entire pediatric age range better than the model with a fixed exponent 
of either 0.75, the ‘classical’ allometric scaling exponent, or the age-dependent exponent 
of 1.44.95 While for neonates and infants below 1 year, the dosing schedule hardly differs 
between these two models, the next step in pediatric morphine research is evaluating this 
morphine dosing regimen based on the BDE model for other indications than postoperative 
pain after major noncardiac surgery.1 An observational study, for example, showed that 
higher dosages for NEC are required, most likely because this is a very painful condition.96 
These studies are important because so far the model-based dosing guidelines1,95 are only 
corrected for differences in PK and not for type of pain or severity of illness.
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Factors contributing to variability
Despite this progress in optimizing exposure to morphine in infants by correcting for struc-
tural pharmacokinetic differences as a result of developmental changes, there is still a 
large random variability in morphine clearance,97,98 with the highest variability in critically 
ill neonates. This may perhaps be attributed to variability in hepatic and renal function and 
hepatic blood flow, which in turn are influenced by positive pressure ventilation.99 Other 
factors such as therapeutic hypothermia,100 extracorporeal membrane oxygenation (ECMO) 
treatment101 or type of surgery92 may also be influential.
Furthermore, it cannot be excluded that genetic differences play a role here. As an example, 
single-nucleotide polymorphisms (SNPs) in the gene encoding for UGT2B7 have been shown 
to alter the pharmacokinetic parameters in adolescents.102 The drug transporter P-glyco-
protein, also known as MDR1 or ABCB1, may alter pharmacokinetics of morphine,103 as 
well as organic cation transporter 1 (OCT1) and ABCC3.104 So far, however, the effects of 
pharmacogenetics on pharmacokinetics in children have been rarely studied. Large sample 
sizes are needed to demonstrate a significant contribution of certain SNPs, because some 
SNPs occur only in 1–5% of the population. Sufficiently large sample sizes can most likely 
be achieved only in (international) multicenter studies.
Plasma concentrations vs. CNS concentrations
While to date most developmental changes in plasma pharmacokinetics of morphine have 
been characterized, another source of variability could be the distribution into the CNS. 
As the blood–brain barrier (BBB) prevents a 1:1 concentration ratio of many substances 
between brain interstitial fluid and plasma, targeting certain plasma concentrations may 
not adequately reflect desired CNS concentrations. Therefore, insight in the transport of 
morphine and its active metabolites across the BBB will contribute to individualized dosing. 
So far, only a few pharmacokinetic studies have considered concentrations in the cerebro-
spinal fluid (CSF) in humans, and such studies in children are rare, and completely missing 
in preterm newborns.
One of the studies in adults showed an increase of the CSF:plasma morphine concentration 
ratio from 0.2 to 0.6 over a two-hour period.105 Another study in patients with chronic use 
of oral morphine reported a ratio of 0.9,106 suggesting that reaching a steady-state bal-
ance between both compartments takes some time. In children, only one study so far has 
linked serum and CSF concentrations of morphine107 after a single infusion. The plasma:CSF 
concentration ratio was nearly 1:1 after 2 h. For M6G, this ratio remained about 10:1, 
as this metabolite is less lipophilic. This finding could be relevant, as it is being debated 
whether morphine itself or M6G is the most important pain relieving substance.108,109 M3G, 
which circulates in substantially higher concentrations than morphine and M6G, is thought 
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to lead to adverse effects such as hyperalgesia, particularly upon prolonged use when 
this metabolite accumulates.110,111 Studies have shown that M3G accumulates in critically ill 
patients, even after a 33% dose reduction.111,112 Morphine plasma levels decreased, but 
M3G levels remained the same after this dose reduction, indicating that M3G could be 
highly responsible for side effects in this specific population. This is an important finding 
and the role of M3G in morphine safety should be studied further.
Even though attempts have been made to describe the CNS pharmacokinetics of morphine, 
the full picture is not yet clear. The BBB is changing throughout childhood, and the fact that 
the P-glycoprotein drug transporter is less readily available in the neonatal brain could 
mean an increase in diffusion of morphine into the brain.103,113 Unfortunately, no human data 
are available to confirm this. Animal models using microdialysis have shown a higher mor-
phine influx in premature sheep than in adult sheep.114 Also, morphine efflux out of the brain 
is reduced in premature rats compared to adult rats.115 In pigs, the plasma:CSF transfer 
ratio decreased from 0.7 to 0.5 during the first 6 weeks of life, which was not statistically 
significant.116 Nevertheless, data of animal models cannot easily be extrapolated to humans, 
notably in view of the considerable differences in BBBs across species.117 Moreover, it is 
very likely that the BBB and related morphine diffusion have undergone changes in CNS 
disorders such as meningitis and encephalitis.
Morphine pharmacodynamics
PK–PD relationship
The pharmacokinetic research described above centralized the plasma concentrations 
of morphine, but unfortunately the pharmacodynamic effects of morphine greatly vary 
between infants, even at similar plasma concentrations. It is known that analgesic needs in 
general depend on the type, severity and duration of pain. In relation to postoperative pain, 
morphine requirements depend on duration and severity of surgery but also on the type of 
surgery, such as cardiac or abdominal surgery.3 Newborns operated for NEC need much 
higher morphine dosages postoperatively than newborns operated on for other conditions.96 
Efforts to establish a minimal effective plasma concentration or a therapeutic window have 
not led to a clear target118 and a concentration–response curve is lacking.119 Future research 
should aim for specific plasma targets for different types of pain or procedures.
Development of morphine sensitivity
Postmenstrual age may play a role in morphine sensitivity, due to maturation of nociceptive 
pathways. Morphine exerts its effects mainly on the mu-opioid receptor and to a lesser 
extent on the kappa and delta opioid receptors.120 Sensitivity to morphine seems to be 
higher at neonatal age, although this has been suggested merely in rat models.121 However, 
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human neonates3 below the age of 10 days needed significantly less rescue morphine than 
older neonates despite similar morphine plasma levels.1 This could be due to less capability 
of pain expression, or to a higher BBB permeability for morphine. Another explanation may 
lie in the postnatal reorganization of opioid receptor expression. In rats,121 during the first 
3 weeks of rat life, the mu-opioid receptor expression is downregulated in the A fibers, but 
remains unchanged in the C fibers. Also, in this period, the central terminals of the A fibers 
are found in the superficial dorsal horn, whereas at adult age only C fibers project into the 
superficial dorsal horn and the A fibers project in the deeper lamina, suggesting a higher 
morphine sensitivity in the early weeks of life.
Pharmacogenetics
Pharmacogenetics may also play a role in morphine sensitivity. In human neonates, a com-
bination of SNPs in two different genes, OPRM1 and COMT, was found associated with 
postoperative morphine consumption.122 The same polymorphisms are associated with the 
severity of neonatal abstinence syndrome.123 While OPRM1 is the coding gene for the 
mu-opioid receptor, COMT is a regulatory gene of mu-opioid receptor expression.124 If both 
expression and function of the mu-opioid receptor are being disrupted by gene mutations, 
this could diminish the response to opioids. 
Paracetamol pharmacokinetics
Paracetamol is different from morphine with respect to safety and efficacy aspects. 
Paracetamol is a weaker analgesic, but on the other hand has a more favorable side 
effect profile. Still, the only side effect to take into account is probably more lethal than 
the opioid-induced respiratory depression, namely acute liver failure. In Western coun-
tries, paracetamol overdose is the most common cause of acute liver failure in adults and 
children.125,126 However, when kept within the therapeutic range, paracetamol provides 
analgesia as well as antipyrexia.
Paracetamol metabolism
Paracetamol is mainly metabolized by phase II enzymes to paracetamol-glucuronide and 
paracetamol-sulfate. Only a small fraction (1–4%) is excreted unchanged by the kidneys. 
The remainder is being metabolized to the hepatotoxic metabolite NAPQI through the action 
of cytochrome P450 (CYP) enzymes such as CYP2E1, CYP1A2, CYP3A4, and CYP2A6.127 
Under normal circumstances, reduced glutathione (GSH) neutralizes NAPQI very rapidly 
and the inactive cysteine and mercaptopuric metabolites are being formed and excreted 
renally. See Figure 4 for the metabolic pathways of paracetamol.
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Figure 4. Metabolic pathways of paracetamol. 
Reprinted with permission from: Roofthooft, D.M.E., Paracetamol and Preterm Infants: a painless liaison? PhD 
thesis, 2015, Erasmus University.
Maturation of paracetamol metabolism
Glucuronidation of paracetamol is very low in preterm infants and matures during early 
childhood, thus simultaneously increasing the relative contribution to paracetamol elimina-
tion128 whereas the sulfation route remains fairly constant.129 CYP enzymes mature during 
early infancy as well, but data on NAPQI formation in neonates are lacking. One modeling 
study in 47 patients could not attribute any clearance to oxidative pathways.128 However, as 
renal clearance is lower in neonates compared to adults, renal metabolite clearance may 
be reduced.130 Expression of CYP2E1, the main isoenzyme responsible for NAPQI formation, 
increases during the first three postnatal months.131 Whether NAPQI formation is reduced in 
this period remains unclear, but clinically there are no clues of NAPQI formation in neonates 
leading to hepatotoxicity, even at higher doses.132 
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The pharmacokinetics of paracetamol in children for different administration routes is well 
described.133–138 Population PK studies showed that weight is the most important predictor 
of paracetamol clearance in neonates.130,139 In a BDE model, this relationship was found to 
be nonlinear between children within the neonatal range and adults.4
Factors contributing to variability
There is, however, a great interpatient variability in paracetamol clearance.129 For instance, 
clearance is lower in preterm neonates than in term neonates.140 Paracetamol is being 
metabolized by many enzymes, thus the current role of pharmacogenetics is small. SNPs 
and mutations in metabolizing enzymes have been described, but often have not been 
studied in relationship to paracetamol.141 Whether genetic variability influences the PK of 
paracetamol is hard to tell. If one or two metabolizing enzymes lose function due to genetic 
polymorphisms, other enzymes may take over. Differences in activity of transporters, epi-
genetic phenomena, and organ-specific activity of metabolizing enzymes probably all play 
a role. System biology-based modeling strategies may contribute to insight in the complex 
interactions between ontogeny, metabolic functions, and genetics.142
 
Paracetamol pharmacodynamics
Unknown site of action
While the pharmacokinetic basis for an evidence-based paracetamol dosing regimen has 
been established,133–138 much groundwork remains to be done on the pharmacodynamics. 
For one thing, the exact mechanism of action remains unclear, even after comprehensive 
research.127, 143 Its primary target has been suggested to lie within the CNS, as CSF concen-
trations corresponded better with analgesic response than did plasma concentrations.144 In 
contrast, another study showed that analgesic response occurred earlier than changes in CSF 
plasma level.145 A delay of the onset of action of the drug, a phenomenon called hysteresis, 
could perhaps explain why it is difficult to relate actual plasma and/or CSF levels to a phar-
macodynamics end point such as temperature or pain score. Therefore, Gibb and Anderson 
recommend to use indirect-response models to describe paracetamol PK and PD.146
PK–PD relationship
As the mechanism of action is unclear, factors influencing the pharmacodynamic effects of 
paracetamol in children are hard to establish. The administration route, though, certainly 
has an impact on its effectiveness3,73,137,147 because of more favorable pharmacokinetics of 
the oral and intravenous routes compared to the rectal route. 
A dose-dependent response in children has been suggested when paracetamol was adminis-
tered as treatment for both pain and fever.148,149 In general pediatrics, an adequate analgesic 
target plasma level of 10 mg/L is suggested.147 It is unclear whether this target fits neonates 
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and infants. Validation of these targets using validated assessment scales is necessary. More-
over, the question remains why there is a great variability in response. Whether this can be 
attributed fully to the action of paracetamol or to other factors such as the interpretation of 
the pain assessment tool needs to be studied further, especially as most trials studying the 
morphine-sparing effect of acetaminophen have been performed in older children.150–152 
Pharmacogenetics also does not help explain variability in response. This is mainly due to 
the lack of knowledge on the mechanism of action, impairing the search for relevant genes.
Short-term and long-term side effects
Morphine
Short-term effects
Morphine has several side effects, observed not only in adults but even more so in children 
and in neonates, such as respiratory depression, nausea, vomiting, constipation, urinary 
retention, and hypotension. Hypotension in neonates, who are more vulnerable to changes 
in blood pressure,79 may have severe consequences such as intraventricular hemorrhage 
(IVH) or periventricular leukomalacia (PVL). On the other hand, pain leads to an increased 
blood pressure which could also contribute to these sequelae. In a large RCT, the incidences 
of PVL and IVH were significantly higher in the placebo group compared to the morphine 
group.79 In another RCT using lower morphine doses, IVH was also less frequent.74 These data 
implicate that adequate analgesia may protect the brain on the short term. Both clinical 
trials concluded, however, that routine administration of morphine in ventilated newborns 
should not be recommended.
An important challenge is detecting side effects of analgesics in neonates and infants, as 
these can overlap with symptoms of their underlying disease. Structural proactive screening 
for side effects should take place in analgesic trials in the neonatal and infant population.
Long-term effects
Drugs administered when the child’s brain is still developing possibly interfere with neuro-
development.153–155 This may especially be applicable to opioids, which directly act on the 
CNS. Moreover, in premature neonates, this interference may be even larger as the third 
trimester of gestation is important in CNS maturation. The current literature is not consistent 
regarding the long-term outcome of neonates receiving opioids. Some studies suggest 
alterations in neurological anatomy or structure,153,154,156 but neuropsychological outcomes 
seem to be not affected by morphine exposure at neonatal age.154, 157,158 Follow-up trials 
cannot include a control group, as adequate analgesia is ethically obligatory and keeping 
neonates without opioids is highly undesirable. In the vulnerable preterms admitted to NICU 
who still receive a large amount of morphine,159 morphine should not be considered the only 
causative factor for abnormal neurodevelopmental outcome.156,160 
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Schuurmans et al. suggest a more standardized approach with large patient samples to 
detect small outcome differences.161 Data about analgesics and long-term effects from such 
large studies are not yet available. Standardization of long-term follow-up should include 
clinically relevant end points, preferably neuropsychological outcomes, especially executive 
function skills, as they determine a person’s functioning in daily life.158,162
Paracetamol
Short-term effects
Paracetamol is regarded very safe on the short term. The major short-term side effect is 
acute liver failure, but no major hepatotoxic events have been reported so far in neonates.132
Long-term effects
Recent studies on atopy development associated with paracetamol exposure in early 
childhood are reason for concern163–165 although they have important methodological lim-
itations.166,167 Prospective studies should be performed to establish this potential causal 
link.168 Such trials should at least incorporate pharmacogenetic assessment,169,170 although 
fundamental research on the mechanism(s) of action should pave the way for targeted 
pharmacogenetic research.
Long-term effects of pain
An important other challenge regarding the long-term effects of analgesics, is the long-
term effect of pain itself. Pain exposure during early infancy also leads to alterations in 
brain structure171,172 and affects pain sensitivity in later life.173 Finding an optimal balance 
between accepting long-term opioid effects, on which the literature is still divided,154,174,175 
and the long-term effects of pain itself, is not yet feasible. Finding this balance could be 
supported by either more optimal dosing strategies, such as always starting with the lowest 
dose possible and up-titrate on the effect, taking into account inter-individual variability, 
or introducing alternative analgesics. This should be the aim of neonatal pain research in 
the near future, including larger sample size studies.
Premature neonates
Special attention should be paid to (extreme) premature neonates when it comes to both 
pain and developmental clinical pharmacology. In the vulnerable premature neonate, pain 
is not only ‘an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage,’ but is harmful on both the 
short and long term.171–173 These children daily undergo many potentially painful proce-
dures,176–178 while it is still unclear how to prevent or treat this pain optimally. What is more, 
the developing brain of the preterm infant is probably extremely vulnerable for the toxic 
effects of pharmacological agents, such as morphine.153 
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Evidence from animal and human studies suggests an inverse relationship between postcon-
ceptional age and pain sensitivity, as measured by the reflex withdrawal test using von Frey 
hairs. However, whether this also means an increased pain sensation is doubtful as cortical 
pain responses seem to increase with increasing gestational age.179 Nevertheless, little is 
known about the premature cortical pain processing and consequently the statement that 
(extreme) premature neonates feel more pain than their term peers is hardly based on solid 
methodological evaluation. At present, the techniques to investigate these phenomena are 
far from ideal. Therefore, investigators developed pain assessment tools based on the heel 
lance as a standardized painful procedure. Heel lancing is associated with an acute pain 
response that differs from more prolonged continuous distress and pain responses that are 
associated with preterm neonatal care. 
The pain experienced by neonates should be treated with adequate analgesics and prefer-
ably be prevented using the concept of preemptive analgesia. Morphine is recommended in 
several guidelines for the treatment of severe pain in premature neonates.12,180 The question 
arises whether the clearance of morphine differs between premature neonates and term 
neonates and if recommended doses can be used in extreme premature neonates. A recent 
study in extreme low birth weight neonates181 compared five population PK models applied 
to their own prospective dataset of PK samples. The model based on data from extreme 
low birth weight infants182 fitted best with their own dataset. The authors concluded that 
not only bodyweight but also maturation (including hepatic and renal function) contributes 
significantly to clearance, independently of bodyweight. 
For paracetamol, clearance changes nonlinearly with bodyweight.4 In premature neonates, 
the paracetamol clearance matures more slowly than morphine clearance, and this could 
be attributed to the complex metabolism of paracetamol.139 However, robust PK data in 
extreme preterm neonates are scarce183 and in this population, more research is warranted 
on PK and its relation with both the analgesic effects and short- and long-term neurode-
velopmental outcomes.
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EXPERT COMMENTARY
Neonatal and infant pain management and research have taken an extensive scientific jour-
ney so far. However, there is still a long way to go. The complex multimodality of pain comes 
along with major challenges in research. The first challenge is the assessment of pain. While 
current pain assessment tools merely reflect the outer circle of Loeser’s pain model, i.e. pain 
behavior, opioids and paracetamol act mainly on the nociception circle or the pain circle. 
This means that end points in pain research in children can only be surrogate end points. To 
measure analgesic effectivity, we should aim at biomarkers reflecting the direct effect of 
analgesics in the CNS. Attempts have been made with pupillometry, skin conductance, and 
HRV. These physiological, objective markers reflect sympathetic nervous system activity and 
are closer to the CNS. NIRS and somatosensory evoked potentials reflect the perception of 
a stimulus by the CNS, and are therefore promising in pain research. Multimodal studies, 
such as performed by Slater et al.27 and Hartley et al.184 demonstrate lack of correlation 
between nociceptive brain activity and behavior at least in an experimental procedural 
pain study, which is a clear call for more clinical research.
The other major challenge is optimal pharmacological pain treatment. Healthcare profes-
sionals need to take two important steps: choosing the right drug and defining the right 
dose. In order to choose the right drug, it is necessary to define type of pain first. From the 
clinical trials performed so far in neonates and infants, it seems that morphine is not the 
best choice for procedural and chronic pain, but has proven effectiveness for postoperative 
pain. Many clinics use fentanyl as an alternative to morphine and fentanyl or alternatively 
one of the synthetic derivatives is proven effective for procedural pain. Paracetamol (Table 
3b) seems to have no effect on procedural pain and a slight effect on postoperative pain. 
It is unknown whether it is effective for chronic pain. However, again it should be taken into 
account that these trials all have used surrogate end points and there is still a long way to 
go to determine true effectivity for each type of pain. 
The choice of drugs is also heavily influenced by the safety profile, and both morphine 
and paracetamol have been ascribed long-term negative effects without convincing evi-
dence.156,160 These speculations call for well-designed trials with long-term outcomes as 
primary end points. Studies have been performed in different patient groups but with 
relatively small sample sizes and therefore underpowered to detect small differences in 
neurological outcome.154,185,186
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Dosing is also a major challenge due to both the rapid changing pharmacokinetics and 
pharmacodynamics in neonates and infants. Many population-based pharmacokinetic 
models have been developed for this population and have provided important data on 
the maturation of drug clearance. Still, there is no clear PK–PD relationship for morphine. 
PK is mainly focused on plasma levels, but PD effects are the result of morphine levels in the 
CNS. Further insight in the plasma–CNS relationship is necessary to define target plasma 
levels. The same holds for paracetamol, for which the PK is well described for term neonates 
and infants but a PK–PD relationship also has great variability.
FIVE-YEAR VIEW
Pain assessment could possibly be improved by techniques reflecting CNS activity such as 
NIRS27,28 or aEEG,29 although the analyses and interpretations of these techniques are yet far 
from optimal to recommend their clinical use as pain measurement instruments. Functional MRI 
seems a promising method to look for specific brain areas involved in pain processing and 
the role of analgesics on these pain areas. Still, it should be kept in mind that activity in these 
areas does not always reflect pain, as these areas are also responding to stimuli in patients 
not capable of experiencing pain.187 This technique should be further developed and applied 
in order to compare the ‘true’ effect of different analgesics, and comparative studies with 
both behavioral assessment tools, fMRI and/or NIRS/SSEP/aEEG may provide further insight 
in how to optimize pain assessment. Meanwhile, behavioral pain assessment tools are not to 
be forgotten. Application of the Item Response Theory63 may identify the most pain-specific 
items of pain assessment scales and further improve bedside pain assessment.
Furthermore, interactions between analgesics, for example paracetamol and opioids, deserve 
attention. A study already found that the use of paracetamol could reduce infants’ opioid 
consumption by 66% after major noncardiac surgery.3 In our center, a similar trial is ongoing 
in cardiac surgery patients (the PACS trial; Dutch Trial Registry ID NTR5448). Trials like these 
could be a great opportunity to address the issue of long-term effects of both analgesics.
The increasing knowledge of the ontogeny of drug metabolizing enzymes and drug trans-
porters provides a good basis for a system-based approach of pediatric pharmacokinetics. 
This approach enhances the development of both individualized evidence-based pharmaco-
therapy of currently existing drugs and new analgesic drugs for children. Knowledge gained 
in the pharmacokinetic modeling of one drug could be applicable to other drugs as well. 
When specific properties such as logP and pKa of other drugs are applied to such models, 
clearance of these drugs can be predicted. Building such physiologically based pharmaco-
kinetic models may save the tremendous effort of describing PK of all drugs separately.188
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Other analgesics are also being introduced to neonatal and infant pain management. This 
review focused on morphine and paracetamol as model drugs, but fentanyl is also often 
used in the NICU.12,189,190 Current use of fentanyl is based on little evidence, and its PK is 
highly variable in preterm neonates.191 Studies performed with fentanyl are small.192–194 
This is a problem in most clinical trials involving neonates, especially in the NICU population. 
Therefore, to improve clinical research in this population, multicenter studies, if possible in 
established international consortia, could increase sample sizes. If this is not feasible, the 
required sample size may be reduced with the use of comparative effectiveness studies 
rather than superiority trials.195 
Another opioid which seems promising, especially for application in procedural pain, is 
remifentanil.196–198 This very-short-acting opioid is being metabolized by plasma esterases, 
independent of organ function or age. However, it does not automatically ‘do away with’ 
the dosing problem as its side effects such as chest wall rigidity can be age dependent.197 
Caution is required with the clinical application of remifentanil.
Last, the focus should be set on long-term effects. We do not know yet which analgesic 
is most harmful in the long term, but must not forget pain is harmful anyway. Finding the 
optimal balance remains challenging199 and calls for standardized long-term follow-up in 
neonatal pain trials.
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ABSTRACT
Introduction: Sedation is an essential part of paediatric critical care. Midazolam, often 
in combination with opioids, is the current gold standard drug. However, as it is a far-
from-ideal agent, clonidine is increasingly being used in children. This drug is prescribed 
off-label for this indication, as many drugs in paediatrics are. Therefore, the CLOSED trial 
aims to provide data on the pharmacokinetics, safety and efficacy of clonidine for the 
sedation of mechanically ventilated patients in order to obtain a paediatric-use marketing 
authorisation.
Methods and analysis: The CLOSED study is a multicentre, double-blind, randomised, 
active-controlled non-inferiority trial with a 1:1 randomisation between clonidine and mid-
azolam. Both treatment groups are stratified according to age in three groups with the 
same size: <28 days (n=100), 28 days to <2 years (n=100) and 2–18 years (n=100). 
The primary end point is defined as the occurrence of sedation failure within the study 
period. Secondary end points include a pharmacokinetic/pharmacodynamic relationship, 
pharmacogenetics, occurrence of delirium and withdrawal syndrome, opioid consumption 
and neurodevelopment in the neonatal age group. Logistic regression will be used for the 
primary end point, appropriate statistics will be used for the secondary end points.
Ethics: Written informed consent will be obtained from the parents/caregivers. Verbal or 
deferred consent will be used in the sites where national legislation allows. The study has 
institutional review board approval at recruiting sites. The results will be published in a 
peer-reviewed journal and shared with the worldwide medical community.
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INTRODUCTION
Unlicensed and off-label drug use
In Europe, <30% of marketed drugs include results from paediatric clinical trials and other 
information on paediatric use in their documentation (Summary of Product Characteristics 
(SPC) or Product Leaflet).1 This results in widespread off-label use in paediatrics, especially 
in the case of old drugs that have never received a paediatric authorisation. Off-label pae-
diatric use (including all the uses not listed in the SPC2) in Europe accounts for 45%–60% of 
the total number of prescriptions, with rates of up to 90% in patients admitted to neonatal 
(NICU) or paediatric intensive care units (PICU).3
The entry into force of the Paediatric Regulation in 20074 gave an important stimulus to 
support the development of medicines for children by introducing a specific measure to 
favour work on off-patent medicines, the so-called Paediatric Use Marketing Authorisation 
(PUMA). A PUMA application should include the submission of paediatric data in accordance 
with an agreed Paediatric Investigation Plan (PIP).
According to article 40 of the Regulation, the European Commission (EC) reserved funds 
‘to develop off-patent medicinal products with recognised therapeutic interest for chil-
dren and included in a ‘Priority List’ adopted by the European Medicines Agency (EMA) 
through its Paediatric Committee (Seventh Framework Programme for Research HEALTH—
(2007–2013) Programme area—topic 4.2–1). Among 20 projects approved,5 the CLOSED 
project was granted with the aim to develop an age-appropriate formulation of clonidine 
for sedation in PICU, in line with the EMA ‘Revised Priority List for Studies into Off-Patent 
Paediatric Medicinal Products’ 2012.6 In order to specifically meet this therapeutic need, 
a comprehensive development plan in the form of a PIP was submitted to the EMA Paedi-
atric Committee (PDCO) in July 2012 and approved in January 2013. In March 2015, a 
modification of the PIP was proposed after the finalisation of the clinical study protocol. 
This modification was approved by the PDCO in August 2015.
Analgosedation in PICU
Approximately 2% of all paediatric patients admitted to hospital require treatment in 
PICU.7 Most PICU admissions are unplanned emergencies, mainly in the context of congenital 
heart diseases (40%), respiratory diseases (20%), major trauma (15%) and neurological 
problems other than trauma (<10%).8
Often, mechanical ventilation is required for facilitating recovery after major surgery or for 
treating respiratory failure. In most of these cases, analgosedation using potent opioids and 
sedatives is mandatory to reduce metabolic rate and oxygen demand, assist mechanical 
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ventilation, avoid inadvertent self-extubation and lower anxiety and distress.9,10 To this 
effect, a variety of agents are used in NICU and PICU, such as opioids, GABA-receptor 
agonists, N-methyl-d-aspartate receptor (NMDA)-receptor antagonists and α2-receptor 
agonists.11
Opioids
The main opioids used in PICU and NICU are morphine, fentanyl and remifentanil. Opioids 
bind to the μ-receptor in the central nervous system (CNS), and provide analgesia as well 
as sedation.
GABA-receptor agonists
GABA receptors have an inhibitory effect on the CNS. Benzodiazepines agonise these 
receptors and therefore have sedative, anxiolytic and anticonvulsant properties. Disad-
vantages are paradoxal reactions (agitation and confusion) and tolerance and withdrawal 
after prolonged use.
Propofol is a unique agent with GABA-ergic properties as well as anti-NMDA and sodium 
channel blocking effects. Propofol is not suitable for long-term sedation, due to the per-
ceived risk of propofol infusion syndrome, a metabolic derangement accompanied by 
severe metabolic acidosis, hyperkalaemia, hyperlipidaemia, rhabdomyolysis and organ 
failure, associated with an increased risk of mortality.12 
Midazolam
Midazolam is the most widely used sedative agent in PICU. It is a short-acting benzodi-
azepine (Tmax of 5–10 min after intravenous injection) with a half-life of 1–3 hours (up to 
12 hours in neonates). Besides sedation and anxiolysis, midazolam also provides antero-
grade amnesia, thus minimising children’s recall of unpleasant experiences after a PICU 
admission.13 Midazolam is mainly metabolised to the equipotent metabolite 1-OH-midaz-
olam (1-OH-MDZ), and then glucuronidated to the renally excreted 1-OH-MDZ-glucuronide. 
Its main adverse effects include tolerance, dependence and withdrawal syndrome following 
discontinuation.
Clonidine
Clonidine agonises the α2-adrenergic receptor. The reduced sympathetic outflow14 in the 
CNS results in sedation, anxiolysis and analgesia.15,16 Because of its analgesic properties, 
it has been used as an adjunct in surgical procedures as premedication or as a supple-
mentary agent in regional anaesthesia.17 The reduction of sympathetic outflow associated 
with clonidine may have specific benefits in critically ill children. A2 agonists can improve 
neurological outcome associated with ischaemic cerebral injury,18–20 the mechanism of action 
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of which is unclear but may be due to suppression of extracellular glutamate and aspartate 
release during energy failure.21 Recent data have also demonstrated that preconditioning 
before the insult can both reduce infarct size and improve neurological outcome after the 
insult.22 Surgery and critical illness are associated with a variety of stress responses, which 
can result in organ dysfunction23: renal function deteriorates after both adult and paediatric 
cardiac surgery, and this effect is due in part to the increase in sympathetic outflow and the 
rise in circulating vasoconstrictors such as norepinephrine, vasopressin and angiotensin.24,25 
Clonidine has been demonstrated to suppress these responses and prevent the associated 
decline in renal function after adult cardiac surgery.26 In addition, clonidine has independent 
local effects on tubular function which promote both diuresis and natriuresis.27 In terms of 
cardiovascular responses, reduction in stress responses by α2-agonists have been shown to 
reduce perioperative myocardial ischaemia in adults undergoing cardiac and non-cardiac 
surgery.28 As the mechanism of action of clonidine is very different from the GABA-agonist 
midazolam, the hypothesis is postulated that it may be less associated with paediatric 
delirium and withdrawal syndrome. Moreover, clonidine is one of the agents used for the 
treatment of withdrawal syndrome.29
Previous clinical trials
Clonidine is commonly used off-label in paediatric anaesthesia and intensive care med-
icine. Its use is recommended for the sedation of critically ill children in PICUs by the UK 
and German consensus guidelines12,30 and local hospital guidelines across Europe. Unfor-
tunately, despite this widespread use of clonidine, there are limited data on efficacy, 
dose requirement and safety when used for sedation on PICUs. A number of studies have 
been performed,31–35 however, to overcome this knowledge gap (see table 1 for a short 
overview).
Study aims
For the purpose of sedation of intubated and mechanically ventilated paediatric patients, 
this clinical study sets out to provide the data needed for a PUMA application for the use 
of clonidine in PICU patients: Data on efficacy and safety of clonidine compared with 
midazolam.
Pharmacokinetic (PK) data on both clonidine and midazolam in critically ill children and 
adolescents, using a population-based approach. Together with the development of age-
adapted and weight-adapted formulations of clonidine, as part of this study, data on 
quality and stability of these new formulations will also be generated.
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Table 1. An overview of paediatric studies involving clonidine for sedation in the intensive care unit. 
Study Sample size and age Design Outcome
Ambrose et al.31 N=30, 0-10 years Three-step: IV low-dose vs. 
high-dose (variable dose 
together with midazolam), 
3rd group fixed dose
No adverse effects on 
haemodynamics, sufficient 
sedation in combination with 
midazolam
Arenas-Lopez et al.32 N=24, 0-5 years Prospective cohort study, 
oral clonidine as additive to 
morphine/lorazepam
Opioid- and 
benzodiazepine sparing, 
safe and effective
Wolf et al.33 N=129, 0-15 years Double-blind, randomised 
controlled trial of IV 
clonidine vs. midazolam
No difference in effectivity, 
underpowered due to 
recruitment problems
Hünseler et al.34 N=219, 0-2 years Double-blind, randomised 
controlled trial of IV 
clonidine vs. midazolam
Opioid- and 
benzodiazepine-sparing in 
neonatal age group
Duffett et al.35 N=50, 0-18 years Double-blind, randomised 
controlled trial of oral 
clonidine vs. placebo in 
addition to physician-driven 
sedation
No significant difference 
in effectivity, study with 
clonidine clinically feasible
METHODS/DESIGN
Study design
The CLOSED study is a multicentre, double-blind, randomised, active-controlled non-inferior-
ity trial with a 1:1 randomisation between clonidine and midazolam. Both treatment groups 
are stratified according to age in three groups with the same size: <28 days (n=100), 28 
days to <2 years (n=100) and 2–18 years (n=100). The primary end point is defined as 
sedation failure within the study period.
Patient recruitment
Patients in five different European Union (EU) member states (Czech Republic, Germany, Italy, 
The Netherlands and Sweden) will be recruited. Patients (neonates ≥34 gestational weeks and 
children <18 years) eligible for inclusion in the trial, according to inclusion and exclusion cri-
teria, will be screened for possible enrolment (see table 2 for inclusion and exclusion criteria).
Surgery schedules will be screened on a daily basis for possible patients expected to be 
admitted to the intensive care unit (ICU). These patients and parents will be identified, 
approached, informed and enrolled prior to surgery by study responsible doctors and/
or nurses. Patients eligible for inclusion transferred to the centres will be identified by 
the transport team. Patients admitted to the PICUs will continuously be screened by PICU 
medical staff to identify patients possible for enrolment. Parents of these eligible patients 
will be approached, informed and enrolled by study-responsible doctors and/or nurses.
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Table 2. Inclusion- and exclusion criteria for the CLOSED trial.
Inclusion criteria Exclusion criteria
Aged from birth (GA ≥34 weeks) to <17 years, 11 
months and one week
Body weight <1200 g or GA <34 weeks
(Expected) admission to the PICU Body weight ≤3 kg AND age ≥28 days
Body weight <10 kg AND age ≥2 years
Body weight >85 kg
(Expected) indication for mechanical ventilation (both 
invasive and non-invasive)
Clonidine within last 7 days prior to admission*
Sedation >72 hours prior to screening
Anticipated need for continuous sedation ≥24 hours Known hypersensitivity to clonidine, midazolam, 
morphine or propofol or any of their formulation 
ingredients and their rescue medication
Informed consent (or deferred consent if applicable) Administration of continuous muscle relaxants or 
other contra-indicated drugs
Informed assent if applicable Post-resuscitation within 24 hours or therapeutic 
whole-body hypothermia
CPAP or ECMO treatment
Severe organ insufficiencies:
•	 Renal failure according to pRIFLE63 or nRIFLE64 
criteria
•	 Cardiac failure as defined by modified Ross class 
3 or 4
•	 Arterial hypotension according to guidelines62
•	 Circulatory failure as defined by Goldstein 
criteria59**
Traumatic brain injury or other intracranial pathology 
including mental retardation and status epilepticus
Phaeochromocytoma, acute asthma or paralytic 
ileus***
Severe bradyarrhythmia 
Pregnancy
Known arterial hypertension in medical history
Previous participation in this trial at any time or 
previous participation in drug trial within last 3 
weeks
Declined informed consent from parent(s)/legal 
guardian(s)
CPAP: continuous positive airway pressure; ECMO: extracorporeal membrane oxygenation; GA: gestational age.
*) This exclusion criteria has been removed in the second protocol amendment 
**) These criteria have been modified in the second protocol amendment and allow for use of inotropes/vaso-
pressor drugs
***) The exclusion criteria acute asthma and paralytic ileus have been removed in the second protocol amendment
Children are often admitted to PICU/ NICU in an emergency setting. Urgent action will most 
likely be required and the subject’s parent(s)/legal guardian(s) may not be immediately 
available to give consent. An example of this is when a critically ill baby is delivered by 
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caesarean section, the mother may still be under anaesthesia while another parent/legal 
guardian of the child may not be present. Therefore, given the nature of the trial, espe-
cially considering that ICU patients are often admitted as a result of emergency, deferred 
consent/assent, as described in Article 35 of the new European Regulation on clinical trials 
(EU) No 536/2014 of the European Parliament and of the Council,36 is foreseen if allowed 
by local legislation, as described in section ‘Ethical considerations’. This allows for the child 
to be enrolled in the trial before the parent(s)/legal guardian(s) are able to give consent, 
which is then sought once they are available. If, subsequently, deferred consent is withheld, 
the subject is removed from the study but a record will remain in the subject’s medical notes.
Study treatments
First, it was necessary to define the dosing scheme so that appropriate drug concen-
trations could be used to maintain double blinding. A plasma clonidine concentration of 
around 2 μg/L gave adequate sedation combined with morphine infusion in ventilated 
PICU patients,32 and 2 μg/L clonidine concentration also drops the Bispectral Index to 71 
in adults.37 Clonidine has a long elimination half-life (16.9 hours in neonates, 11.4 hours in 
infants and 7.4 hours in children38), so loading doses are proposed. It was therefore decided 
that loading and maintenance doses aimed at achieving steady-state concentrations of 
around 2 μg/L would be aimed for, and this scheme was designed by a PK/pharmaco-
dynamic (PD) expert working group within the CLOSED consortium. Based on these doses, 
a similar dose scheme of midazolam was designed that would maintain double blinding.
The agreed dosing scheme consists of 15 min loading doses followed by a maintenance 
infusion rate. Increases or decreases, based on the evaluation of COMFORT-B and Nurses 
Interpretation of Sedation Score (NISS) score, in infusion rate are permitted, and preceding 
any increase, a loading dose over 15 min is specified. There are also compulsory lock-out 
times between each dose escalation or de-escalation to allow for new steady-state condi-
tions to be approached. Participants will follow the dosing regimen, with 1 unit meaning 1 
μg for clonidine, or 100 μg for midazolam:
First bolus (T=0). Initial loading dose is 2 units/kg over 15 min and the following continuous 
infusion 1 unit/kg/hour will be administrated to all patients followed by 15 min lock-out 
period.
Second bolus. If insufficient sedation after the first lock-out period, the second loading 
dose is 2 units/kg over 15 min and the following continuous infusion 1 unit/kg/hour will be 
administrated with a 15 min lock-out period.
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Third bolus. If insufficient sedation after the second lock-out period, the third loading dose 
is 2 units/kg over 15 min and the following continuous infusion 1.5 units/kg/hour will be 
administered with a minimum of 105 min lock-out period.
Fourth bolus. If insufficient sedation after the third lock-out period, the fourth loading dose 
is 2 units/kg over 15 min and the following continuous infusion 2 units/kg/hour will be 
administered followed by a 105 min lock-out period.
Fifth bolus. If insufficient sedation after the fourth lock-out period, the fourth loading dose 
is 2 units/kg over 15 min and the following continuous infusion 2 units/kg/hour will be 
administered with 24 hours lock-out period.
Sixth to 11th bolus. If insufficient sedation after 24 hours lock-out period, the 6th–11th 
loading dose of 2 units/kg over 15 min and the following continuous infusion 2 units/kg/
hour would be administered with at least 24 hours lock-out period between.
All doses are halved in patients younger than 1 month. Figure 1 shows the scenario of all 
loading doses of study drug administered for subjects. Decreasing the maintenance dose will 
be possible in the case of oversedation (i.e., COMFORT-B >22 OR COMFORT-B=11–22 and 
NISS=3).
Figure 1. Minimum time line of infusion rate increases for all loading doses of IMP administered for subjects (half 
doses in neonates).
Following steps will be taken to decrease the dose (doses are halved in neonates):
• 2 units/kg/hour will be decreased to 1.5 units/kg/hour.
• 1.5 units/kg/hour will be decreased to 1 unit/kg/hour.
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• 1 unit/kg/hour will be decreased to 0.75 units/kg/hour.
• 0.75 unit/kg/hour will be decreased to 0.5 units/kg/hour.
If patients are still oversedated with the minimum dose, the Investigational Medicinal Product 
(IMP) administration will temporarily be stopped until patients need sedation again, and 
they will start back at T=0.
During the preparation of the trial, the consortium faced one unknown challenge. In V.1.0 of 
the protocol, dose reduction should be performed when a child is oversedated. After 30 min, 
a new sedation assessment should be performed and acted on the same. In an oversedated 
child, this could lead to a child being without IMP after 90 min (three dose reductions). This 
is certainly not a desirable situation, but not unthinkable as the half-life of both drugs are 
longer than 90 min. Therefore, a 6-hour observation period has been implemented. After 
a dose reduction, it is recommended to wait for 6 hours before the next dose reduction.
In this same amendment, another problem has been mitigated. Version 1.0 did not provide 
clear information about increasing the dose again after a prior decrease. In the amend-
ment, it has been made clear that subjects having a decrease of maintenance infusion to 
<1 unit/kg/hour will return to 1 unit/kg/hour, irrespective of the current infusion rate. If the 
decrease has been made while increases before have led to a maintenance infusion rate 
of ≥1 unit/kg/hour, re-increase will be following the precedent step (e.g., if a decrease 
has taken place from 1.5 to 1 unit/kg/hour, re-increasing will return the rate back to 1.5 
unit/kg/hour).
Pharmaceutical development
To overcome the potential for administration errors associated with commercially avail-
able clonidine ampoules, three different strengths of clonidine HCl—low (250 μg/50 mL), 
medium (500 μg/50 mL) and high (2500 μg/50 mL)—have been developed. Based on the 
dosing regimen described above, the concentrations of the low, medium and high strengths 
of midazolam (25 mg/50 mL, 50 mg/50 mL and 250 mg/50 mL) were 100-fold higher than 
for clonidine HCl. For study blinding purposes and to avoid dosing errors, a simple three-co-
lour scheme based on strength will be used.
To avoid the administration of preservatives, all formulations will be stored in single-use 
glass phials, with any contents remaining after 24 hours to be discarded. A 50 mL volume 
has been selected to limit the number of children requiring more than one phial in 24 hours 
(only subjects weighing over 46 kg and receiving the maximum dose in 24 hours will require 
two phials in a 24-hour period).
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Efficacy end points
Level of sedation was evaluated using the COMFORT-B score (ranging from 6 to 30), which 
is a validated scoring system commonly used in PICU.39 Level of sedation was also evalu-
ated by NISS when the COMFORT-B score fell between ≥11 and ≤22. NISS is the nurse’s 
expert opinion of the level of sedation (1: insufficient sedation; 2: adequate sedation; 3: 
oversedation). A subject is considered to be undersedated in cases of COMFORT-B score 
of >22; or COMFORT- B score of 11–22 in combination with NISS of 1.
In addition to COMFORT-B score (and NISS where appropriate), pain was assessed using 
the Numerical Rating Scale (NRS) at the same time intervals. The 11-point NRS is a global 
pain rating scale with which the nurse rates pain intensity by number (0=no pain and 
10=worst imaginable pain).40 In this study, to simplify matters, the NRS score was addressed 
first, so, if the pain score was ≥4, morphine treatment was escalated while sedation treat-
ment remained the same, regardless of the COMFORT-B score. This means that any pain 
score took precedence over the sedation score.
Primary objective
To assess the non-inferiority of the sedative properties of continuous intravenous clonidine 
compared with continuous intravenous midazolam in mechanically ventilated children and 
adolescents (0–18 years) admitted to a PICU.
Primary end point
The primary end point is defined as sedation failure within the study treatment period (a 
maximum of 7 days). Sedation failure is defined as:
When a subject’s assessment results are:
NRS score <4 and COMFORT B score >22 OR
NRS score <4 and COMFORT B score ≥11 and ≤22 AND NISS score 1 at a point during 
the study where no further increase in IMP dose are permitted as described in the dose-es-
calation scheme.
In summary, there are two possible outcomes (success or failure) of the primary end point.
Secondary objectives
• To evaluate the safety and tolerability (including withdrawal effects) of clonidine 
compared with midazolam in ventilated children and adolescents admitted to PICU.
• To determine clonidine dose-dependent effects on sedation.
• To establish the PK/PD relationship of clonidine for sedation in PICU.
• To compare the cumulative total morphine consumption/kg between the two arms in 
the first 48 hours of IMP administration.
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Secondary end points
Primary PK parameters estimated will be clearance (CL), volume of distribution (VD) and 
intercompartmental clearance (Q). PK measurements will be made using sparse opportu-
nistic sampling.
PK/PD modelling will seek to elucidate the relationship between IMP PKs and sedation as 
measured by COMFORT-B score. The PK/PD covariate model will include demographics 
(e.g. age, weight), clinical characteristics (eg. reason for admission) and pharmacogenomics 
(see the ‘Pharmacogenomic end points’ section).
Safety and tolerability assessments
Safety and tolerability assessments include:
Extent of withdrawal effects using the Sophia Observation withdrawal Symptoms-Paediatric 
Delirium (SOS-PD) scale measured three times a day in subjects who receive sedatives and/
or opioids for 5 days or more and after cessation of treatment in all subjects for at least 
24 hours after treatment. The extent of delirium measured by the SOS-PD scale.41
• Rebound hypertension monitored for at least 72 hours postcessation of treatment.
• Percentage of respiratory depression per group.
• Adverse event reporting of symptoms indicative of post-ICU stress (e.g. nightmares, 
confusion, hallucinations).
• Neurodevelopment of subjects recruited in lower age group (from birth to 27 days) at 
12 months after cessation of IMP, as measured using the Bayley II score.42 
Effect size justification
The primary objective of this study is to evaluate the efficacy of clonidine compared with 
midazolam in the sedation of ventilated children and adolescents admitted to PICU, with 
a view to demonstrate non-inferiority of clonidine.
Every patient enrolled will be in need of sedation, thus a placebo cannot be considered. 
Intravenous midazolam is the standard treatment for long-term sedation in children. It is 
licensed in this population, regarded as standard of care and recommended by treatment 
guidelines.12,30
Based on clinical experience and the limited data available regarding the use of clonidine 
as a sedative agent in PICU, it is assumed that the sedation success rate for clonidine is 
higher than for midazolam. The estimated difference in success rate between the two drugs 
was assumed to be 5%.
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The primary end point is the success or failure of the subject’s sedation treatment. Failure 
is defined as inadequate sedation with no further dose increases allowed in the dose titra-
tion scheme. This will be assessed by a nurse or physician using the COMFORT-B sedation 
assessment and, if appropriate, NISS. These assessment scales are open to a degree of 
subjectivity and it is therefore considered essential to have a double-blind study design to 
minimise bias due to knowledge of treatment group by the assessor.
In order to define the effect size, the expected success rate for midazolam was needed. 
The target concentration for midazolam was taken from the paper by de Wildt et al.
showing around 311 μg/L is required for sedation.43 The maximum midazolam dose of 
200 (100–200) μg/kg bolus followed by 200 (50–200) μg/kg/hour for all age groups 
(including neonates) is recommended by Dutch clinical consensus guideline.44 According to the 
proposed dosing schedule, the exposure of midazolam is similar to the Dutch recommended 
dosing regimen from the simulation (figure 2).
Figure 2. The proportion of average midazolam plasma concentration above the target value (0.311 mg/L) after 
the time of 5th bolus according to the proposed dose scheme(left) and the maximum Dutch recommended dosing 
regimen(right).
Furthermore, after the fifth bolus according to the proposed dose scheme, the proportion 
of average midazolam plasma concentration above the target value (0.311 mg/L) is 74% 
and from the Dutch dose scheme is 72%. Thus, we assumed that the sedation success rate 
in the midazolam arm given our dosing scheme would be 75%, and in the clonidine group 
this would be 80%.
Sample size calculation
Given this assumed effect size of a 75% success rate for midazolam, a sample size of 258 
(129 per treatment arm) provides at least 80% power to show non-inferiority of clonidine 
compared with midazolam. The sample size calculation is based on a logistic regression 
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for the primary efficacy end point of sedation success, with adjustment for study arm, age 
category and baseline COMFORT-B score. Non-inferiority of clonidine requires that the 
lower limit of the one-sided 97.5% CI for the OR of sedation success using clonidine (vs.
midazolam) is at least 0.583, which is equivalent to a 10% non-inferiority margin in case of 
a sedation success rate of 80%. The required sample size was calculated using simulation.
It is assumed that the total drop-out rate will be <13% and hence 300 subjects will be 
recruited, 150 in each arm and 100 in each age subgroup. The sample size of 300 subjects 
also provides at least 70% power to prove non-inferiority with respect to sedation success 
rate for each age subgroup (>90 subjects per age subgroup). Since the sample size for the 
age subgroup analyses is limited, a 15% non-inferiority margin at a one-sided alpha level 
of 0.025 is used, with an assumed sedation success rate of 80% in the midazolam group 
and 85% in the clonidine group. Subgroup analyses will be performed using a CI for the 
Mantel-Haenszel risk difference, with stratification by centre.
Statistical analysis
Analysis populations
The safety evaluation set (SES) is the subset of all subjects who were randomised into the 
trial and exposed to study medication (also referred to as the intention-to-treat (or ITT) 
population). Safety analyses will be performed in the SES.
The full analysis set (FAS) is the subset of subjects in the SES for whom the primary efficacy 
variable is available. Data analysis for the efficacy end points will be performed in the FAS.
The per protocol set (PPS) is the subset of subjects in the FAS without major protocol devi-
ations. Major protocol deviations will be defined during the Blinded Data Review Meeting.
The PK/PD analysis set (PKS) is the subset of subjects in the SES with evaluable PK samples 
defined as drug concentration measurements.
Primary efficacy analysis
Logistic regression of the primary end point, sedation failure, with treatment group, base-
line sedation assessment (i.e., the baseline COMFORT-B score), centre and age group as 
covariates, at a one-sided significance level of alpha=2.5% will be used. The statistical 
hypotheses are the following:
H0: OR≤ δOR and H1: OR>δOR,
OR=pC*(1−pM)/((1−pC)*pM), where pC and pM are probabilities of sedation success in 
the clonidine group and midazolam group, respectively; δOR is the non-inferiority margin 
which is predefined as 0.583.
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H0 will be rejected if the lower bound of the one-sided 97.5% Wald CI for the OR of 
sedation success proportion will be >0.583. The primary analysis will be based on the ITT 
principle. The primary end point will be evaluated for FAS. An equivalent analysis for the 
PPS will be performed as a sensitive analysis. No interim analyses are planned for the 
primary end point.
Secondary efficacy analyses
All secondary efficacy analyses will be conducted on FAS. Secondary efficacy end points 
will be analysed in detail as follows:
The proportion of subjects with sedation success between treatments within each age group 
will be based on the Mantel-Haenszel risk difference, with stratification by centre.45 A 15% 
non-inferiority margin at a one-sided alpha level of 0.025 will be used.
The aggregate intervals (i.e., the total time) (based on the planned assessment points) with 
COMFORT-B score >22 or <11 during treatment period between treatment groups were 
analysed using the Mann-Whitney U test.
The proportion of subjects with COMFORT-B score ≤11 between treatment groups and 
within each age group will be analysed using the χ2 test or Fisher’s exact test.
 
The morphine consumption in units of μg/kg/day during the first 24 hours of IMP admin-
istration and for the remaining study period between treatment groups will be analysed 
using linear regression analysis, with adjustment for centre and age group. An appropriate 
transformation of morphine consumption may be used to ensure normality of the residuals 
in the linear regression model.
An age subgroup analysis will be performed for each age group, using centre as a strat-
ification variable.
PK/PD analyses
The primary objective of PK/PD analyses in this trial is to evaluate the pattern and extent 
of covariates affecting the PK/PD profiles of clonidine and to provide the information of 
optimal dose for patients based on their particular age and other related covariates for 
future clinical practice. Three PK/PD interim analyses will be undertaken, whereby samples 
will be shipped and assayed for drug concentrations in order to ensure the systems for 
sample transport and analysis, along with data linkage to the electronic Case Record Form 
(eCRF) are fully operational, and to allow preliminary PK/PD model development. PK/PD 
interim analyses will be conducted after 15, 100 and 200 subjects will complete the study.
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PK/PD data will be modelled using the Fortran-based non-linear mixed effects soft-
ware NONMEM. Typical PK dispositional compartmental models will be tested, along 
with investigation of linear and non-linear elimination. Multivariate covariate analysis will 
be undertaken to investigate the impact of subject factors on PK model parameters. In 
particular, we will focus on the effect of body size with allometric models, and age (both 
postmenstrual and postnatal) possibly using literature prior models in order to delineate 
the effect of size and age from other factors. We will also look at the impact of drug 
metabolising enzyme genotype on interindividual variability. The link between PK and PD 
(COMFORT-B score) will be investigated by sequential and simultaneous modelling, possibly 
including an effect compartment. The Item Response Theory (IRT) will also be considered for 
PK/PD modelling, whereby effect is considered an unobserved normally distributed latent 
variable, and each item score of COMFORT-B is allowed to contribute to this through link 
functions.46 Since subjects will receive other sedative agents for procedures, the concentra-
tions of which may not be measured, a PK/PD approach will be taken to model sedation 
requirements in this period.
Mixed effects models will be fitted with maximum likelihood and addition of a single 
fixed effect will be guided by improvement of fit using the likelihood ratio test. Model 
evaluation will consist of goodness-of-fit (residual plots) and simulation-based diagnostics 
(visual predictive check), and parameter precision and robustness will be investigated with 
non-parametric bootstrapping.
Safety analyses
All safety analyses will be performed on the SES. Analyses will include the following end 
points:
• Adverse Event (AE)s, Serious Adverse Event (SAE)s and Suspected Unexpected Serious 
Adverse Reaction (SUSAR)s.
• Deaths.
• Clinical laboratory evaluations and vital signs. Descriptive summaries of laboratory 
values (including clinical chemistry, haematology, coagulation and urinalysis variables) 
and changes from baseline throughout the study will be generated. Shift tables will 
also be used for comparing changes from baseline and the proportion of subjects 
experiencing abnormalities between treatment groups.
• The SOS scores will be descriptively summarised and analysed with a linear mixed 
model (with between-arm differences at baseline constrained to be 0).
• Neurodevelopment will be evaluated using the Bayley Scales of Infant and Toddler 
Development. The scale will be descriptively summarised and compared between treat-
ment groups using linear regression analysis, with adjustment for centre and age group.
The CLOSED trial – study protocol 103
4
Quantitative variables will be by the number of subjects analysed (N), mean, median, 
minimum and maximum. Categorical variables will be analysed by frequencies and per-
centages for each category.
Randomisation and kit assignment
Randomisation is stratified by both age subset and clinical site. Each stratum consists of 99 
prerandomised numbers (randomisation numbers), assigned to either clonidine or midaz-
olam. These randomisation lists were prepared by a statistician not otherwise involved in 
the study, with the use of blocked randomisation consisting of small variable block sizes, in 
order to maintain blinding and conceal allocation.
At each clinical site, the kits marked with the random numbers for each age subset will be 
assigned to subjects in the order they are enrolled into the study. Each subject kit will contain 
two IMP boxes of seven phials, in order to supply the subject with enough medication for 
the maximum 7-day study period. The contents of each subject kit is outlined in table 3.
Table 3. Composition of the subject kit for each age group.
Age Subset Age group Formulation strength Subject bodyweight Number of boxes
1 <28 days Low 
Medium 
≤3 kg
>3 to <10 kg
1
1
2 28 days to <2 years Medium
High 
>3 to <10 kg
≥10 kg to <47 kg
1
1
3 ≥2 years to <18 years High ≥10 kg to 85 kg 2 (in case ≥47 kg)
Emergency unblinding will be possible as for each randomised subject kit, two complete 
sets of sealed emergency envelopes have been prepared (one set for safekeeping by 
the investigator, the other will be delivered to the group responsible for overseeing phar-
macovigilance of the study). Unblinding of the treatment allocation for a subject will be 
performed in an emergency that, in the opinion of the investigator, is warranted for a given 
subject for safety reasons.
PK/PD end points
PK/PD analyses will be carried out as a secondary end point to give further information on 
the dose-concentration-effect relationship primarily of clonidine, and also of midazolam. 
The PK/PD model will be used to evaluate the dose scheme used in the study, and if nec-
essary recommend an updated dose scheme for clinical use. PK/PD data will be modelled 
using non-linear mixed effects modelling. The impact of drug metabolising enzyme geno-
type on interindividual PK/PD variability will be considered alongside other demographics 
in the multivariable covariate analysis. The link between PK and PD (COMFORT-B score) 
104 Chapter 4
will be investigated by sequential and simultaneous modelling, possibly including an effect 
compartment. IRT will be explored for PK/PD modelling, whereby effect is considered an 
unobserved normally distributed latent variable, and each item score of COMFORT-B is 
allowed to contribute to this through link functions.46
Mixed effects models will be fitted with maximum likelihood and addition of a single fixed 
effect will be guided by improvement of fit using the likelihood ratio test (change in objec-
tive function of 3.84 is significant at p=0.05 level for 1 df by the χ2 distribution). Model 
evaluation will consist of goodness-of-fit (residual plots) and simulation-based diagnostics 
(visual predictive check), and parameter precision and robustness will be investigated with 
non-parametric bootstrapping.
Pharmacogenomic end points
Patients treated with sedatives and analgesics may respond very differently to the same 
dosage of medication. Several gene polymorphisms have been discovered to influence the 
PK and PD of clonidine, midazolam and morphine. PK data collected in this study can be 
interpreted more completely if data on pharmacogenomics are available.
Moreover, to study candidate polymorphisms gives further insight into the response of crit-
ically ill children to clonidine, midazolam and morphine. Most candidate genes have been 
established in adult subjects, this study is an opportunity to study the effects in children. The 
candidate genes which will be genotyped are shown in table 4.
Table 4. Candidate genes for linking pharmacogenomics to pharmacokinetic and pharmacodynamics end points.
Midazolam Clonidine Morphine 
CYP3A4, CYP3A5, POR, ABCB1, GABA, 
MDR1, MRP1, MRP2, MRP4, BRCP. 
ADRA2A, CYP2D6. COMT, OPRM1, OCT1, UGT2B7, ABCC3, 
MC1R, IL-1Ra, IL-6
Ethical considerations
Ad hoc considerations and measures have been set up to ensure safe and ethical conduct of 
this multinational trial, including a population requiring special protection such as children. 
In order to guarantee the respect of ethical rules regardless of the country in which the trial 
is carried out, an ethical standard based on the EU ethical and legal framework has been 
agreed among centres. All submissions are based on the current European ethical and legal 
framework and on the international ethical principles and guidelines.
Based on the Council of Europe Convention on Human Rights and Biomedicine47 and EU 
Ethical Recommendations 2008,48 research involving vulnerable populations is allowed if 
the results of the research are expected to provide real and direct benefit to the health of 
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the patient, or some benefit for the population represented by the patient, and the trial will 
pose only minimal risk and burden to the individual concerned. The risk-benefit assessment 
has been carefully addressed considering IMP-related risks (including pharmacological 
properties and proposed dosing regimen of the IMP, information on use in target popula-
tion, IMP development, IMP management) and expected benefits, the trial design (including 
study population inclusion and exclusion criteria), study-related procedures, qualification 
of the study team and host sites, rights of patients (including informed consent and assent 
procedures and data protection and confidentiality). Minor increase over minimal risk is 
anticipated for the CLOSED trial, as the study deals with a novel treatment modality in vul-
nerable paediatric patients and carries minor risk based on the available information about 
the study drug as well as randomised controlled trial (RCT)-related procedures. Important 
benefits for PICU population as a group are anticipated, since the study will provide clini-
cally relevant and directly applicable results, expected to influence future standard of care.
The informed consent and assent process in this trial is in line with the applicable relevant regu-
latory documents, including Good Clinical Practice (GCP) guideline,49 Directive 2001/20/EC,50 
the EC Detailed Guidance 2006,51 Directive 95/46/EC,52 the International Ethical Guidelines 
for Biomedical Research Involving Human Subjects CIOMS-WHO (2002),53 the Additional 
Protocol to the Oviedo Convention (2005),54 ICH Topic E11 and the EC 2008 Paediatric Rec-
ommendations. Accordingly, clear and appropriate information sheets and informed consent 
forms for parents/legal representatives, and patient information sheets and assent forms are 
prepared for patients and customised according to the local requirements.
Given the nature of the trial, especially considering that ICU patients are often admitted 
as a result of emergency, deferred consent/assent, as described in Article 35 of the new 
European Regulation on clinical trials (EU) No 536/2014 of the European Parliament and 
of the Council,36 is foreseen if allowed by local legislation. Informed consent of the legal 
representative and, if feasible, the patient’s assent will be sought for as soon as possible. 
If informed consent is not obtained, the possibility of withdrawing all collected data from 
the trial will be explained and appropriate measures, based on patient’s decision will be 
taken. A record will remain in the subject’s medical notes. In the Netherlands, deferred 
consent is permitted under national legislation (‘Wet medisch-wetenschappelijk onderzoek 
met mensen’, Paragraph 2 Article 6.4).
As the protocol includes pharmacogenetic tests, informed consent and assent to perform 
genetic tests will be obtained separately, in line with the most relevant provisions in the field 
(International Declaration on Human Genetic Data, UNESCO, 200355; Ethical Guidelines 
CIOMS-WHO, 2002). Accordingly, the participants will have the possibility to join the trial 
without participating in the pharmacogenetic part.
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Finally, involvement of appropriate external expertise in the form of Data Safety Moni-
toring Board (DSMB), Independent Scientific Advisory Board (ISAB) and Patient Advisory 
Board (PAB) is foreseen. In details, the DSMB will review the study’s safety data and assess 
subject safety data throughout the study; the ISAB will input in the final protocols, monitor 
the progress of the project and ensure the ongoing scientific and ethical integrity of the 
clinical trial; the PAB will advise the Sponsor to ensure that the subjects’ rights and subjects’ 
protection will outweigh any commercial considerations and conflicts of interest that may 
appear in relation to the project.
In accordance with GCP, as implemented at national level, the study protocol and related 
documents have been approved by the competent ethics committees in Rotterdam, the 
Netherlands, and in Erlangen, Germany. Submission is currently being prepared for the 
three other centres (Stockholm, Prague and Rome).
Dissemination
The results will be published in a peer-reviewed journal and shared with the worldwide 
medical community.
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DISCUSSION
Study design
Sedation management in PICU mainly consists of the use of intravenous midazolam by 
continuous infusion. Midazolam has several advantages, but is by far not the ideal agent 
for longer-term sedation. Other agents have made their off-label entry into PICU, mainly 
based on adult practice. One of these agents is clonidine, which could have some specific 
advantages over midazolam. It is being used increasingly, but is still off-label. This study 
design allows for data collection on safety, efficacy, PK, pharmacogenomics and to a lesser 
extent neurological outcome. This multimodal approach generates data that is very useful 
for licensing clonidine for sedation in children. Moreover, application of different formula-
tion strengths, allows for easier paediatric clinical implementation as the current available 
formulation (Catapresan®) has only been developed for adults.
Study limitations
Despite the careful design of this trial, some limitations exist. First, we have chosen a non-in-
feriority design for this trial because, based on clinical experience and limited available 
data, we estimate the difference in sedation success rate will be very low. This would mean 
that showing superiority of clonidine requires a large sample size and thus compromising 
feasibility. This design, however, means that we cannot demonstrate possible superiority of 
clonidine. However, if equal efficacy is shown under safe circumstances, clonidine can be 
licensed for sedation in PICU.
Second, the recruitment window has been set on 72 hours. This could lead to confounding as 
having a large time window could increase the risk of tolerance and withdrawal symptoms. 
A smaller recruitment window may reduce these risks but parents need some time to consider 
participation and not every study site has 24/7 research nurse availability.
Third, this trial has an extensive list of exclusion criteria. This could compromise the external 
validity of the results and could complicate implementation of the results in new guidelines. 
This is a known limitation of almost any controlled trial.56 However, these exclusion criteria 
are based on expected elements affecting both primary outcome and patient safety. Our 
primary end point is based on a validated behavioural scale. Therefore, any disease status 
that can cause many fluctuations in behaviour (such as neurological injury) needed to be 
excluded from this trial for the results to be valid. The same holds for safety end points such 
as cardiovascular stability. The decision to allow for inotropes/vasopressors in the second 
amendment is a big step towards generalisability of the results.
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Role of researcher-driven studies, Seventh Framework Programme-funded projects CLOSED 
is one of the 20 projects approved in the framework of the Seventh Framework Programme 
for Research that should specifically meet both criteria for scientific excellence and reg-
ulatory standards for high-quality paediatric research, as prescribed by the Paediatric 
Regulation, in order to put paediatric drugs on the market. A very recent publication 
demonstrated that these projects face the need for overcoming the existing methodological 
and ethical difficulties affecting research in the paediatric population.5
In fact, paediatric clinical trials are often multinational and researchers need to know and 
apply rules from the regulatory, legal and ethical frameworks, acting both as investigators 
and as sponsor and/or other concerned parties. This is not simple considering the lack of 
harmonisation of clinical trial procedures among countries (http://www.ncbi.nlm.nih.gov/
pubmed/26037896) and makes it necessary to prepare, agree and apply guidelines 
based on the EU rules.
Challenge to perform a trial compliant with GCP and other regulations
Clinical trials must follow the same rules, notwithstanding if sponsored by industry or non-
profit organisations, from GCP to the new clinical trials regulation49 to recommendations 
and guidelines.
Accordingly, the new regulation49 recognises that a large proportion of clinical trials are 
conducted by non-commercial sponsors, frequently supported by public funds or charities 
and that these trials should be encouraged.
However, this means a heavy work from researchers and a deep knowledge of both EU 
and national rules. This issue is aimed to be overcome by the international public-private 
cooperation between different stakeholders foreseen by EU-funded projects (researchers, 
clinicians, regulatory and ethical experts, clinical research associates). On the other hand, 
it seems that the paediatric consortia generated by the FP7 paediatric projects are con-
ducting these studies and trials using a limited amount of money in comparison with the 
recognised cost of paediatric trials in an approved PIP which is estimated to be three to 
four times higher.5
Challenges of maintaining double-blinding
Clonidine and midazolam have different half-lives: 1–3 hours for midazolam (up to 12 hours 
in neonates) and 9–17 hours for clonidine, thus maintaining double-blinding is challenging. 
PK/PD simulations have played a major role in the strategy to overcome this challenge. 
It has led to the implementation of a loading dose, which is in line with the current clinical 
recommendations for midazolam.44 Target plasma levels have been achieved based on the 
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literature.32,43 It should be noted, however, that the PK/PD relationship is assumed, but not 
formally studied. This study will contribute to the determination of a PK/PD relationship.
Risk to patients
Both clonidine and midazolam are frequently used sedatives in PICU. However, a careful 
assessment of possible study-related risks has been performed. In general, side effects of 
IMP are the major cause of study-related risk. As midazolam is the gold standard treatment, 
the side effects do not contribute to an increased risk in this study. For clonidine, bradycardia 
and hypotension are the most clinically relevant side effects and are likely to occur most 
often during the loading doses and the early starting phase.33 Therefore, a loading dose will 
be given as a 15 min infusion instead of a direct bolus. Moreover, the setting where patients 
are being monitored consists of five well-equipped and experienced PICUs. Treatment of 
hypotension and/or bradycardia is common practice in the study population and should 
therefore not increase the risk to subjects dramatically.
Rebound hypertension could also be a side effect after sudden discontinuation of clonidine. 
In a comparable trial,31 this was observed once in 64 patients and resolved quickly without 
any intervention. Monitoring of blood pressure up to 72 hours after IMP cessation has been 
included in the study protocol with the recommendation to treat hypertension according to 
local common practice.
Blood sampling is a possible risk to small children participating in drug research.57 In this 
study, the amount of sampled blood will not exceed the 3% of patient’s plasma volume, 
which is a general limit of study-related blood sampling.
In general, as most elements of this study are similar to current clinical practice, the study-re-
lated risk to patients is deemed low.
Pharmacogenetics
This study incorporates a pharmacogenetics assessment of recruited patients. Both PK and 
PD may be influenced by gene polymorphisms. The current proposed pharmacogenetics 
assessment has been based on the literature available, but a degree of flexibility has been 
built in when more information on these genes or medications will come available.
In accordance with the appropriate regulations,51,53,55 separate consent and assent will 
be obtained from participants. This strategy enables the possibility of participating in the 
CLOSED trial without the genetic assessment.
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Anticipated difficulties
A comparable RCT, the Safety profiLe, Efficacy and Equivalence in Paediatric intensive care 
Sedation (SLEEPS) study, has been previously undertaken in the UK.33 One of the major 
challenges faced by the investigators was the recruitment. The sample size had been cal-
culated on 1000 subjects. Unfortunately, only 129 subjects were randomised. Contributing 
factors to this impaired recruitment have been identified by the investigators, including:
• Conflict with other studies
• Earlier extubation in elective cardiac surgery patients
• Parental issues and timing of consent
• Clinicians’ issues
• Research nurse time
• Delay in study start
• Compliance with the protocol.
It is likely that in the participating centres with excellent research facilities, multiple trials 
are being performed at the same time. Children are not allowed to participate in multiple 
intervention studies, so we recommend to have a thorough look at the inclusion and exclusion 
criteria of studies and set up clear agreements about patient allocation.
Early extubation in cardiac surgery patients is now common practice, and estimations of 
recruitment rates have excluded these patients. However, it is likely that ventilation strategies 
will change over the coming years. We have recognised the increasing use of non-invasive 
ventilation such as Non-Invasive Positive Pressure Ventilation (NIPPV). As these patients 
may still need continuous sedation, we will include these in the study. In general, patients 
on continuous positive airway pressure (CPAP) do not need additional sedation, thus these 
will be excluded.
Parental issues are to be expected in any clinical trial in the PICU. Parents having their child 
admitted to an ICU are under high stress and may therefore be reluctant to participate. In 
the calculations of estimated recruitment, a high refusal rate (approximately 40%–50%) 
should be taken into account, based earlier experience with other trials. Also, a parent 
organisation is involved in the trial and they will provide information to parents from their 
perspective. We anticipated to include 300 patients within 18–24 months in total. In The 
Netherlands, deferred consent is used in emergency care trials. The Ethical Committee of 
the Erasmus Medical Centre, Rotterdam, has approved the use of deferred consent in this 
trial so this could be applied in the largest recruitment centre.
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When faced with a critically ill child, doctors and nurses may tend towards conservatism. 
At the beginning of the SLEEPS trial, the involved professionals could have been afraid of 
the cardiovascular side effects of clonidine especially in unstable patients. Their study has 
shown that its use is relatively safe in critically ill children, as well as other literature.34,58 
Moreover, in the CLOSED consortium recruitment centres, a lot of clinical experience with 
clonidine has been built so caregivers may be less hesitant to support this clinical trial.
Research nurse time is always an issue, especially in the 24/7 business of an ICU. In the 
larger centres, dedicated researchers/nurses have been identified and trained adequately 
to perform this trial. In the smaller centres, Principle Investigators (PI)s may be able to coor-
dinate the lower amounts of participants.
During the first months of patient recruitment in two centres, no patients could be included. 
In the majority of cases, exclusion criteria made the screened patients ineligible. No consent 
was given in the very few eligible patients. Therefore, a revision of the exclusion criteria 
has been made.
The major exclusion criteria on which patients failed screening are:
• Anticipated need for sedation <24 hours. It has been considered to change this dura-
tion. It has been decided however to keep this minimum as the therapeutic aim of the 
study is long-term sedation.
• No sedation despite ventilation. To our surprise, many newborn patients on the ven-
tilator would not need any sedation, or were comfortable on low-dose opioids. This 
could not be mitigated.
• Circulatory insufficiency. The Goldstein criteria59 have been used for the definition 
of this exclusion criterion. However, many patients received inotropic or vasopressor 
agents as supportive therapy in both recruiting centres. We have therefore modified 
these criteria and removed the use of inotropes/vasopressors in the second protocol 
amendment.
• Neurological pathology. It has been suggested to include patients with minor head 
trauma, but as the clinical picture may change very rapidly, we have decided not to 
include these patients into the trial.
• Use of clonidine in the last 7 days. As clonidine has a long half-life, patients would be 
excluded if they have received clonidine for any indication in the previous 7 days. How-
ever, for midazolam, there was no similar exclusion criterion; instead, patients would 
undergo an extra PK blood sample before start of the study medication. This has now 
been introduced for clonidine as well in the second protocol amendment.
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A delay in study start has been encountered in the CLOSED study. Several obstacles, such as 
obtaining the appropriate licenses for handling, importing and exporting controlled drugs, 
have caused a significant delay in recruitment start. A second major issue has also been 
an amendment of the dose reduction scheme (see the ‘Study treatments’ section). A third 
issue has been the generation of robust quality data that is sensitive enough to support a 
future PUMA application as well as the Investigational Medicinal Product Dossier (IMPD) 
and clinical trial application.60 
Compliance with the protocol was a significant issue in the SLEEPS trial, as they provided 
a strict sedation regimen. Therefore, the CLOSED sedation regimen merely reflects clinical 
practice, although some important aspects may cause difficulties in clinical practice. The lock-
out periods, for example, are not according to clinical practice and special attention needs 
to be paid by the research nurses and other investigators to keep the protocol compliance 
as tight as possible. When problems are recognised, the possibility of amendments should 
be discussed early. Early recognition is facilitated by implemented monthly investigators’ 
teleconferences.
Also, there will be an ongoing evaluation of the COMFORT-B scale training of the nurses 
in the participating centres. Good interobserver reliability is defined by a Cohen’s kappa 
>0.65 and nurses in all centres have received training by trained nurses.
In summary, many known challenges should be managed by appropriate measures taken. 
However, there could always be unknown challenges and it is therefore crucial to have 
regular contact between principal investigators of each recruitment site.
Reflection
After 9 months of recruiting, we included far fewer children than anticipated. Therefore, two 
amendments have now been added to potentially increase the number of eligible patients. 
Unfortunately, recruitment did not improve. Even though we had been warned by the 
early discontinuation of the SLEEPS trial,33 we faced other challenges. For example, many 
postoperative neonates do not need any additional sedation to intravenous paracetamol 
and continuous intravenous morphine. Also, parents are reluctant to participate. Either they 
think their child is not stable enough, or their child is finally stable and therefore changes 
in treatment for study purposes are not welcomed.
Also, the anticipated recruitment rate was based on the number of admitted ventilated 
patients in previous years. However, this turned out to be a significant overestimation, a 
phenomenon also known as Lasagna’s Law.61 These challenges have a big impact on the fea-
sibility of the trial and force us to consider alternative options. We will open (at least) two 
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new recruitment sites, Bari (Italy) and Tallinn (Estonia). Furthermore, we need to rethink the 
primary objective of this study and may change it to a PK/PD study for which 50 patients 
in each arm are sufficient instead of the original 150 patients per arm.
The lessons from both the SLEEPS trial and this trial are important for further investigations 
in paediatric critical care and careful preparation is warranted for any trial performed in 
this population. This preparation should at least include adequate piloting over a longer 
period. In our experience, we monitored eligible patients over one month in one centre and 
expected no significant recruitment problems. This monitoring was performed during winter 
time, when many patients with respiratory viral infections in need of mechanical ventilation 
were admitted. This caused our expectations of eligible patients to be high; if we had 
performed this during summer time, we may have been warned earlier.
Other aspects to enhance the number of included patients are adequate staff training and 
motivation, collaboration with investigators having experience in paediatric critical care 
trials and keeping the exclusion criteria of a trial to a minimum.
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ABSTRACT
Objective: To determine the anticholinergic drug burden in critically ill children with pedi-
atric delirium (PD) and/or iatrogenic withdrawal syndrome (IWS).
Design: Single-center, retrospective observational cohort study. 
Setting: A 28-bed level III pediatric intensive care unit (PICU). 
Patients: All patients admitted to the PICU between January 1st 2014 and 31st Decem-
ber 2016; and receiving one or more anticholinergic drugs. The cohort was divided into 
4 subgroups: 1) patients with diagnosed PD but without diagnosed IWS; 2) patients with 
diagnosed IWS but without diagnosed PD; 3) patients with diagnoses of both PD and IWS; 
and 4) patients without a diagnosis of either PD or IWS.
Interventions: None. 
Measurements and main results: The anticholinergic drug burden was calculated using the 
Anticholinergic Drug Scale (ADS) and the Anticholinergic Cognitive Burden Score (ACBS). 
The average anticholinergic drug burden in affected patients was higher than that in the 
unaffected group: median ADS score in PD patients was 2 (IQR 2-3), in IWS patients 2 
(2-2.5) and in PD/IWS patients 3 (2-4) vs. 1.5 (1-2) in the unaffected group, p-value 
<0.001. In none of the affected subgroups the anticholinergic drug burden had increased 
in the seven days prior to onset of PD and/or IWS.
Conclusions: Patients with PD and/or IWS have a higher anticholinergic drug burden 
compared to unaffected patients receiving anticholinergic drugs. These findings warrant 
both scientific and clinical consideration of the contribution of anticholinergic drugs to PD 
or IWS symptom development.
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INTRODUCTION
Iatrogenic withdrawal syndrome (IWS) and pediatric delirium (PD) are frequently encoun-
tered in the pediatric intensive care unit (PICU). The reported prevalence of IWS in the PICU 
ranges from 17% to 57%1; that of PD from 5-47%.2-6 Early detection of both conditions is 
crucial, as both are associated with increased mortality and longer length of stay.1,7 Thus, 
several PD screening tools and IWS screening tools have been developed and validated 
for children1,5,8,9 to detect these conditions early on. Yet, symptoms of IWS and PD seem 
to overlap to a great extent, such as sweating, agitation, tremors and increased muscle 
tension. This overlap has been used in the development of a delirium assessment tool, the 
Sophia Observation withdrawal Symptoms-Pediatric Delirium,10 with the use of ten overlap-
ping items derived from the previously existing Sophia withdrawal Observation Symptoms 
scale.8 In a recent literature review of several IWS and PD screening tools. Another possible 
overlapping phenomenon was identified: the anticholinergic toxidrome (AT).11 This toxidrome 
may be caused by the use of direct anticholinergic agents such as glycopyrronium or atro-
pine, medications with anticholinergic properties such as oxybutynine, or other exposures 
outside the hospital. These agents block the muscarinic acetylcholine receptors in the periph-
eral and central nervous systems. Classically, the AT leads to a clinical presentation as ‘dry 
as a bone, blind as a bat, red as a beet, hot as a hare and mad as a hatter’,12,13 but more 
subtle signs, such as isolated agitation, confusion and/or tachycardia may also occur.14,15 
No data are available on the prevalence of AT in the PICU, but the literature contains multiple 
case reports of drug-induced AT in children.14,16-22 Yet, the authors of the above-mentioned 
review hinted at a possible association between AT and PD/IWS.11 Moreover, a recent study 
reported a high anticholinergic drug exposure in children admitted to the PICU for more 
than two weeks.23 They also reported a possible association between a high anticholinergic 
drug burden and the development of withdrawal syndrome. Therefore, we have carried out 
a retrospective, case-control study of critically ill children, with the goal of determining the 
anticholinergic drug burden in those who developed IWS and/or PD. To see whether there 
is an association with the development of PD or symptoms of IWS we compared this drug 
burden with that of critically ill children who did not develop IWS or PD.
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METHODS
Study design 
The Erasmus MC medical ethics review board provided a waiver for ethics approval and 
informed consent according to the Dutch law on research in humans (MEC 2017-358) for this 
retrospective case-control study of patients admitted to the PICU of the Erasmus MC-Sophia’s 
Children’s Hospital between January 1st 2014 and December 31st 2016 and having received 
at least one anticholinergic drug. 
The cohort was divided into 4 subgroups: 1) patients with diagnosed PD but without diagnosed 
IWS; 2) patients with diagnosed IWS but without diagnosed PD; 3) patients with diagnoses of 
both PD and IWS (the overlap group); and 4) a control group of patients without a diagnosis 
of either PD or IWS. Patients in the first three groups are classified as ‘affected’ whereas 
patients in group four are classified as ‘unaffected’ controls. Diagnosis of PD and/or IWS 
was made according to the following criteria:
For pediatric delirium:
Two or more consecutive SOS-PD scores ≥4 in 24 hours AND/OR PD confirmed by consulting 
child psychiatrist 
For iatrogenic withdrawal syndrome:
Two or more consecutive SOS scores ≥4 in 24 hours
There were no exclusion criteria. In patients with multiple admissions we only examined the 
first admission. 
Instruments
PD and IWS assessment
IWS is screened for by the validated Sophia Observation withdrawal Symptoms (SOS) scale,24 
which consists of 15 items representing symptoms of the opioid and/or benzodiazepine with-
drawal syndrome and with a score ranging from 0-15. At least two consecutive scores ≥4 are 
considered to indicate the presence of IWS. The SOS scale is used in children who have received 
continuous infusions of opioids and/or benzodiazepines for more than 4 days, or whenever IWS 
was suspected. PD is screened for with a modification of the SOS scale, – the Sophia Obser-
vation withdrawal Symptoms-Pediatric Delirium (SOS-PD) scale10 – which in total consists of 22 
items). Seventeen items refer to symptoms of PD (10 of which overlap with the SOS scale). At 
least two consecutive SOS-PD scores ≥4 and/or confirmed diagnosis by the child psychiatrist 
are considered to indicate the presence of PD. A child psychiatrist is in any case consulted when 
there are two consecutive scores ≥4, or whenever “unrecognizable behavior” is present. All 
patients who are admitted for >48 hours have PD assessments 3 times a day.
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Anticholinergic burden assessment 
The anticholinergic burden was assessed with the Anticholinergic Drug Scale (ADS)25 and the 
Anticholinergic Cognitive Burden Score (ACBS).26 These two scales have been selected because 
they include drugs that are frequently administered in the PICU.27 Drugs are rated numeri-
cally from 0 to 3, whereby 0 indicates no anticholinergic activity and 3 indicates significant 
anticholinergic activity. The total sum of all drugs indicates the total anticholinergic burden 
per admission day, calculated separately for both scales. 
We calculated the anticholinergic burden per day of admission for the three patient groups and 
the control group. Since many drugs are used off-label, or administered by continuous infusion in 
rapidly changing doses, we have not applied a dose-dependent coefficient (e.g., when a patient 
receives double the standard dose, the score should be doubled). We also specifically looked 
at the anticholinergic burden from analgesics and sedatives. As such, we classified these agents 
into three groups: benzodiazepines (including clonazepam, diazepam, lorazepam, midazolam 
and temazepam); opioids (including fentanyl, meperidine, morphine, oxycodone, tramadol); and 
antihistamines (including alimemazine, chlorpromazine, promethazine).
Data collection
Data were collected from the electronic patient data management system, which also includes 
the digital drug prescription system. The following patient characteristics were retrieved: 
age, sex, length-of-stay (LOS), use of mechanical ventilation, use of anticholinergic drugs, 
and mortality.
For the affected subgroups, we retrieved also data on reason for admission, severity of illness 
as assessed by the pediatric risk of mortality (PRISM-III) score,28 pre-existing developmental 
delay and the time of onset of PD and/or IWS. To determine whether the anticholinergic drug 
burden and symptoms of IWS/PD had increased before the onset of PD and/or IWS we also 
collected ADS, ACBS, SOS and SOS-PD scores from the seven days before the onset of PD 
and/or IWS. For comparison we collected ADS and ACBS scores from the first ten days of 
admission in the control group as the mean onset of PD and/or IWS was 8 days. For logistics 
reasons, PRISM-III scores could not be calculated for the unaffected group.
Statistical analysis
Demographic data are summarized using descriptive statistics. For comparisons between the 
affected subgroups we used the Kruskal-Wallis test for non-normally distributed data or a 
one-way analysis of variance (ANOVA) for normally distributed data, using a Dunn-Bon-
ferroni correction for multiple comparisons. For comparisons of the affected group with the 
unaffected group we used the Mann-Whitney U test for non-normally distributed data and 
the Student’s t-test for normally distributed data. Chi-square tests or Fisher exact tests were 
used for categorical data. 
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RESULTS
Over the 3-year period (2014 – 2016), in total 3241 patients had been admitted to the 
PICU. Of those, 2,340 (72.2%) met the inclusion criteria. We included 174 affected patients 
and 2166 unaffected patients. Demographic data are shown in Table 1. Affected patients 
were significantly older and had a longer PICU LOS. Also, more affected patients died 
during admission compared to the unaffected group, 9.2 % versus 3.9% (p=0.016). The 
affected group consisted of 64 children with PD, 33 with IWS and 77 with both (Table 2).
Table 1. Demographic data of the cohort.
Variable Affected group
(n=174)
Unaffected group
(n=2166)
p-value
Age, median (interquartile range [IQR]) in months 29 (6-125) 20 (1-101) 0.01
Sex (n,%) M 104 (59.8%)
F 70 (40.2%)
M 1254 (57.9%)
F 912 (42.1%)
0.63
Length of stay, median (IQR) in days 19 (10-42) 2 (2-5) <0.001
Mechanical ventilation (n, %) 149 (85.6%) 905 (41.8%) <0.001
PICU mortality (n, %) 16 (9.2%) 85 (3.9%) 0.016
Reason for admission (n, (%))
Respiratory
Neurological
Cardiac
Surgical (non-cardiac)
Infection/sepsis
Post resuscitation
Metabolic
Hematologic/oncologic
Polysomnography
51 (29.3)
35 (20.1)
34 (19.5)
25 (14.4)
10 (5.7)
7 (4.1)
7 (4.1)
3 (1.7)
2 (1.1)
-
-
-
-
-
-
-
-
-
Table 2. Affected subgroup characteristics.
PD group IWS group Overlap group Overall
Primary diagnosis (n, %) 64 (36.8%) 33 (18.9%) 77 (44.3%) 174 (100%)
Developmental delay (n, %) 8 (12.5%) 4 (12.1%) 5 (6.5%) 17 (9.8%)
Time to onset IWS and/or PD in days
(median, IQR)
4 (2-6) 13 (8-27) 10 (7-17) 8 (5-17)
PRISM-III score (median, IQR) 10 (5-19) 12 (5-19) 13 (8-21) 12 (7-20)
Both the median and highest anticholinergic scores during admission were higher in the 
affected group than in the control group (Table 3). Figure 1 shows the boxplot of distribution 
of data. Within the affected subgroups, median ACBS was slightly higher in the overlap 
group than in the PD group (2, IQR 1-2) vs. 1 (IQR 1-2). 
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In all three affected subgroups the anticholinergic burden from analgesics and sedatives 
was not higher than in the unaffected group (see Table 4). 
Table 3 a. Medians with IQR of the median and highest ADS and ACBS score per patient. P-values are given 
for across-group comparisons(a). Adjusted significance levels of pairwise comparisons using Dunn correction are 
given below (b). 
PD group 
(n=64)
IWS group
(n=33)
Overlap 
group (n=77)
Control group 
(n=2166)
p-value
Median score per patient
ADS score (median, IQR)
ACBS score (median, IQR)
2 (2-3)
1 (1-2)
2 (2-3.5)
1 (0-2)
3 (2-4)
2 (1-2)
1.5 (1.0-2.1)
1.0 (0.5-1.5)
<0.001
<0.001
Highest score per patient
ADS score (median, IQR)
ACBS score (median, IQR)
4 (2-5)
2 (1-3)
5 (4-6)
3 (2-5)
6 (4-7)
3 (2-5)
2 (1-3)
1 (1-2)
<0.001
<0.001
Table 3 b. Medians with IQR of the median and highest ADS and ACBS score per patient. P-values are given 
for across-group comparisons(a). Adjusted significance levels of pairwise comparisons using Dunn correction are 
given below (b). 
Control-PD Control-IWS Control-Overlap PD-IWS PD-Overlap IWS-Overlap
Median ACBS 1.0 1.0 <0.001 1.0 0.013 0.105
Median ADS <0.001 <0.001 <0.001 0.655 0.069 1.0
Highest ACBS <0.001 <0.001 <0.001 0.303 0.005 1.0
Highest ADS <0.001 <0.001 <0.001 0.052 0.001 1.0
In the seven days before the onset of the IWS and/or PD, the anticholinergic burden had 
not increased and the PD and/or IWS scores had not changed (see figures 2a and 2b) 
There was also no change in anticholinergic drug burden in the first ten days of admission 
in the control group (figure 2c).
126 Chapter 5
Figure 1. Boxplot showing the average anticholinergic scores for the patient groups and the control group (left). 
Table 4 a. Median anticholinergic drug scores of analgesics and sedatives per study subgroups and controls. 
P-values are given for across-groups comparisons. Adjusted significance levels of pairwise comparisons using Dunn 
correction are given below (b).
PD group 
(n=60)
IWS group
(n=32)
Overlap group 
(n=77)
Control group 
(n=1636)
p-value
Benzodiazepines
No. of patients receiving (n, %)
Median ACBS (median, IQR)
Median ADS (median, IQR)
56 (93.3)
0 (0-0)
1 (1-1)
32 (100)
0 (0-0)
1 (1-1)
76 (98.7)
0 (0-0)
1 (1-1)
1107 (67.7)
0 (0-0)
1 (1-1)
0.719
0.011
Opioids
No. of patients receiving (n, %)
Median ACBS (median, IQR)
Median ADS (median, IQR)
50 (83.3)
1 (1-1)
1 (1-1)
28 (87.5)
1 (1-1)
1 (1-1)
74 (96.1)
1 (1-1)
1 (1-1)
1386 (84.7)
1 (1-1)
1 (1-1)
0.006
0.052
Antihistaminics
No. of patients receiving (n, %)
Median ACBS (median, IQR)
Median ADS (median, IQR)
10 (16.7)
0 (0-0)
1 (1-1)
12 (37.5)
0 (0-0)
1 (1-1)
19 (24.7)
1 (1-1)
0 (0-0)
59 (3.6)
1 (1-1)
0 (0-0)
0.684
0.684
Table 4 b. Median anticholinergic drug scores of analgesics and sedatives per study subgroups and controls. 
P-values are given for across-groups comparisons. Adjusted significance levels of pairwise comparisons using Dunn 
correction are given below (b).
Control-PD Control-IWS Control-Overlap PD-IWS PD-Overlap IWS-Overlap
Benzodiazepines
Median ADS 0.008 1.0 1.0 1.0 0.008 1.0
Opioids
Median ACBS 0.004 1.0 1.0 0.491 0.01 1.0
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Figure 2a-c. Boxplots showing anticholinergic drug scores (2a) and SOS/SOS-PD scores (2b) in the seven days 
before onset of PD and/or IWS. For the control group, anticholinergic drug scores of the first 10 days of admis-
sion are displayed (2c).
a.
b.
c.
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DISCUSSION
From this exploratory, retrospective case-control study it appeared that the PICU patients 
who had developed PD, IWS, or both, had on average a higher anticholinergic burden 
from the received medications than other PICU patients receiving anticholinergic drugs. 
This could implicate an association between anticholinergic drugs and the development of 
PD and/or IWS.
To date, little is known about the association between anticholinergic drug burden and the 
development of PD, or PD symptoms, in critically ill children. A prospective observational 
study from the United States in 1,547 children found that those who had received any 
anticholinergics during PICU admission had an increased risk of PD development (OR 2.17, 
95% CI 1.41-3.42).7 But in an international point prevalence study of PD in 994 patients 
across 25 PICUs worldwide, anticholinergic drug consumption was not associated with PD, 
whereas narcotics, benzodiazepines, antiepileptics and vasopressors were. In a geriatric 
population an association was found between the use of anticholinergic drugs and the 
development of delirium (odds ratio [OR] 1.5, 95% confidence interval [CI] 1.04-2.17).29,30 
Yet, studies in adults receiving intensive care have reported conflicting results. A prospective, 
observational single-center study in the Netherlands in 1,112 patients found no association 
between anticholinergic drug burden and the development of delirium.31 But a Canadian 
prospective, observational single-center study in 520 patients found an increased risk for 
delirium development with the use of high-potency anticholinergics in the preceding 48 
hours (hazard ratio [HR] 2.45, 95% CI 1.08–5.54).32
Regarding IWS, Madden et al. found an association between high anticholinergic drug 
scores and the development of IWS. This may not be surprising as midazolam and morphine 
accounted for the majority of high ADS scores. Data on the time of IWS onset after such high 
scores were not provided, unfortunately. In our study, we did not find a higher contribution 
of sedatives to the anticholinergic burden in the IWS subgroup, however. 
We found a median ADS score of 1 (IQR 0.8-2.0) in the control group, whereas the 
median scores for the affected group did not exceed 3 (2.2 (IQR 1.3-3.1), 2.5 (IQR 
1.8-3.2) and 2.7 (IQR 2.1-3.7), respectively). However, in the retrospective study of 
Madden et al., a median score of 5 (IQR 3-7) was found.23 Also, their maximal ADS per 
patient was higher (8 (IQR 6-10) versus 6 (IQR 4-7) in our overlap subgroup, which had 
the highest maximal ADS in our study). This could possibly be attributed to a difference 
in clinical practice, as we did not use diphenhydramine for example, which is a strong 
anticholinergic drug (3 score points in the ADS) and accounted for 40% of high ADS 
scores in the Madden et al. study.
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One of the problems with studying the role of anticholinergic drugs is the use of 
different definitions of ‘anticholinergic’ drugs. In previous studies of Traube et al. a 
clear definition is lacking.2,7 Burry et al. used a classification of drugs with low or high 
anticholinergic potency,32 and Wolters et al. calculated anticholinergic drug burden 
with use of the ADS.31 Valid comparisons between studies can only be made if a clear 
definition is provided. 
Moreover, a limitation of using anticholinergic drug burden scales is that they list different 
drugs list and also rate the burden of the same drug differently.29 For example, frequently 
used drugs in the PICU such as midazolam, vancomicin and gentamicin are only assessed by 
the ADS, but alimemazine, metoprolol, haloperidol and paracetamol are only assessed by 
the ACBS. This could be attributed to the fact that expert opinion plays an important role 
in the development of these individual scales. Some scales have used validation against 
serum anticholinergic activity (SAA) as an objective measurement.25,33 Yet, SAA may not 
reflect CNS anticholinergic activity as the blood-brain-barrier has different permeability 
for different drugs.34 Cut-off or threshold values in the scales are lacking. Boustani et al. 
suggest the use of a ACBS cut-off value of ≥326 for having an increased risk of cognitive 
problems. However, this value has been established in a geriatric population with cognitive 
function as primary end point. In future pediatric studies, existing anticholinergic scales 
should first be validated for the population in question.
Another problem that limits this study is the identification of PD and the discrimination from 
IWS and preferably also AT. This is illustrated by the fact that almost half of affected 
patients in this study had been diagnosed with an overlapping condition, which could lead to 
misdiagnosis. It is therefore important to be able to discriminate between PD as a condition 
and the expression of PD-like symptoms in for example IWS or AT.
This exploratory study describes a possible association between anticholinergic drugs 
and the development of PD and/or IWS. Although this study has several limitations, our 
findings warrant further study on the contribution of drugs with anticholinergic properties 
to the development of delirium and/or withdrawal symptoms. We would recommend 
prospective evaluation of risk factors for PD, IWS and AT in patients admitted to the 
PICU. Candidate risk factors should include ‘sweating’ and ‘seizures’. Sweating could 
possibly discriminate between PD/IWS on the one hand and AT on the other. As AT is 
characterized by dry skin, there could be a role for skin conductance here35 besides the 
use of a validated screening tool. Seizures may also be typical for AT but seizures may 
be triggered by many other events. 
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As we found that critically ill children with PD and/or IWS have a higher anticholinergic 
drug burden compared to patients who did not develop PD and/or IWS despite receiving 
anticholinergic drugs, clinicians should be aware that the anticholinergic drug burden may 
be associated with symptoms of PD or IWS in children. AT is probably rare, which makes 
it difficult to identify this in a standardized way.
Although more causative research is needed to support this association, the role of anti-
cholinergic drugs in children with PD and/or IWS should be considered in future research 
and in clinical practice.
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ABSTRACT
Background: Adequate analgesia and sedation is crucial in critical care. There is little 
knowledge on the extent of painful and stressful procedures on children admitted to a 
paediatric intensive care unit (PICU) and its analgesic and/or sedative management.
Objective: The primary objective was to determine the number of painful and stressful 
procedures per patient per day in our PICU patients, including the numbers of attempts. A 
secondary objective was to map PICU nurses’ perceptions of the painfulness of the included 
procedures.
Methods: A prospective, single-centre observational cohort study in a tertiary PICU. All 
patients admitted to the PICU over a 3-month period were eligible. Readmissions, poly-
somnography patients, and patients without any data have been excluded. The number 
of painful and stressful procedures was collected daily, and use of analgesics and seda-
tives was assessed and recorded daily. Twenty-five randomly assigned nurses rated the 
painfulness of procedures based on their personal experience using a numeric rating scale 
from 0 to 10.
Results: In a 3-month period, a total of 229 patients were included, accounting for 855 
patient days. The median number of painful and stressful procedures per patient per day 
was 11 (interquartile range = 5 - 23). Endotracheal suctioning was the most frequent proce-
dure (45%), followed by oral and nasal suctioning. Arterial and lumbar puncture, peripheral 
IV cannula insertion, and venipuncture were scored as most painful ranging from 3 to 10. 
Procedural analgesia or sedation was often not used during these most painful procedures.
Conclusions: Mechanically ventilated patients undergo more than twice as many painful 
procedures than non-ventilated patients, as endotracheal suctioning accounts for almost 
half of all. Nurses regarded skinbreaking procedures most painful; however, these were 
rarely treated by procedural analgosedation and only covered in the minority of cases by 
adequate background analgosedation.
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INTRODUCTION
Adequate sedation and analgesia (or analgosedation) are crucial elements of paediatric 
critical care. Paediatric guidelines recommend continuous administration of both a sedative 
(mainly benzodiazepines) and an analgesic (mainly opioids)1,2 to reduce pain and stress. 
This continuous background analgosedation may not be sufficient to alleviate procedural 
pain and distress in critically ill children, who are subjected to multiple possibly painful and 
stressful procedures everyday.3
Several studies have determined numbers of daily painful and stressful procedures and 
analgesic management in the neonatal intensive care unit (NICU),4-8 summarised in a system-
atic review of 18 studies which reported a mean of 7.5 - 17.3 daily painful procedures per 
patient in the NICU setting.9 Only two studies to date have addressed this issue in paediatric 
intensive care unit (PICU) patients. One is a retrospective multi-centre chart study published 
in 2011 which reported a median number of 12 (interquartile range [IQR] = 6 - 18) painful 
procedures per patient day in 799 PICU patients aged between 0 and 18 years.3 The 
second study, dating back to 1993, is a single-centre, prospective observational study in 
55 PICU patients aged between 0 and 12 years which reported median numbers of 2 
and 3.5 procedures per day, depending on length of stay.10 These two studies were limited 
to painful procedures only and did not account for the numbers of procedural attempts. 
To provide an in-depth analysis of the prevalence of painful and stressful procedures in 
our PICU, a prospective observational cohort study, also including stressful procedures and 
numbers of attempts per procedure, was undertaken.
The aim of this study was to determine the numbers of daily painful and stressful procedures, 
including numbers of attempts and to determine whether there is a relationship with age, 
mechanical ventilation, and surgery as these factors were found to be risk factors in NICU 
patients.5-7 The secondary aim was to map PICU nurses’ perception of the painfulness of 
the procedures and to evaluate procedural pharmacological analgesic and/or sedative 
treatment for the most frequent painful procedures.
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MATERIALS AND METHODS
Design, patients and setting
In this prospective observational cohort study, all patients admitted to the PICU between 
9th May 2016 and 9th August 2016 were eligible. This PICU is a 28-bed tertiary care 
unit for all medical and surgical specialities - including extracorporeal life support – for 
children aged 0 - 18 years including neonates with major congenital anomalies. The centre 
has a standard analgosedation protocol in place that has been published previously.11,12 
If a patient was admitted more than once in the study period, only the first admission was 
included for analysis. Patients admitted for observation only during polysomnography 
were excluded. The Institutional Review Board waived the need for informed consent (MEC 
2016-310).
Data collection
A paper checklist was designed including 40 possibly painful and stressful procedures, 
with a blank field to add a procedure if applicable. The list was based on literature find-
ings and expert opinion of the study team (MvD, EI, MB, KA). The checklist was tested for 
completeness during a 1-week pilot study among all attending PICU nurses. The data from 
this pilot have not been included for analysis. After this pilot study, two items were added: 
“Activities of Daily Living” and “Nebulising”. The final version (see Appendix 1) contained 
42 procedures, of which 31 were regarded painful and 11 stressful. Painful procedures 
were defined as skinbreaking procedures, skin-manipulating procedures or procedures 
involving the insertion or removal of lines, tubes, or catheters. Stressful procedures were 
defined as all other procedures without risk for pain, e.g. electrocardiography, magnetic 
resonance imaging, or computed tomography scans, physiotherapy, etc. Although painful 
procedures are likely to be stressful as well, we classified them separately as pain and 
stress and treated them differently.
The bedside nurses were instructed to record the listed procedures that each patient under-
went during the shift. New checklists were provided daily to nurses on the morning shift. 
Furthermore, the nurses were asked to record the numbers of attempts needed to suc-
cessfully perform the following procedures: heel and finger stick, venipuncture, peripheral 
intravenous (IV) cannula insertion, lumbar puncture, arterial puncture (arterial catheter 
insertion), central venous catheter insertion, nasogastric tube insertion, urinary catheter inser-
tion, nasopharyngeal tube insertion, and endotracheal intubation. Each failed attempt and 
the final successful one was counted as a separate procedure in the overall analysis. Data 
were collected related to relevant patient characteristics such as age, gender, mechanical 
ventilation (collected per patient-day), extracorporeal membrane oxygenation treatment 
(collected per patient-day), severity of illness, and reason for admission. Severity of illness 
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was calculated using the paediatric index of mortality-2 (PIM-2)13 score and the paediatric 
risk of mortality (PRISM-III) score.14 Further, any use of background analgesics, including 
paracetamol, non-steroidal anti-inflammatory drugs, fentanyl, morphine, tramadol, and 
remifentanil, and sedatives, including propofol, midazolam, lorazepam, clonidine, ketamine, 
chloral hydrate, and pentobarbital was assessed daily and recorded as having been 
received (yes/no). Procedural analgesics and sedatives were not collected prospectively. 
Retrospective collection of procedural drug prescription was often incomplete and could 
only be done for the top five of most painful procedures.
For each patient, data were recorded across the entire PICU stay. The data collected at the 
bedside were double-checked by one investigator (SJ) for completeness in - and completed 
by data from - the patient data management system and the electronic patient records.
To determine the painfulness of procedures, 25 randomly chosen nurses (with number of 
experience years in the PICU ranging from 1 to 30 with a median of 15) were asked to 
assign a numeric rating scale (NRS) pain score (ranging from 0 to 10; 0 represents no pain 
and 10 represents the worst pain imaginable) to all procedures based on their general 
impression of painfulness, so no patient observation was involved. Procedures routinely 
performed under sedation or analgesia, such as thoracic drain insertion/removal, were 
not selected. Subsequently, we recorded the administration of procedural sedatives and 
analgesics during these top five procedures.
In the study PICU, endotracheal suction is performed based on a set of clinical indications, 
including increasing ventilation pressures, decreasing oxygen saturations, decreasing tidal 
volume or ventilator minute volume, increasing end-tidal CO2, visible secretions, and saw-
tooth pattern in the expiratory curve of the flow-volume loop.
Statistical analysis
Demographics are presented with descriptive statistics as medians with IQRs. Neonatal vs. 
non-neonatal, postsurgery vs. non-postsurgery, and mechanically ventilated vs. non-me-
chanically ventilated patient group comparisons were based on the mean number of daily 
procedures per patient (i.e. the total number of recorded procedures per patient divided 
by the number of observation days) and performed with the Mann-Whitney U test for 
non-normal distributions of variables and Student t test for normally distributed variables. A 
Pearson correlation coefficient was performed for the linear correlation of severity-of-illness 
and the number of painful/stressful procedures. Data were collected per calendar day, 
and therefore, the patient’s first observation day is not equal to the first 24 h of admission. 
SPSS (version 21; IBM Corp.,Armonk, NY, USA) was used for all analyses. A p-value <0.05 
was considered statistically significant.
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RESULTS
Four hundred admissions occurred during the study period, one-quarter of the total number 
of admissions (n = 1597) in 2016. After exclusion of readmissions (n = 22), of patients of 
whom no record forms were available (n = 121) and of patients admitted for polysomnog-
raphy (n = 28), 229 patients were enrolled, accounting for 855 patient days (see Figure 1). 
Of the 121 excluded patients with missing record forms, 91 (75%) had been admitted for 
less than 24 h and 28 (23%) had been admitted for 24-48 h. Of all included patients, 97 
(42%) had been admitted for less than 24 h. Patient characteristics are displayed in Table 1. 
Figure 1. Inclusion flowchart. 
400 admissions in study period 
378 patients 
257 patients 
Enrolled in the study: n=229 
Readmissions: n=22 
Polysomnography 
 patients: n=28 
Excluded patients due to  
missing data: n=121 
Painful and stressful procedures
In total, 14,723 procedures were recorded during 855 patient days. A median number of 
11 (IQR = 5 - 23) procedures had been recorded per patient per day, with a maximum of 
113 in a patient who needed frequent endotracheal suctioning (93 times).
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Table 1. Patient characteristics.
Characteristic Value
Age in months (median, IQR) 15 (3-111)
Neonate (aged ≤28 days) n, (%) 40 (17.5%)
Boy/girl, n (%) 131/98 (57.2/42.8)
Length of stay in days (median, IQR) 2 (2-5)
Study observation days per patient (median, IQR) 2 (1-4)
Mechanical ventilation during data collection period, n (%)
 Not
 Part of admission
 Whole admission
166 (72 %)
36 (16 %)
27 (12 %)
ECMO, n (%) 5 (2.2%)
PRISM-III score (median, IQR) 3 (0-6)
PIM-2 score (median, IQR) 0.7 (0.3-2.1)
Diagnosis category N (%)
Postoperative
Yes
No
116 (51%)
113 (49%)
Cardiac 56 (25%)
Respiratory 54 (24%)
Neurological 47 (21%)
Gastro-intestinal 24 (11%)
Musculoskeletal 14 (6%)
Infection 5 (2%)
Urogenital 4 (2%)
Otolaryngological 3 (1%)
Other 22 (10%)
Abbreviations: ECMO: extracorporeal membrane oxygenation; IQR: Interquartile range; PIM: Pediatric Index of 
Mortality; PRISM: Pediatric RISk of Mortality
Further exploration of painful and stressful procedures identified that the median number 
of painful procedures was 7 (IQR = 2 - 19) and the median number of stressful proce-
dures was 3 (IQR = 1 - 5). Endotracheal suctioning was the most frequent procedure (n = 
6697, 45.5%). Table 2 identifies the top 10 most frequent painful and stressful procedures, 
including the median (IQR) pain score assigned by the 25 nurses (see also Fig. 2). The daily 
number of procedures tended to increase with longer duration of admission (Fig. 3). 
The number of painful and stressful daily procedures in the group of neonates (median = 
9, IQR = 7 - 17) was significantly higher than in the group of children >28 days (median 
= 7, IQR = 4 - 14) (p = 0.05). Regarding a comparison between mechanically ventilated 
and non-mechanically ventilated patients, the total number of procedures was significantly 
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higher in the former group: median = 15 (IQR = 9 - 22) versus median = 6 per day (IQR = 
3 - 10), (p < 0.001). Non-ventilated patients received significantly less painful procedures 
than ventilated patients: median = 2 (IQR = 1 - 6) versus median = 10 (IQR = 5 - 19). They 
also received fewer stressful procedures: 2 (IQR = 1 - 5) versus 3 (IQR = 2 - 5).
Table 2. Top 10 most frequently performed painful and stressful procedures with their perceived painfulness accord-
ing to 25 nurses. All failed attempts and the final successful ones are counted as separate procedures. 
Procedure Total number of 
procedures (%)
Median (IQR) NRS 
pain
Painful procedures
1 Endotracheal suctioning 6697 (45.5%) 2 (1-5)
2 Oral suctioning 1166 (7.9%) 2 (2-5)
3 Nasal suctioning 1153 (7.8%) 3 (2-5)
4 Adhesive removal 326 (2.2%) 3 (2-4)
5 Heel stick attempts 282 (1.9%) 4 (3-6)
6 Finger stick attempts 220 (1.5%) 4 (3-6)
7 Nasal flow cannula or nasal prongs placement 176 (1.2%) 1 (0-1)
8 Peripheral IV cannula insertion attempts 170 (1.2%) 6 (4-8)
9 Peripheral IV cannula removal 137 (0.9%) 1 (1-2)
10 Wound dressing 119 (0.8%) 4 (4-6)
Stressful procedures
1 Spraying 1074 (7.3%) 0 (0-1)
2 ADL care 930 (6.3%) not asked
3 EMV score 421 (2.9%) not asked
4 X-ray 202 (1.4%) not asked
5 General ultrasonography 127 (0.9%) not asked
6 Weighing 103 (0.7%) not asked
7 Electrocardiography 82 (0.6%) not asked
8 Physiotherapy 69 (0.5%) not asked
9 Cranial ultrasonography 33 (0.2%) not asked
10 Electroencephalography 26 (0.2%) 1 (0-3)
Postoperative patients underwent significantly fewer procedures per day (median = 7, 
IQR = 4 - 12 versus median = 9, IQR = 4 - 17, p = 0.03), with no significant difference in 
the number of painful procedures but a significantly lower number of stressful procedures: 
median = 2 (IQR = 1 - 4) versus median = 3 (IQR = 1 - 5).
There was a low correlation between severity of illness and the mean number of procedures 
per patient per day. Correlation for the PRISM-III score was 0.26 (95% confidence interval 
= 0.13 - 0.38) and for the PIM-2 score 0.20 (95% confidence interval = 0.07 - 0.32).
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Figure 3. Number of procedures per admission day and the number of patients per admission day included for 
analysis. 
Day 1 of admission reflects calendar day 1, not the first 24 h of admission.
Table 3 shows the total numbers of attempt per intended procedure. We observed a lower 
success rate (i.e. procedures without multiple attempts) for lumbar puncture, arterial line 
insertion, peripheral IV cannula insertion, and venipuncture (Table 4).
Procedural analgesia and sedation
Background analgosedation during procedures is illustrated by Figure 4a (for the proce-
dures rated most painful) and Figure 4b (for the most frequent procedures).
Continuous opioid administration was used in less than 40% of these procedures. For a full 
overview of background analgosedation during all procedures see Appendix 3. Table 5 
shows the procedural analgesic and sedative treatment of the top five most painful proce-
dures: arterial line insertion, lumbar puncture, peripheral IV cannula insertion, venipuncture, 
and subcutaneous injection. Although in the top five, venipuncture and subcutaneous injection 
have not been treated with procedural systemic analgesics or sedatives at all. Arterial line 
insertion was also covered in 25% of procedures. Two out of three lumbar punctures were 
covered by procedural analgosedation. Ketamine was the most frequently used agent, 
often accompanied by midazolam or propofol.
One patient underwent endotracheal suctioning 93 times in a day. This patient was admitted 
for a viral airway infection and received continuous midazolam and morphine. 
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Table 3. Numbers of attempt and success rate per painful procedure. 
Procedures Number of
intended procedures
Total number 
including failed 
attempts
Percentage of 
procedures with 
success in one 
attempt
Subcutaneous injection 34 34 100%
Thoracic drain insertion 5 5 100%
Urinary catheter insertion 25 26 95.8%
Nasogastric tube insertion 90 93 95.7%
Finger stick for blood sampling 192 220 90.2%
Heel stick for blood sampling 256 282 89.9%
Central venous catheter insertion 23 36 86.4%
Endotracheal intubation 9 11 77.8%
Peripheral IV cannula insertion 88 170 68.8%
Lumbar puncture 3 7 66.7%
Arterial line insertion 23 45 65.0%
Venipuncture for blood sampling 28 50 57.9%
IV = intravenous
Table 4. Number of painful and stressful procedures covered by an analgesic or a sedative.
Painful procedures Stressful procedures
Paracetamol 1950 (17.1%) 791 (23.7%)
Paracetamol + NSAID 119 (1.0%) 102 (3.1%)
Any opioid 321 (2.8%) 111 (3.3%)
Sedative alone 988 (8.7%) 189 (5.6%)
Sedative + PCM 1128 (9.9%) 211 (6.3%)
Sedative+opioid 4378 (38.5) 888 (26.6%)
No analgesic or sedative 2502(22%) 1045 (31.3%)
NSAID = non-steroidal anti-inflammatory drugs; PCM = paracetamol.
Table 5. Procedural analgesic and sedative bolus administration for treatment of pain during the 5 most painful 
procedures. 
Procedure Covered by procedural 
analgosedative (n, %)
Drugs used
Top 5 most painful procedures
1. Arterial line insertion (n=20) 5 (25%) Ketamine (n=3)
Propofol (n=3)
Fentanyl (n=2)
Midazolam(n=1)
2. Lumbar puncture (n=3) 2 (67%) Ketamine (n=2)
Propofol (n=1)
Midazolam (n=1)
3. Peripheral IV cannula insertion (n=77) 5 (6.5%) Midazolam (n=3)
Ketamine (n=1)
Propofol (n=1)
4. Venipuncture (n=28) 0 (0%)
5. SC injection (n=27) 0 (0%)
IV= intravenous; SC=subcutaneous 
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Figure 4. Background analgosedation in patients during the most painful (a) and most frequent (b) procedures. 
NSAID = non-steroidal anti-inflammatory drugs; SC = subcutaneous
a)
b)
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DISCUSSION
This first prospective observational cohort study on the frequency of painful and stressful 
procedures in the PICU setting revealed a median number of 11 per patient per day. 
Endotracheal suctioning was most frequent, followed by oral and nasal suctioning. Nurses 
ranked lumbar puncture, arterial puncture, peripheral IV cannula insertion, and venipuncture 
as the most painful procedures, and for those, often more than one attempt was needed 
to be successful.
The findings of this study are comparable to findings from previous studies in the NICU 
setting,5-7,9 although the total population differs. The current study includes neonates, and 
this group formed 17.5% of the total population. The median number of procedures (9, 
IQR = 7 - 17) in this group was lower than that in the NICU studies. Possible explanations 
are the inclusion of more premature neonates in the NICU studies compared to the study 
PICU where neonates are admitted after surgery only. Additionally, the neonates in this 
study had already undergone many procedures before admission at the PICU, for example 
endotracheal intubation and the insertion of arterial lines, central venous lines, peripheral IV 
cannulas, bladder catheters, and nasogastric tubes as part of the perioperative procedures 
in the operating room. The number of procedures also varied between studies. The current 
study included a total of 40 procedures compared to the study by Carbajal et al.5 which 
included 24, and the studies by Simons et al.7 and Roofthooft et al.6 included 34 proce-
dures. The current study overlapped with the total of these two studies, but extracorporeal 
membrane oxygenation and tracheal cannula care, nebulising, computed tomography and 
magnetic resonance imaging scans, and urinary catheter insertion were not listed. The inclu-
sion of these additional procedures in the NICU studies could have increased their number 
of painful and stressful procedures. 
With regard to the PICU, a multi-centre study in 15 Canadian PICUs from 2007 to 2008 
recorded a median of 12 painful procedures per day.3 In our present study, 9 years 
later, we found a median of seven painful procedures per day. This lower number could 
be explained by the fact that this study did not include procedures performed before 
admission to the PICU, such as endotracheal intubation, line insertion, and needle sticks in 
the emergency department, operating room, or referring hospitals. Whether Stevens et 
al. included these procedures is not clear. In addition, healthcare professionals may have 
become more aware of the amount of consistent procedural pain and tried to minimise the 
number of painful procedures, for example by changing routine endotracheal suctioning 
to criteria-led suctioning.
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Not surprisingly, the number of daily procedures is highest in the mechanically ventilated 
patients, as suctioning involves almost half of all procedures. In the NICU studies, nasal 
and endotracheal suctioning are also the most frequent procedures.6,7 In the current study, 
low numbers of both procedural and background analgosedation were observed for the 
most painful procedures, despite a well-balanced and published analgosedation regimen 
in place.11,12 Background analgosedation was used more often during the most frequent 
procedures; this could be attributed to the fact that suctioning is performed more often in 
mechanically ventilated patients who are usually sedated. 
Limitations
One of the limitations of this study is the risk of bias by underreporting. For lack of time 
or attention, nurses may not have recorded all procedures on the checklist during a shift or 
considered some procedures not painful or stressful as they could have not had enough time 
to review the case report form. Also, selection bias could have occurred due to the missing 
data from short admissions, although the majority of these patients were admitted for 
polysomnography and otherwise excluded from the study. The researchers double-checked 
reporting against the medical records, which nevertheless might also be incomplete. Also, the 
most painful procedures were selected based on survey results among 25 randomly selected 
nurses (accounting for 15% of total PICU nursing staff). This is a method prone to a certain 
degree of subjectivity. Still, in another observational study, skin-breaking procedures were 
ranked most painful as in the current study.15 Moreover, painfulness and stressfulness cannot 
always be easily distinguished. For example, the most frequent procedure, endotracheal 
suctioning, has been regarded as painful in the literature16,17 but may be stressful as well.18-
20 Our survey shows a high variability in responses by nurses to endotracheal suctioning. 
The observed pain behaviour during endotracheal suctioning in studies using several pain 
scales could also be a response to stress, as this is a very frightening, unpleasant procedure.
Interpretation
The painfulness of a procedure can vary within and between patients, although this needs 
further study. For example, activities of daily living may normally not be painful but may 
be very painful in a patient after severe trauma. Perceptions of painfulness may also 
affect pain management. For example, in our hospital, topical anaesthesia is frequently 
used before peripheral IV cannula insertion but is rarely ever used before heel or finger 
sticks. This is remarkable as these procedures may not differ in painfulness. Further study 
is warranted to explore the perception of painfulness of procedures and standardisation 
of procedural pain management by performing prospective evaluation of pain during 
procedures.
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FUTURE PERSPECTIVES
Painful and stressful procedures are, unfortunately, unavoidable in paediatric critical care. 
Measures to reduce the number of these procedures should be considered. To reduce the 
frequency of endotracheal suctioning, which was found most frequent, we could recommend 
re-considering the indications for endotracheal suctioning. In the study centre, suctioning is 
performed only at indications supported by current evidence. Prospective evaluation of 
these indications in relation to the need of suction could possibly reduce the frequency of 
suctioning by identifying the strongest indications and by performing suctioning only for 
the strong indications.21
Another way of reducing the frequency of painful procedures is to improve technical skills 
to reduce the number of attempts for certain procedures that required multiple attempts. 
These were also ranked as most painful procedures: lumbar puncture, peripheral cannula 
insertion, arterial puncture, and venipuncture. The number of lumbar puncture attempts may 
be improved through the use of simulation training22 or with the use of ultrasound.23,24 Ways 
of improving venipuncture and peripheral IV cannula insertion are yet to be established 
because so far vein visualisation techniques have not been proven to be effective in reducing 
the number of failed attempts of IV cannula insertion or venipuncture.25-27
Standardisation of pain-reducing measures, both pharmacologic and non-pharmacologic, 
could improve the quality of care for critically ill children. NICU guidelines recommend 
several measures such as oral sucrose administration, facilitated tucking position, and 
non-nutritive sucking.28 However, guidelines for the PICU are not available yet. In the study 
centre, oral sucrose is administered to neonates; however, this is not a standardised practice. 
Eutectic mixture of local anaesthetic is also available but is only used in older children and 
is also not standardised. Uniform guidelines should be established to improve the analgesic 
management of painful procedures.
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CONCLUSIONS
The PICU patients in this study on average underwent seven painful and three stressful 
procedures per day. Mechanically ventilated patients undergo more than twice as many 
painful procedures than non-ventilated patients, as endotracheal suctioning accounts for 
almost half of all. Nurses regarded skin-breaking procedures most painful but these pro-
cedures were rarely covered by procedural analgosedation and only in less than half of 
the cases continuous background analgosedation was used. Measures to reduce the number 
of painful procedures could include revision of indications for endotracheal suctioning 
and improving technical skills through training and/or the use of assistant devices such as 
ultrasound guidance.
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ABSTRACT
Background: A previous RCT showed equipotency of paracetamol IV compared to morphine 
IV after surgery in infants, and significantly reduced morphine consumption. Many RCT 
results are neither implemented nor evaluated in real-life clinical care. We implemented 
and studied the efficacy of and adherence to a protocol dictating paracetamol IV instead 
of morphine IV as primary analgesic in infants.
Methods: Data were collected from infants after major surgery. The protocol prescribed a 
morphine bolus dose (100 mcg/kg, IV) followed by paracetamol IV and rescue morphine if 
needed. Outcome measures were: 1. for therapeutic efficacy: total morphine need, rescue 
morphine, pain scores and adverse events; and 2. for protocol adherence: type of analge-
sics and doses given. These data were compared to RCT results.
Results: Of 75 patients, 62 were aged <11 days (82.7%). 1. Therapeutic efficacy: The 
median cumulative morphine consumption 48 hours postoperatively, was 121 mcg/kg (IQR 
93-320). This was similar to the RCT paracetamol arm: 121 mcg/kg (IQR 99-264), p=0.72. 
Forty (53.3%) patients did not receive rescue morphine; 8 patients only received boluses 
(median n=2, IQR 1-4), 27 also received continuous morphine (median 7.9 mcg/kg/hr 
(IQR 5-10)). 2. Adherence: Seventy-four (98.7%) patients received IV paracetamol. Sixty 
(80.0%) patients received a median morphine (n=50) or other opioid (n=10) loading dose 
of 100 mcg/kg (IQR 88.2-112.4). Morphine was started sooner and at higher doses than 
the protocol dictated. 
Conclusions: IV paracetamol as primary analgesic in postsurgical infants was successfully 
implemented. This finding supports wide-spread implementation of IV paracetamol as 
primary analgesic in infants.
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INTRODUCTION
Applying findings of a randomized controlled trial (RCT) in clinical practice is a big chal-
lenge. It will take around 17 years and is affected by barriers such as low acceptance by 
health care professionals, lack of motivation and lack of awareness about and ‘forget-
ting’.1-3 Moreover, clinical outcomes of an intervention in real-life clinical practice may differ 
from those in a research setting. An important cause is the difference in study population 
of trials and clinical practice, as in most trials strict inclusion and exclusion criteria limit the 
inclusion of ‘outlier’ patients. Clinical implementation studies are needed to determine the 
success of new interventions in clinical practice after good RCT results have been obtained. 
This implementation study describes the successful implementation of a new postoperative 
pain protocol in infants undergoing major non-cardiac surgery.
Opioids have a key role in the postoperative analgesia of children after major thoracic 
and abdominal surgery. Regrettably, these can cause adverse effects such as respiratory 
depression, oversedation, urinary retention and gastrointestinal paralysis.4 Paracetamol as 
an alternative analgesic was found to be potentially opioid-sparing in adults and older 
children.5-8 Another study with rectal paracetamol in children below the age of 4 did not 
find a morphine-sparing effect after major surgery.9 This was explained by the plasma 
level variability of rectal paracetamol. Both study groups also received a high background 
morphine infusion, which could not be decreased in the first 24 hours after surgery.9 In 2013 
we published the results of a double-blind RCT in our institution: infants between 0 and 1 
years old received either intravenous (IV) paracetamol (n=33) or IV morphine (n=38) as a 
first-choice analgesic after major abdominal or non-cardiac thoracic surgery.10,11 Morphine 
rescue medication was given on demand in both groups. The main finding was a 66% lower 
overall morphine consumption in the paracetamol group with similar pain scores.12 This 
motivated our team to implement these study findings into our hospital’s clinical practice. 
The aim of this study was to evaluate 1. The ‘real-life’ efficacy of paracetamol IV as primary 
analgesic after major surgery in neonates and young infants and compare this efficacy to 
the trial results, and 2. Staff adherence to the new clinical protocol.
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METHODS
Study design
This retrospective implementation study was performed in the level-three intensive care unit 
(ICU) of the Erasmus MC-Sophia Children’s Hospital, Rotterdam, the Netherlands. Patients 
were included from 1st February 2014 till 1st December 2015.
Patients younger than 1 year admitted to the ICU after major (non-cardiac) thoracic or 
abdominal surgery were eligible for inclusion. For patients operated more than once in the 
study period, only the first surgery was included. Patients having received morphine in the 
24 hours before surgery were excluded, as well as patients having received loco-regional 
blockade or epidural anesthesia perioperatively. The Erasmus MC research ethics board 
provided a waiver for ethics approval and informed consent according to the Dutch law 
on research in humans (MEC 2016-087). 
Figure 1. Bedside Pain Protocol flowchart.
PAIN?  
NRS: 4-10 and 
COMFORT-B score ≥17 
Protocol postoperative 
pain PICU 0-1 years 
Start Paracetamol IV 
Loading dose: 20mg/kg;  
Maintenance:10 mg/kg Q6h (term neonates <30days) or 15 mg/kg q6h   
Morphine IV loading dose 100 
mcg/kg, 30 min before end of surgery 
Morphine bolus each 10 min.,  
max. 3 x per hour 
 age ≤10 days: 10 mcg/kg 
 age ≥11 days :15 mcg/kg 
Start Morphine IV: 
Loading dose morphine 100 mcg/kg and 
start continuous infusion: 
<10 days: 1.25 mcg/kg1.5/h  
≥10 days: 2.5 mcg/kg1.5/h 
Increase: Double current dose 
Yes, after 
3rd  bolus 
Yes,1st to 3rd 
bolus 
Pain free? (>12 hours: NRS<4 and 
COMFORT-B 6-16): reduce infusion 
rate with 50% until stop. 
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Postoperative Pain Protocol
By the new protocol (Figure 1), an IV morphine bolus of 100 mcg/kg was administered +/-30 
minutes before the end of surgery. The previous protocol then prescribed continuous morphine 
infusion (10-20 mcg/kg/h) but this was now changed to paracetamol IV as follows: postoper-
atively, patients were given a loading dose of IV paracetamol (20 mg/kg) within 1 hour of 
arrival on the ICU. Intravenous paracetamol was given in accordance with the Dutch Pediatric 
Drug Handbook (Figure 1).13 Pain and distress were assessed with the COMFORT Behavior 
scale (COMFORT-B scale) and the Numeric Rating Scale-11 (NRS-11) by the attending nurse 
every two hours or when clinically indicated. Both scales have been validated for this age 
group and indication.14-17 Up to three morphine rescue boluses (Figure 1) were given within 
one hour if scores indicated pain (COMFORT-B ≥17 and/or NRS-11 ≥4). Another change to 
the protocol concerned the dose of the morphine rescue infusion. If pain persisted, continuous 
morphine was started (1.25 mcg/kg1.5/h if ≤10 days vs. 2.5 mcg/kg1.5/h if ≥11 days) after 
a bolus of 100 mcg/kg. These morphine infusion rates were validated in a previous population 
PK model, resulting in similar morphine plasma concentrations across the age range of 0 to 1 
year, and was also used in the RCT.18 The morphine infusion rate could be increased until ade-
quate analgesia was reached, each increase preceded by a 100 mcg/kg IV loading dose. 
Implementation 
During a three-month implementation period, nurses and physicians were educated in a 
30-minute session, in which the background of the protocol changes and the revised pro-
cedure was explained. New staff recruited during the study period was also instructed. To 
remind the nurses and physicians using the new pain protocol we used a bedside flowchart 
(Figure 1), pocket cards, and screen-savers on all the desktops in the PICU. Further, we 
appointed local opinion-leaders encouraging colleagues to work according to the protocol 
(e.g. during daily rounds).
 
Study end points 
The primary end points were: 
1. Efficacy of paracetamol IV as defined by the total opioid consumption (mcg/kg in 
morphine equivalent doses) in the first 48 hours postoperatively, including the intra-
operative loading dose, the rescue morphine doses and the continuous infusion dose. 
Secondary end points were: the number of rescue morphine doses per patient, number 
of patients receiving rescue doses and/or continuous morphine, time to first rescue dose, 
mean NRS-11 and COMFORT-B scores, and morphine-related respiratory adverse 
effects. Morphine-related respiratory adverse effects were defined as: (1) apnea, 
defined as oxygen saturation less than 92%, or longer than 15 seconds, or reported 
by the nurse with a subsequent intervention like extra oxygen supply; (2) reintubation; 
(3) naloxone administration.
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2. Adherence to the protocol, defined by correct morphine loading dose, correct IV parac-
etamol loading and maintenance doses, rescue doses given on the basis of pain scores, 
cases in which at least three morphine rescue boluses had been given before the start 
of continuous morphine, morphine rescue infusion dose.
Data collection
Data were retrieved from the electronic patient data management system. Collected patient 
data included age at surgery, sex, type of surgery, severity-of-illness scores (PIM-2),19 
surgical stress score20 (calculated retrospectively), postoperative mechanical ventilation 
duration, and relevant co-medication. 
The collected drug dosing data included administration route, dosage, the use of a morphine 
or equivalent opioid loading dose, the use of a paracetamol loading dose, number of 
morphine rescue boluses and dosages, and the use of continuous morphine and its dosages 
during the first 48 hours. Complete protocol adherence was defined as having received an 
intra-operative opioid loading dose of 100 mcg/kg (+/- 10%), and having received an 
IV paracetamol loading dose of 20 mcg/kg (+/- 10%) and having received appropriate 
IV paracetamol maintenance doses. For patients who received rescue morphine, the next 
criteria apply as well: Up to three boluses of IV morphine in the appropriate dose and in 
case of continuous morphine, started with the correct dose and having been preceded by 
three boluses. 
During data analysis, we noticed that not all patients had received a morphine loading 
dose during surgery; either because they were given piritramide instead of morphine or 
received additional fentanyl boluses towards the end of surgery. In the latter case, the 
anesthesiologist refrained from giving the morphine bolus as these fentanyl doses were 
expected to provide similar analgesia directly postoperatively. We included the piritramide 
and fentanyl doses by calculating morphine equivalents as follows: 1 mg morphine equaled 
0.015 mg fentanyl, and 1 mg piritramide.21 
Statistical analysis
Summary statistics are presented as medians (interquartile range [IQR]) or means (standard 
deviation [SD]) for continuous variables and as percentages for categorical variables. Pri-
mary and secondary outcomes of this study were compared with individual patient data 
of the intervention group of the RCT by Ceelie et al.10 using a Mann-Whitney U test as the 
data were not normally distributed. Categorical data were tested with Fisher exact test. 
Mean COMFORT-B and NRS scores were calculated for the individual patient during the 
first 48 hours. A two-side p-value of < 0.05 indicated statistical significance. All statistical 
analyses were performed using SPSS version 21.0 (IBM SPSS Statistics).
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RESULTS
Patients
Data of 75 of 135 eligible patients were included in the analysis (Figure 2). Excluded 
patients were significantly older (49% ≥ 11 days of age; p <0.0001), but sex, type of 
surgery, and mechanical ventilation did not differ from the included patients. The median 
age of included patients was 3 days (IQR 1-6) and 62 (83%) were ≤ 10 days of age (Table 
1). Sixty-one patients were ventilated after surgery with a median duration of 24 hours 
(IQR 16-78.5). The included patients were significantly younger; more often mechanically 
ventilated; and had higher surgical stress scores than the patients in the paracetamol group 
of the RCT (see Table 1).
Figure 2. Inclusion flowchart
N=149 patients with first 
surgery from Feb 2014 until 
Dec 2015 
N=14 patients received 
morphine 24h before surgery 
N=75 patients included 
for analysis 
N=45 received a loco-regional block 
N=15 received epidural anesthesia 
N=135 patients eligible 
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Table 1. Patient characteristics
Implementation
cohort
(n=75)
RCT – paracetamol 
group 
(n=33)
p-value
Age in days [median (IQR)] 3 (1-6) 5 (2-65) 0.07
Age groups [n=(%)] 
-≤10 days 
-≥11 days 
62 (82.7)
13 (17.3)
17 (51.5)
16 (48.5)
0.001
Weight in kg [median (IQR)] 3.0 (2.7-3.6) 3.4 (2.7-4.7) 0.04
Sex [n= (%)]
-Male
-Female
48 (64.0)
27 (36.0)
18 (54.5)
15 (45.5)
0.39
Major surgery in history [n=(%)] 3 (4.0) ND -
Type of surgery [n= (%)]
-Thoracic
-Abdominal
24 (32.0)
51 (68.0)
5 (15.2)
28 (84.8)
0.17
Ventilation after surgery [n=(%)] 61 (81.3) 15 (45.5) <0.0001
Duration of ventilation after surgery in h 
[median (IQR)]
24 (16-78.5) 34 (15-45) 0.03
PIM2 percentage [median (IQR)] 1.5 (0.5-4.1) 1.3 (0.6-1.9) 0.39
Surgical stress score [median (IQR)] 9 (8-10) 10 (9-11) 0.001
RCT – Randomized Controlled Trial; ECMO - Extracorporeal Membrane Oxygenation; PIM – Pediatric Risk of 
Mortality; IQR – Interquartile range
Efficacy: Morphine loading and rescue dosing
The median cumulative morphine dose per patient was 121.1 (IQR 92.6-319.9) mcg/kg per 
48 hours (Table 2) and an overall median of 0 (IQR 0-3.0) bolus doses. More in detail: sixty 
(80.0%) patients received a median 100.0 mcg/kg (IQR 88.2-112.4) morphine (n=50) or 
morphine equivalent (n=10) loading dose before transfer to the PICU. Thirty-five (46.7%) 
patients received morphine rescue bolus doses with a median number of 2 per patient (IQR 
1-4). Twenty-seven of those (36.0%) also received continuous morphine, at a median rate 
of 7.9 mcg/kg/hr (IQR 5.0-10.0). 
The cumulative morphine dose in patients ≤ 10 days of age was significantly lower than 
that in older patients (p=0.034). The median cumulative morphine dose was similar to that 
in the RCT (p=0.42); the proportion of patients receiving rescue morphine was almost sig-
nificantly lower than in the RCT (46.7% vs 66.8%, p=0.06) (Table 2). The overall median 
number of morphine rescue doses per patient was significantly lower than that in the RCT: 0 
(IQR 0-3) vs 2 (0-5) (p=0.012). The median loading dose of morphine or equivalent other 
opioid was not significantly different from the dose in the RCT (p=0.185). 
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Table 2. Outcome measures of implementation cohort versus original RCT
Implementation 
cohort
(n=75)
RCT – paracetamol 
group
(n=33)
p-value
Morphine consumption‡ in mcg/kg/48h 
[median (IQR)]
[mean (SD)]
According age groups
- ≤10 days
- ≥11 days
121.1 (92.6-319.9)
234.3 (256.5)
111.7 (89.7-267.2)a
262.3 (134.5-542.9)b
121 (99-264)
209.6 (196.4)
111.1 (96.4-169)c
151.6 (112-346)d
0.724
0.624
0.361
0.121
Morphine equivalent loading dose*‡ 
[median (IQR)]
[mean (SD)]
100.0 (88.2-112.4)
94.0 (6.7)
98.7 (95.0-100.2) 
99.4 (2.1)
0.185
Rescue morphine dose in mcg/kg
[median (IQR)]
[mean (SD)]
0 (0-194.9)
140.3 (27.9)
25 (0-164.0)
110.2 (34.2)
0.365
Number of rescue morphine doses 
[median (IQR)] all patients
0 (0-3.0) 2 (0-5.0) 0.012
Number of patients receiving rescue 
morphine [n= (%)] 
35 (45.5) 22 (66.8) 0.06
Number of patients receiving continuous 
morphine [n= (%)]
27 (35.1) 8 (24.2) 0.372
Number of rescue morphine doses 
[median (IQR)] in patients receiving 
rescue (n=35)
2 (1-4) ND
Time to first morphine rescue dose in 
minutes [median (IQR)]
120 (66-366) ND
COMFORT-B score [mean (SD)] 12.1 (2.1) 13.1 (2.1) 0.03
COMFORT-B ≥17 [n= (%)] 30 (40) 22 (66.7) 0.008
NRS Score [median (IQR)] 0 (0-0.4) ** 1 (0-1) *** 0.003
NRS ≥4 [n= (%)] 21 (28.0) ** 22 (68.8) *** <0.0001
RCT – Randomized Controlled Trial; NRS – Numeric Rating Scale; IQR – Interquartile Range; SD – Standard 
deviation; a: n=64; b: n=13; c: n=17; d: n=16; * n=69 patients received an intraoperative loading dose of 
morphine or other opioid; NRS scores available in **n=67 patients; ***n=32 patients; ‡ morphine consumption 
and loading dose depict morphine and morphine-normalized doses of other opioids.
The median COMFORT-B and NRS-11 scores were significantly higher for patients who had 
received rescue morphine compared with patients who received only intravenous parac-
etamol (COMFORT-B score: 13.7 [IQR 11.2-14.8] vs 11.0 [IQR 10.1-11.7], p<0.0001; 
and NRS-11: 1.3 [IQR 0.5-2.3] vs 0 [IQR 0-0.3], p<0.0001). Also, the proportion of high 
COMFORT-B scores (≥17) was significantly higher in patients who had received rescue 
morphine 77% vs 23% (p<0.0001). 
166 Chapter 7
Morphine-related respiratory adverse events were observed in 13 of 75 (17 %) patients. 
These were counteracted by the following interventions: oxygen supply (n=6), change in 
ventilator setting (n=4), administration of naloxone (n=1), and re-intubation (n=2). Re-intu-
bation was needed in one case for tube dislocation and in one case for bradypnoea after 
abdominal surgery.
Protocol adherence 
Sixty of 75 patients received an opioid loading dose before transfer to the PICU, of whom 
10 received piritramide or fentanyl instead of morphine. Seventy-four (98.7%) patients 
received an intravenous paracetamol loading dose and maintenance doses. One other 
patient received rectal paracetamol. For 63/75 (84.0%) patients the paracetamol loading 
and maintenance doses were in accordance with the Dutch Pediatric Drug Handbook guide-
lines. Twenty-seven patients started on continuous rescue morphine, of whom only 7 (25.9%) 
correctly received 3 bolus rescue doses before start; all other patients received fewer 
boluses prior to the start of continuous infusion. Five of those 27 (18.5%) patients received 
the correct infusion dose; all others received higher doses than the protocol prescribed. 
Of all 62 morphine rescue boluses given, 57 (91.9%) were given after a NRS≥4 and/or 
a COMFORT-B score ≥17. In total, 10/75 (13.3%) patients of patients were treated with 
complete protocol adherence.
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DISCUSSION
Intravenous paracetamol as primary analgesic in neonates and young infants after major 
surgery was effectively implemented in clinical practice as the morphine consumption was 
as low as in the paracetamol arm of the RCT. Moreover, only half of patients needed small 
morphine rescues doses and one third an additional continuous morphine infusion. In the RCT, 
the additional rescue morphine dose did not differ between patients receiving paracetamol 
IV and those receiving morphine continuous infusion, and pain scores were similar in these 
groups.10 These findings suggest that we have overcome some of the traditional barriers to 
successful implementation, such as lack of awareness and agreement.22,23
Adherence to the first part of the protocol, i.e. the instruction to give an opioid loading dose 
followed by IV paracetamol as first-choice analgesic, was high. Also, rescue boluses were 
given in more than 90% of cases when pain scores indicated pain. Interestingly, morphine 
infusions were often started before the patient had received all 3 boluses doses and at a 
higher rate than the protocol dictated, contributing to the relatively low overall protocol 
adherence. The relative complexity and newness of the morphine dosing might explain that 
the infusion doses prescribed were higher than the protocol recommendation. Nevertheless, 
the earlier start of rescue morphine infusions with higher doses did not result in overall higher 
morphine requirements. Hence, we still consider the clinical implementation of paracetamol 
IV as primary analgesic successful in daily practice.
We also found that patients under the age of 11 days needed less rescue morphine than 
older children, in line with earlier findings.10,18 This might suggest either that the opioid-spar-
ing effect of IV paracetamol with morphine rescue is more pronounced in this age group 
or that older infants (10 days to one year) experience more postoperative pain. The latter 
explanation is supported by a similar observation in our RCT: in the trial arm receiving 
continuous morphine, the neonates needed less rescue morphine than the older children, 
while morphine plasma concentrations were similar.18 A PK-PD study showed an increasing 
hazard ratio for additional morphine doses post cardiac surgery with increasing age, with 
the largest increase in the first year of age, which may support our findings.24 
This study has several limitations. Several patients received other opioids than morphine 
as loading dose at the end of surgery. We included this dose after correction for opioid 
strength, but this still may have biased the comparison of total morphine dose between the 
RCT and the present study. Also, the number of children older than 10 days in our study was 
relatively small, which may limit the extrapolation of the results to the children older than 
10 days. Reassuringly, though, like in the RCT, the older children needed more morphine 
than the younger children.10 Moreover, demographics of our cohort differed from those 
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of the paracetamol group in the RCT. The median age was lower, albeit not significantly, 
and more patients were ventilated and for a longer period of time. Yet this did not affect 
the cumulative morphine doses. Further, the statistically significant 1-point difference in the 
surgical stress score cannot be considered as clinically relevant. Lastly, the present study 
was performed in the unit that was the setting of the original trial. The continued attention 
to adequate pain assessment by trained nurses and nurse-led protocolized analgesia in 
this unit may have positively influenced the results of the present study. Implementation of 
our protocol to other PICUs may be more challenging as many studies indicate that pain 
assessment is not systematically performed in neonates and infants; in developing and 
developed countries alike.25-29 
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GENERAL DISCUSSION
This thesis addresses several important issues of pain and sedation management in the PICU. 
Chapters 2 and 3 make clear that solid evidence for the current clinical practices is lacking. 
We identified the problems of trial design and absence of objective and reliable clinical 
end points. Chapter 4 describes a planned RCT which for several reasons was significant 
delayed and had a dismal inclusion rate. Chapter 5 is an exploratory study on anticho-
linergic drug burden in patients with and without pediatric delirium and/or iatrogenic 
withdrawal syndrome. We found a higher drug burden in affected patients and this calls 
for further research. In chapter 6 we counted a median of 11 painful and stressful proce-
dures in patients admitted to the PICU and this leaves room for improvement. Chapter 7 
addresses the facilitators and barriers to implementing a new pain management protocol 
for postoperative infants, with paracetamol as first line analgesic drug. These studies raised 
a lot of questions and in this general discussion several of these questions will be addressed. 
Drug therapy in the pediatric intensive care unit
Pediatric intensive care patients receive a median of 14 (IQR 9-19) different drugs during 
their admission,1 often including analgesics and sedatives.2 It has been realized for years that 
children are not ‘small adults’ and that their drug metabolizing capacity is still developing 
during the first years,3 or even the first days,4 of life. However, children admitted to a PICU 
are not representative of healthy children and their drug metabolizing capacity is influenced 
by other factors. Many extrinsic factors such as mechanical ventilation altering the hepatic and 
renal blood flow,5-7 extracorporeal membrane oxygenation (ECMO), surgery8 or therapeutic 
hypothermia,9 can alter both pharmacokinetics (PK) and pharmacodynamics (PD). 
Critical illness itself impacts PK. For example, inflammation, by affecting CYP3A metabolism, 
reduces midazolam clearance by 65%.10 Patients with severe inflammation should therefore 
receive lower than usual midazolam. Multi-organ failure also reduces clearance due to liver 
and kidney dysfunction. On the other hand, treatment may also have an impact. ECMO 
affects both drug elimination and the volume of distribution.6,7 Therapeutic hypothermia 
strongly reduces morphine clearance by diminishing enzymatic activity.6,7,9 Positive pressure 
ventilation as well as cardiac surgery alters hepatic blood flow,5 thereby affecting the PK 
of morphine.11 It is therefore not surprising that critically ill children and neonates show 
greater inter-individual variation in clearance than their non-critically ill comparators.12,13 
Inter-individual variation in PK and PD means that a one-size-fits-all drug dosing approach 
is not appropriate. ‘Personalized’ or ‘precision’ medicine is the way to go in the PICU.14 But 
how can we achieve this? Most recent advances in pediatric critical care drug research have 
been made in silico, which means that trials are now being simulated in silico. The results 
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can be used in adaptive trial designs.15 This approach allows for changing the sample 
size during the trial using pre-specified rules, based on the results from interim analyses. 
Also, population-PK models, and even PK-PD models, have led to a more precise dosing 
of morphine in children.16,17 Yet, there are way more steps to be taken in this direction. An 
integrative, system-based approach, in which many variables are taken into account such 
as hepatic blood flow, critical illness, pharmacogenomics, could determine what drug dose 
is needed for an individual patient.18 Hepatic blood flow can be measured non-invasively 
using Doppler ultrasound,19 but there are no time- or age-dependent normalized values 
and the technique needs real expertise. Despite modeling efforts that take hepatic blood 
flow into account,20 the contribution of hepatic blood flow to the clearance of high hepatic 
extraction ratio drugs in children has seldom been studied. Hence, we need pediatric 
physiologically based PK (PBPK) studies that take hepatic blood flow into account as a 
covariate with subsequent measurements of the hepatic blood flow in each patient with the 
exact date and time recorded.
There is a growing body of literature on the influence of pharmacogenomics on PK and PD 
in children.21 Matic et al. found two genes that play a role in morphine pharmacokinetics 
in neonates, UGT2B722 and SLC22A1 (OCT1),23,24 and two genes that could be involved 
in opioid pharmacodynamics in neonates, COMT and OPRM1.25,26 However, this genetic 
influence needs to be quantified in prospective studies and I would therefore recommend to 
sample blood or oral swabs for DNA analysis in future analgesic trials in the PICU. Residual 
material should be stored, as new candidate genes can be discovered. The storage costs 
should be budgeted and separate informed consent for sampling and DNA analysis should 
be asked. Still, most of these developments would only contribute to appropriate drug 
dosing. The evidence for using a drug in a specific population is predominantly based on 
the drug’s safety and efficacy. First I will highlight a specific safety issue which applies to 
drug therapy in the PICU population: the long-term effect of drug exposure on the brain. 
A developing brain might be impacted much more than a ‘fully matured’ brain by the 
administration of a drug acting on the central nervous system. Animal studies have shown 
alterations in brain development and neuroapoptosis after administration of opioids,27 
benzodiazepines28 and narcotics in infant animals.29 This could be explained by the ‘growing 
into deficit’ phenomenon, where early damage may have larger consequences later in life.30 
Fortunately, human data so far do not suggest a dramatic impact of opioid administration 
in young infants.31-35
This is nevertheless challenging to study further, as several factors may influence study end 
points. For example, untreated pain has also its effects on the developing human nervous 
system.36-39 So if we observe altered brain structure in later life of neonates who received 
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opioids, does this mean the dosing was not sufficient to prevent pain-induced damage38,40 
or were they overdosed? Also, critical illness and its treatment influence neurodevelopment.41 
So how can we unravel the effects of the different components?
A good example of a trial addressing the long-term safety of anesthetics is the GAS-trial,42 
which compared the effects of local anesthesia on cognitive performance with those of 
general anesthesia. The study population consisted of children undergoing elective inguinal 
hernia repair. This study used stratification according to gestational age to control for pre-
maturity. The investigators found no significant influence of short-term general anesthesia 
(sevoflurane) on cognitive performance two years later, like in other similar studies.31,32 It 
should be noted, however, that the GAS-trial concerned relatively healthy children, and 
that the general anesthesia exposure was shorter than 60 minutes. 
But how can we translate such research to the PICU, where children systematically receive 
opioids and benzodiazepines and sometimes need multiple surgeries? One possibility is a 
clinical trial with stratification according to diagnosis. Sedatives might have different effects 
in fairly healthy children with respiratory insufficiency than in children with brain injury. 
Moreover, local anesthesia techniques such as epidural or locoregional anesthesia may 
reduce the consumption of opioids in children and could serve as a basis for comparison 
between patients with low or high opioid consumption after surgery.43
Another important point of interest is our hypothesis that the earlier the damage has 
occurred, the larger the consequences later in life (growing into deficit).44 However, the brain 
is known for its plasticity, especially the young and maturing brain.45 Therefore, deficits may 
on the one hand cause bigger deficits in later life, but it could also be that the brain is able 
to compensate by restructuring mechanisms in order to “repair” damage. This could explain 
why a significant long-term effect of neonatal exposure to anesthetics, benzodiazepines or 
opioids has not been found yet. 
De Graaf et al. investigated the long-term effect of routine morphine infusion in mechan-
ically ventilated neonates.31,32 At the age of 5 years, these children had a lower IQ on 
‘visual analysis’ than those who had not received morphine; other significant differences 
were not found. At the age of 9 years, none of the outcomes was significantly different 
between the groups. These findings were supported by Van den Bosch et al. who found 
an average neurocognitive performance, assessed by the NEPSY-II-NL test, in 10-year-old 
who had been exposed to morphine at neonatal age.35 Therefore, no major concerns about 
neonatal morphine exposure have been raised.
178 Chapter 8
Table 1. An overview of studies investigating the possible harmful long-term effect of anesthesia exposure in 
young children.
Author, year of 
publication
Study design N= Primary outcome Follow-up 
duration
Overall outcome on 
neurodevelopment
Age subgroup analysis?
Ing et al., 201448 Retrospective observational cohort study. in children 
exposed to anesthetics exposure ≤3 years of age
112 patients Neuropsychological 
assessment, 
comorbidity and 
school grades
Up to 10 years 
of age
Increased risk of 
deficit assessed by 
neuropsychological 
testing, no difference in 
school grades
Not available
Sun et al., 2014, 
PANDA trial49
Sibling matched ambidirectional cohort study 105 sibling pairs IQ Up to 15 years 
of age
No difference exposed 
vs. unexposed
No difference across age groups
Backeljauw et al., 
201550
Observational cohort study, patients exposed to 
anesthetics exposure ≤4 years of age
53 patients, 53 controls Neurocognitive 
assessment and MRI
Up to 18 years 
of age
Diminution of language 
abilities and cognition
Not available
Hansen et al., 
201551
Retrospective observational case-control study. 
Cases: Anesthetics exposure for neurosurgery in 
infancy
228 patients
14,698 controls
Mortality and 
school grades
Up to 16 years 
of age
Significant but very 
small difference in 
school grades (lower 
grades in exposed 
group)
Not available
Graham et al., 
201652
Population-based case-control cohort study in 
children undergoing minor surgery <4 years of age
4,470 patients with one 
exposure,
3,640 patients with multiple 
exposures, 13586 controls
Early Development 
Index
Age 5-6 years Decreased performance 
on the EDI in the 
exposed group
Age at exposure:
≤2 years: no significant difference
>2 years of age: significant difference
O’Leary et al., 
201653
Population-based case-control cohort study in 
children undergoing minor surgery <4 years of age
28,366 patients, 55,910 
controls
Early Development 
Index
Age 5-6 years Decreased performance 
on the EDI in the 
exposed group
Age at exposure:
≤2 years: no significant difference
>2 years of age: significant difference
Conrad et al., 
201754
Longitudinal follow-up study in children with cleft 
palate
87 Cognitive, growths 
and brain measures
Up to 17 years 
of age
Increased frontal lobe 
size, no other significant 
effects
Not available
Davidson et al., 
2017, GAS-trial42
RCT between local anesthesia vs. general 
anesthesia for a short-term procedure
722 randomised Neurocognitive 
function (BSID-III)
2 years of age No difference exposed 
vs. unexposed
Not available
Glatz et al., 201755 Population-based case-control cohort study in 
children undergoing minor surgery <4 years of age
33,514 patients, 159,619 
controls
School grades at 
16 years of age
Age up to 16 
years
Lower school grades in 
exposure group
Significant difference for age 3-4 years 
at exposure, younger age groups no 
significant difference
Hu et al., 201756 Retrospective observational case-control study. 
Cases: single or multiple anesthetics exposure <3 
years of age
1,057 Learning 
disabilities, 
ADHD, individual 
education programs 
or performance on 
standardized tests
Up to 18 years 
of age
Single exposure: 
Increased risk of lower 
reading and language 
achievement
Not available
Ing et al., 201757 Retrospective observational case-control study. 
Cases: Anesthetics exposure ≤5 years of age
38,493 patients
192,465 controls
Mental disorder in 
later life
Up to 18 years 
of age
Increased risk of mental 
disorder after anesthetic 
exposure (HR 1.26)
11 subgroups: no differences across 
age categories
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Table 1. An overview of studies investigating the possible harmful long-term effect of anesthesia exposure in 
young children.
Author, year of 
publication
Study design N= Primary outcome Follow-up 
duration
Overall outcome on 
neurodevelopment
Age subgroup analysis?
Ing et al., 201448 Retrospective observational cohort study. in children 
exposed to anesthetics exposure ≤3 years of age
112 patients Neuropsychological 
assessment, 
comorbidity and 
school grades
Up to 10 years 
of age
Increased risk of 
deficit assessed by 
neuropsychological 
testing, no difference in 
school grades
Not available
Sun et al., 2014, 
PANDA trial49
Sibling matched ambidirectional cohort study 105 sibling pairs IQ Up to 15 years 
of age
No difference exposed 
vs. unexposed
No difference across age groups
Backeljauw et al., 
201550
Observational cohort study, patients exposed to 
anesthetics exposure ≤4 years of age
53 patients, 53 controls Neurocognitive 
assessment and MRI
Up to 18 years 
of age
Diminution of language 
abilities and cognition
Not available
Hansen et al., 
201551
Retrospective observational case-control study. 
Cases: Anesthetics exposure for neurosurgery in 
infancy
228 patients
14,698 controls
Mortality and 
school grades
Up to 16 years 
of age
Significant but very 
small difference in 
school grades (lower 
grades in exposed 
group)
Not available
Graham et al., 
201652
Population-based case-control cohort study in 
children undergoing minor surgery <4 years of age
4,470 patients with one 
exposure,
3,640 patients with multiple 
exposures, 13586 controls
Early Development 
Index
Age 5-6 years Decreased performance 
on the EDI in the 
exposed group
Age at exposure:
≤2 years: no significant difference
>2 years of age: significant difference
O’Leary et al., 
201653
Population-based case-control cohort study in 
children undergoing minor surgery <4 years of age
28,366 patients, 55,910 
controls
Early Development 
Index
Age 5-6 years Decreased performance 
on the EDI in the 
exposed group
Age at exposure:
≤2 years: no significant difference
>2 years of age: significant difference
Conrad et al., 
201754
Longitudinal follow-up study in children with cleft 
palate
87 Cognitive, growths 
and brain measures
Up to 17 years 
of age
Increased frontal lobe 
size, no other significant 
effects
Not available
Davidson et al., 
2017, GAS-trial42
RCT between local anesthesia vs. general 
anesthesia for a short-term procedure
722 randomised Neurocognitive 
function (BSID-III)
2 years of age No difference exposed 
vs. unexposed
Not available
Glatz et al., 201755 Population-based case-control cohort study in 
children undergoing minor surgery <4 years of age
33,514 patients, 159,619 
controls
School grades at 
16 years of age
Age up to 16 
years
Lower school grades in 
exposure group
Significant difference for age 3-4 years 
at exposure, younger age groups no 
significant difference
Hu et al., 201756 Retrospective observational case-control study. 
Cases: single or multiple anesthetics exposure <3 
years of age
1,057 Learning 
disabilities, 
ADHD, individual 
education programs 
or performance on 
standardized tests
Up to 18 years 
of age
Single exposure: 
Increased risk of lower 
reading and language 
achievement
Not available
Ing et al., 201757 Retrospective observational case-control study. 
Cases: Anesthetics exposure ≤5 years of age
38,493 patients
192,465 controls
Mental disorder in 
later life
Up to 18 years 
of age
Increased risk of mental 
disorder after anesthetic 
exposure (HR 1.26)
11 subgroups: no differences across 
age categories
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Table 2. An overview of studies investigating the possible harmful long-term effect of opioid or benzodiazepine 
exposure in young children.
Author, year of 
publication
Study design N= Primary outcome Follow-up 
duration
Overall outcome on neurodevelopment Age subgroup 
analysis?
Brain imaging studies
Van den Bosch et 
al., 201535
Follow-up of prematurely born neonates participating in an RCT of 
routine morphine infusion for ventilated neonates 
19 Brain morphology with MRI and 
neuropsychological functioning
10 years after 
admission
No overall deviations from the Dutch 
average
Not available
Zwicker et al., 
201638
Prospective cohort study of very preterm neonates 136 MRI brain volume and BSID-III 18 months of 
age
Greater morphine exposure was 
associated with smaller cerebellar growth 
and poorer neurodevelopmental outcome 
(uncorrected)
Not available
Duerden et al., 
201658
Follow-up study of very preterm born neonates exposed to 
midazolam
138 MRI brain volume and BSID-III 18 months of 
age
Higher midazolam cumulative dose was 
associated with decreased hippocampal 
volumes and microstructural alterations, 
poorer cognitive function
Not available
Neurodevelopmental studies
MacGregor et 
al., 199859
Follow-up study of premature infant participants in two RCTs of 
morphine vs. other interventions during mechanical ventilation
95 (62 exposed) WPPSI-R, Movement ABC, and
the Child Behaviour Checklist
5-6 years of 
age
No significant difference between groups, 
trend toward better performance in 
exposed group
Not available
Roze et al., 
200860
Population-based follow-up study of extremely premature born 
neonates (GA≤33 weeks)
1572 Presence of moderate or severe
disability at 5 years of age 
(Kaufman Assessment Battery 
for Children)
5 years of age No association between prolonged 
sedation and/or analgesia and poor 
neurodevelopmental outcome
Not available
De Graaf et al., 
201131
Follow-up of prematurely born neonates participating in an RCT of 
routine morphine infusion for ventilated neonates 
90 (49 of the 
morphine group)
RAKIT, Beery test, CBCL 5 years of age Lower performance on visual analysis 
in morphine group, no other differences 
observed
Not available
Guerra et al., 
201161
Prospective follow-up of infants with cardiac surgery ≤6 weeks of 
age
135 BSID-II and BSID-III, and parent-
derived Adaptive Behavior 
Assessment System
18-24 months 
of age
No association between cumulative 
analgesia or sedative dose and 
neurodevelopment
Not available
Ferguson et al., 
201262
Pilot follow-up study of extreme premature infants (GA 23-32 
weeks) that participated in an RCT of routine morphine infusion for 
ventilated neonates (NEOPAIN trial)
19 (14 exposed) Head circumference, several 
parent-guided behavior 
assessment, Stanford-Binet test 
and WRAT4
5-7 years of 
age
Lower head circumference in exposed 
group, lower performance of memory 
tasks in exposed group, increased 
parent-reported behavioral issues in 
exposed group
Not available
De Graaf et al., 
201332
Follow-up of prematurely born neonates participating in an RCT of 
routine morphine infusion for ventilated neonates 
80 WSIC-III, Beery test, CBCL, 
CANTAB
8-9 years of 
age
No effect of morphine on 
neurodevelopmental outcome
Van Zellem et 
al., 201446
Follow-up study of children admitted to the PICU with meningococcol 
septic shock
77 WSIC-III, Stroop, TMT, Score!, 
Beery test and 15 Word test
Up to 6-17 
years of age
Opioid use was associated with 
poorer neurodevelopmental outcome, 
barbiturates and benzodiazepines 
showed no effect
Not available
Kocek et al., 
2015
Retrospective chart review study of 100 extreme low birth weight 
infants
100 (60 high-
dose patients)
BSID-III 20 months of 
age
No effect of cumulative morphine dose Not available
Steinhorn et al., 
201563
Follow-up study of very preterm neonates admitted to the NICU 230 (57% 
exposed to 
morphine)
MRI and WASI, WRAT4, SDQ, 
CELF4 and BRIEF
7 years of age No difference in cortical volumes. At 2 
years, behavioral dysregulation was 
observed but at 7 years there were no 
significant difference between exposed 
and non-exposed patients
Not available
Van den Bosch et 
al., 201534
Follow-up of prematurely born neonates participating in an RCT of 
routine morphine infusion for ventilated neonates 
19 NEPSY-II-NL 8-9 years of 
age
Neurodevelopment was in line with Dutch 
reference
Not available
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Our group did find a statistically significant effect of opioids on the long-term neurodevel-
opmental outcome in survivors of meningococcal septic shock; that is, poor test outcomes on 
several neuropsychological domains.46 These children (n=77), tested at an age of 5-6 years, 
had a median age of 2 years when admitted to the PICU. It could be hypothesized that 
severe damage such as from a meningococcal meningitis,47 considerably alters the plasticity 
of the brain, and that the possible second damage hit of opioid-induced neuroapoptosis has 
a larger detrimental effect on the brain. On the other hand, prolonged exposure to opioids 
and anesthetics may be more damaging in older children like in this 2-years old patients, as 
plasticity of the brain decreases over time. To illustrate this, I will focus on anesthetics, which 
have been much studied regarding their long-term effects. Table 1 provides an overview 
of pediatric studies investigating the long-term effect of anesthetics in children.
These studies had relatively large sample sizes, but had a retrospective design with a great 
risk of confounding. Therefore, the question on long-term effects of anesthetics cannot yet 
be properly answered. However, the O’Leary study,53 the Graham study52 and the Glatz 
study55 all found significant differences only in the oldest age category, which could possibly 
contradict the current hypothesis of ‘the earlier the exposure, the greater the damage’ due 
to the greater plasticity of the younger brain covering up the evoked damage. 
Prospective trials such as the GAS-trial are needed to provide a more robust insight in 
the long-term effects of anesthetics. Although an RCT comparing surgery with or without 
anesthesia is not at all feasible, as surgery will never be performed without anesthesia, 
efforts can be made to reduce the dose of general anesthesia. A good example of such a 
trial is the upcoming T-REX study (NCT03089905, clinicaltrials.gov), which investigated the 
long-term outcome of surgery performed with high-dose general anesthesia (2.5-3% of 
end-tidal sevoflurane concentration) or with dexmedetomidine + remifentanil + low-dose 
sevoflurane (0.8% of end-tidal sevoflurane concentration or less). 
With regards to future studies of opioids and benzodiazepines, the focus should shift away 
from the neonatal age towards the entire developmental life span. Table 2 provides details 
of studies investigating the long-term neurocognitive outcome of opioids and benzodiaze-
pine exposure. There is a trend for a possible negative long-term outcome in older children 
when compared to prematures.
Besides the recommendation to stratify according to diagnosis, age stratification can be 
recommended. This approach requires large sample sizes, for which both national and 
international collaboration is warranted. Nevertheless, such clinical trials will be only suc-
cessful if several barriers have been overcome. These are addressed in the next section.
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Challenges in pediatric clinical trials
A randomized controlled trial in young children will take much effort and resources, and is 
subject to many regulatory and ethical considerations. These efforts and resources are spent 
in vain, however, if a trial is not as successful as hoped for. Yet, in pediatrics, 19% of all trials 
were discontinued before the end of the trial, and another 30% of trial results remained 
unpublished.64 The main reasons for discontinuation were poor recruitment, logistic conduct 
problems and trial futility. A scoping review of published RCTs found a comparable percent-
age of early discontinued trials in the PICU setting: 15%.65 The actual percentage may be 
even higher as such trials have a higher chance not to be published.66 For the sake of com-
parison, percentage of 25% of prematurely discontinued trials in adults has been reported.67
The CloSed trial (Clonidine for Sedation of mechanically ventilated children; NCT02509273) 
was designed as a European multi-center, non-inferiority, active-controlled phase III trial 
investigating clonidine as sedative for mechanically ventilated children.68 This study adhered 
to EMA regulations in that a Paediatric Investigational Plan was prepared. It was to lead 
to licensing clonidine for sedation purposes and developing pediatric-specific formulations 
of clonidine. This could be achieved by obtaining a Paediatric-Use Marketing Authorisation 
(PUMA), which means that off-patent drugs can be patented again for the exclusive use in 
children, whilst retaining the existing brand name. Also, we had planned to study PK, PD, 
pharmacogenomics of morphine, clonidine and midazolam, and the effects of clonidine com-
pared to midazolam in neonates on neurodevelopmental outcome at age 1. Yet, we were 
confronted with poor recruitment and logistic issues. A timeline of predicted vs. observed 
milestones is shown in figure 1.
In general, we can identify three major reasons for failure of recruitment of patients in 
this trial:
1. Logistic issues
2. Inadequate trial design
3. Dismal inclusion rate
Logistic issues
Several regulatory, ethical and logistic issues need to be solved before one can start with 
actual patient recruitment. In the CloSed trial, handling controlled drugs appeared to raise 
several unforeseen barriers such as obtaining an import license and a license for handling 
controlled drugs in a research setting, as the study drugs had to come from Germany. 
Moreover, after obtaining the import license, the exporting country needed to apply for an 
export license as well. This surprised us because both clonidine and midazolam are being 
used in standard clinical practice but still a separate handling license was needed for the 
pharmacy as it now concerned an Investigational Medicinal Product (IMP).
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Figure 1. Expected vs. observed timeline of the CloSed trial. 
Expected Observed
LPLV
PUMA
LPFV
FPFV
Ethics approval
First manuscript draft
Ethics submission
Protocol completion
Preparation
The solid line represents the expected timeline. The dotted line represents the actual timeline. DSMB: Data Safety 
Monitoring Board; EC: Ethics Committee; FPFV: First Patient First Visit; LPFV: Last Patient First Visit; LPLV: Last 
Patient Last Visit; PUMA: Paediatric Use Marketing Authorization
These issues have delayed the start of trial in our center for months. However, in other 
centers, even after several years, the ethics and regulatory approval still has not been 
obtained. This is something to be aware of when performing an international multi-center 
trial.69 For example, in the Netherlands, the Competent Authority (CCMO: Central Commit-
tee on Research Involving Human Subjects, or the Ministry of Health, Welfare and Sport) 
only performs an extra review of a clinical trial and delegates all other approval to the 
Ethical Committee. This extra review is nothing more than checking international pharma-
covigilance databases for any suspected adverse reactions that may increase the risk to 
potential subjects. However, in the Czech Republic and Sweden, for example, the comments 
received from the Competent Authorities were very detailed. 
Inadequate trial design
Even after the logistic issues had been solved, we were faced with another unexpected 
problem. The sedative dose decrease schedule was designed to prevent oversedation, 
but did not fully take into account the half-life of drugs. Therefore, if a patient would be 
oversedated, the study drugs would be tapered off very quickly and the patient would be 
without any study drug at all within 90 minutes. This oversight necessitated an amendment 
to the schedule, which took months to establish and to get ethical committee approval again. 
To prevent this in future trials, we recommend to involve independent treating physicians 
and ICU nurses in the design of the trial, as well as parents. In the CloSed trial, a parents’ 
support group from the Dutch national patient umbrella organization for rare and genetic 
disorders (the VSOP) was consulted, but adequate patient representation is hard to realize 
considering the heterogeneity in diagnoses found in the PICU.
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Overall, the CloSed trial can be regarded as fairly complex, and not easy to explain to 
health professionals whose cooperation is needed. Complex trial design is an important 
reason for RCT failure.67 Alternative trial designs such as comparative effectiveness trials 
could be a solution (see: ‘RCT validity’).
Dismal inclusion rate
“As soon as a study begins, the number of patients available instantly drops from a theo-
retical pool of 100 percent down to 20 percent; as soon as a study stops, the pool jumps 
back to 100 percent”, Bachenheimer 2007.70 Researchers have always been too optimistic 
about inclusion rates for their studies. Insufficient trial preparation, lack of pilot studies71 
and over-estimation of consent rate72 could belie their optimism. This holds also true for the 
CloSed trial. For our center, inclusion of subjects was based upon the number of mechanically 
ventilated patients receiving midazolam >24 hours: around 300 eligible patients yearly. 
Based on previous experience we assumed that informed consent would be withheld in 
50% of cases. Thus, 150 patients were expected to be included within one year. The actual 
number included in the first year was 2.
And why was that? Not taking into account the exclusion criteria may have been a major 
reason. Figure 2 illustrates the main reasons for exclusion of patients in the first year in 
Rotterdam. 
To our surprise, thirty-eight patients were excluded because they did not need sedation 
although they were mechanically ventilated for at least 24 hours. These were mainly post-
operative neonates <14 days of age receiving adequate analgesia with IV paracetamol 
and low-dose opioids. 
This is an example of the changing ‘unmet medical need’, for which investigators should 
be warned. Also the SLEEPS-study (ISRCTN 02639863), the ‘predecessor’ of the CloSed 
trial,73 should have put us on alert. This study, too, was terminated due to poor recruitment. 
The aim was 1000 participants, but no more than 129 could be included in two years, 
even though the inclusion and exclusion criteria were adapted several times. The new early 
extubation strategy for cardiac surgery patients, with often extubation within 12 hours 
after surgery was identified as one of the main reasons for the dismal inclusion rate in that 
study. The investigators nevertheless could demonstrate theoretical non-inferiority of cloni-
dine vs. midazolam for sedation, although the 95% CI was too large to demonstrate ‘true’ 
non-inferiority. Unfortunately, this study did not gather data on PK and a PK-PD relation-
ship. Analysis of these data could have been interesting as clearance may be decreased 
in cardiac surgery patients8 and the CloSed-trial could not include these patients due to 
their short ventilation period.
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Figure 2. Reasons for exclusion in 214 screened patients; a total of 344 reasons (a number of patients were 
excluded for more than one reason). 
The consent rate for the CloSed trial in Rotterdam was much lower than the assumed 50%, 
that is: 23% (5/22 parents). Three of the consenting parents had been approached before 
surgery, but their child was unfortunately not eligible after the surgery. In-depth analysis of 
reasons for refusal showed a Catch-22 situation: Parents either felt that the child was too ill 
for participation and possible changes in the sedation regimen, or that the child was finally 
stable enough and therefore should not be exposed to a change in the sedation regimen.
A disadvantage of the CloSed-trial is the timing of consent. Early participation is desired 
but this means consenting in the acute setting. Parents may be very distressed in the acute 
setting and therefore refuse participation. However, not all parents declined and there were 
even parents who desperately wanted their child to participate (but unfortunately the child 
became ineligible after surgery). This asks for a deeper look into parental motivating and 
discouraging factors for participation in a clinical trial. Tromp et al. systematically reviewed 
reasons for participation and refusal of parents.74 They identified several motivating and 
discouraging factors, which are balanced against each other in figure 3.
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Figure 3. Balance between motivational and discouringing factors for parents to letting their child participate in 
a clinical trial. 
MOTIVATIONAL 
 
• Personal health benefit 
• Altruism 
• Trust in safety of researcher 
• Relation to researcher 
• More contact with medical team 
• Benefits for parents themselves 
• Minimal burden for child 
• Financial reimbursement 
• Felt as only option 
• Influence of family and friends 
DISCOURAGING 
 
 
• Fear of risks 
• Distrust in research 
• Logistics/disruption of daily life 
• Burden for child 
• Decision too stressful 
• Fear of randomization 
• No direct benefit for child 
• Financial constraints 
• Discomfort with proxy consent 
Bold factors could theoretically be applied to the Closed trial; bold and italic factors have explicitly been mentioned 
in the informed consent approaches. Derived from Tromp K et a.l, Motivations of children and their parents to 
participate in drug research: a systematic review. Eur J Pediatr 2016;175(5):599-612.
When applied to the CloSed trial, this figure shows that discouraging factors dominate. 
Especially ‘decision too stressful’ was a discouraging factor, and this is not only applicable 
to the CloSed trial. In another study in our PICU, a randomized controlled trial investigating 
the calming influence of ear plugs during ‘rush hours’ at the ICU, thirty-four of 166 screened 
patients were regarded eligible and asked for informed consent. Only 2 patients or the 
parents consented in participation, as they felt the decision was too stressful as well. Other 
PICU trials have shown to be more successful. A comparable trial with the CloSed trial is 
the Daily Sedation Interruption trial performed by Vet et al.,75 which had a consent rate of 
60% (after exclusion of clinically ineligible patients). The inclusion period was five years, 
however. A pediatric microdosing study of paracetamol had a consent rate of 40%76 – still 
much higher than the CloSed trial with a consent rate of 23%.
A strategy to make the decision-making less stressful is the use of deferred consent,77 when 
patients are recruited in the acute setting, and consent is being asked afterwards. This 
should not be applied if there is a possibility that the intervention is postponed, but can be 
applied to critical care interventions. The use of deferred consent is accepted by families,78 
healthcare professionals and institutional research boards and has increased inclusion rates 
in other trials.79 Our study group applied deferred consent in the PePANIC trial (early vs. 
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late parenteral nutrition in critically ill children),80 with 593 children included in three years 
– all with the use of deferred consent. This study had less impact on the children, however, 
as it was not a drug study that could affect the child’s comfort. 
Participation in a trial may also be influenced by culture. A large RCT in Brazil on vasopres-
sors/inotropes in children with sepsis had a surprisingly high recruitment rate of 96%.81 In 
their reply to an editorial, the authors mentioned the specific cultural aspect of informed 
consent, which is the hierarchal relationship between patients and doctors.82
Implementation of RCT results
Even if a RCT has been successful, it may take several years for the results to be imple-
mented in daily clinical practice. Several barriers may impede implementation, such as low 
acceptance by health care professionals, lack of motivation and lack of awareness and 
‘forgetting’.83 We investigated the implementation of IV paracetamol as primary analgesic 
in infants after major surgery, and found that this was adhered to in 98.7% of patients. 
Furthermore, 80% of patients received an adequate loading dose of morphine at the 
end of the surgery. This success could be attributed to staff being aware of the trial and 
enthusiastic to cooperate, as well as good implementation strategies such as the mini-course 
offered to new personnel. 
On the other hand, implementation of certain elements of this new pain management proto-
col was less successful. For example, morphine continuous infusion dosing was often too high, 
probably because we have a national formulary in place84 which dictates other doses than our 
new protocol. It is telling that in 21 of 22 cases (95%) these ‘wrong’ doses were in accordance 
with the national formulary. Even though the new morphine dosing had been used in the RCT, 
staff seemed not aware of this. Therefore, results of a trial should not only be implemented 
in specialty-related guidelines, but also in other national or international guidelines. 
RCT validity
Another major general issue in implementation is the validity of RCT results.85 The study pop-
ulation often does not reflect the majority of patients in daily clinical practice due to strict 
in- and exclusion criteria. Moreover, the setting of a RCT is often different from daily clinical 
practice, as experienced and well-trained research personnel is available to secure protocol 
adherence. Therefore, we need to reconsider the status of RCTs providing the highest level 
of evidence. There is a tendency in research to move away from the ‘classical’ RCTs, aimed 
at establishing the efficacy of an intervention (explanatory trials), towards trials and other 
studies aimed at establishing the effectiveness of an intervention, also taking the routine 
clinical practice into account (pragmatic trials).86 This ‘comparative effectiveness’ research 
also focuses mainly on patient-centered outcomes, which are receiving increasing attention.87
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To take the CloSed trial as an example, an exhaustive list of exclusion criteria ensured the 
validity of the primary end point (neurological injury impedes scoring of the COMFORT-B 
scale) or patient safety (patients at risk for hypotension are excluded). Still, clonidine is 
being used in clinical practice: despite no more than two participants in the CloSed trial, 
continuous clonidine was given to 75 patients in the one-year screening period in Rotterdam. 
It has been proven safe in patients after cardiac surgery, so maybe the cardiovascular 
exclusion criteria might have been less strict.88-90 For future studies comparing the effect of 
clonidine with midazolam in ventilated children, I would suggest to include all patients for 
who the treating physician would consider clonidine or midazolam administration in clinical 
practice, while still using a population-PK derived dosing scheme.
Lastly, drug approval is mainly based on the results of phase-III trials, which are mainly 
explanatory trials. Classically, drug studies are in three phases (dose finding - phase I, 
safety assessment -phase II and clinical efficacy - phase III). Sometimes, pharmacovigilance 
studies after marketing authorization are added as a phase IV (see figure 4).91
Figure 4. Classical route of clinical trials in drug research.
I would, however, suggest that the current phase IV be changed to comparative effectiveness 
research, just after approval on the market, in combination with pharmacovigilance, which 
then should be the new phase V (figure 5). 
Figure 5. New proposed route of clinical trials in drug research, with a fixed place for comparative effectiveness 
research.
Fortunately, all roads lead to Rome, and other studies have been published on the use of 
clonidine in the PICU. Kleiber et al. studied the pharmacokinetics of clonidine in ECMO-
treated patients (n=22) with or without continuous veno-venous hemofiltration using a 
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population-PK approach.92 They found a significant increase of the volume of distribution 
(55%) and clearance (100%), indicating that higher loading doses and maintenance doses 
are needed in ECMO-treated patients. 
In another study, Kleiber et al. investigated targeted vs. pre-emptive sedation regimens in 
children after cardiac surgery (n=66).93 The targeted sedation group received boluses of 
clonidine until adequate sedation was reached; the pre-emptive group received routine 
midazolam infusion. The primary end point was cardiovascular stability and this did not 
differ between both groups. This study underscores the feasibility of clonidine use in hemo-
dynamically compromised patients.
These studies illustrate that information on clonidine can be obtained in separate studies 
with smaller sample sizes. If the CloSed trial will not lead to success, we need to consider 
alternatives like these studies. 
The problem of outcome measures
The issue of good outcome measures in clinical trials has been recognized for years.94-96 Many 
trials make use of surrogate markers for clinical end points. Clinical trials can also be used to 
validate outcome measures.97 We identified several problems in analgesic outcome measures. 
In this section I will address some of these problems and present future perspectives.
Outcome measures in pain studies
Pain is a subjective experience. Therefore the golden standard in pain research in subjects 
from the age of 6 years is the self-reported pain intensity on a numeric rating scale from 
0-10. This is not feasible, however, for infants and young children. To assess these children’s 
pain, several physiological and behavioral scales for observation have been developed. The 
downside of these scales is that pain may interfere with other conditions and the question could 
be raised, for example: does a COMFORT-B score of 25 indicate pain or distress? The vali-
dated cut-off point is 17 for pain98 and 22 for undersedation,99 so what should we treat first?
This problem also holds for other, more physiology-based assessment methods, such as heart 
rate variability,100 pupillometry101 and skin conductance,102 which are all based on phenom-
ena caused by the sympathetic nervous system. Therefore, we need to take a deeper look 
inside the brain where pain perception takes place.
Near-infrared spectroscopy (NIRS)103,104 reflects the oxygen consumption in a certain, as yet 
unknown, region of the brain. Once ‘the’ brain region for pain has been identified, we can 
measure changes in oxygen consumption after noxious stimuli in this region. To date, NIRS has 
not yet been validated for measuring pain. Interestingly, in a multimodal study using both a 
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behavioral observational tool (the Face, Legs, Activity, Cry, Consolability (FLACC) scale105) and 
NIRS, a NIRS response was noted in both conditions (the same noxious stimuli with and without 
sucrose administration), whereas a FLACC response was noted only in the ‘without sucrose’ 
condition.106 This means that the noxious stimulus was recorded in the brain, but we do not know 
whether it was painful to the neonate and whether oral sucrose is an effective analgesic.107
A more promising method of neuronal pain assessment is the EEG-based nociceptive brain 
activity measurement,108 which recently has been validated in both preterm and term born 
clinically stable neonates under controlled circumstances. The EEG response to noxious stimuli 
has been extensively investigated in 18 infants; activity of all electrodes has been analyzed 
over a 1000 msec poststimulation period. The activity in the Cz region, which is the vertex 
position on the midline of the scalp, was identified as the strongest, in a time range from 
400-700 msec poststimulation. 
This method has also shown a discrepancy between pain responses assessed by physiologic 
parameters (cortisol and HRV) and behavioral parameters (PIPP score), as a linear rela-
tionship between the EEG measurement and cortisol or HRV was found but no relationship 
was found between the EEG measurement and the PIPP score. Yet, in children with low 
background stress, i.e. low baseline cortisol levels, a linear relationship between the PIPP 
and EEG measurement was found, indicating that children in stress are less capable to 
express their pain109 or express if differently, in a way that cannot be picked up by the 
PIPP. It has been described earlier that exposure to multiple stressors attenuates behavioral 
stress responses, although the mechanism of action is unclear.110
The EEG-derived method allows for non-invasive assessment of procedural pain. However, 
patients admitted to a PICU or a NICU also may experience postoperative or continuous 
pain, for example the pain caused by an endotracheal tube111 or by pressure ulcers due 
to immobilization.112 Table 3 provides an overview of current pain assessment methods, 
including the type of pain for which it has been designed, whether it has been validated, 
which part of Loeser’s pain model113 it is reflecting, and whether there could be overlap with 
undersedation or distress. The pain model as developed by Loeser reflects the multimodality 
of pain and illustrates the path from the actual noxious stimulus (nociception) towards the 
‘ouch’ or grimacing of a patient (pain behavior). It shows that pain is not only biological, 
but biopsychosocial and should be approached as such.
From this table we appreciate that nociception itself is not being measured, as this would 
require measurement of the nerve potentials in A and C fibers of the dorsal horn. Using 
reduction of distress and other factors as outcome measures could improve the research 
of HRV and pupillometry, as these measures are objective and have the potential to be 
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continuous. Yet, bedside behavioral tools are the current practice in NICUs122 and PICUs.123 
We should look further to identify the most sensitive items to pain of these behavioral scales. 
Multimodal studies comparing for example the COMFORT-B scale to the EEG-derived 
nociceptive brain activity measurement could be a way to go.
Table 3. Currently available pain assessment methods.
Assessment method Types of pain 
assessment
Validated 
in children
Part of Loeser’s 
pain model
Overlap with distress 
or undersedation?
Behavioral scales98, 105, 
114-117
Procedural, chronic + Pain behavior +
Nociceptive brain 
activity108
Procedural + Pain perception -
NIRS103 Procedural - Pain perception
aEEG118 Procedural - Pain perception +/-
Skin conductance102 Procedural - Suffering +
SSEP119 Procedural - Pain perception +/-
Pupillometry101 Procedural, chronic - Suffering +
HRV100 Procedural, chronic - Suffering +
fMRI120 Procedural - Pain perception/
suffering
-
Salivary and plasma 
cortisol levels121
Chronic - Suffering +
Adrenaline 
assessment121
Procedural, chronic - Suffering +
Noradrenaline 
assessment121
Procedural, chronic - Suffering +
Outcome measures in sedation
Adequate sedation entails a combination of distress reduction, anxiety reduction, metabolism 
reduction and allowing for cooperation with procedures and/or mechanical ventilation.124,125 
Sedation is usually assessed either by level of consciousness (e.g. the Ramsay score126) or 
by level of comfort (COMFORT(-B) scale,99,127 State Behavioral Scale128). However, these 
measures are subject to a certain degree of subjectivity and may also be influenced by 
other factors such as pain and critical illness. For example, a patient may be too ill to 
express discomfort and therefore may appear oversedated. 
Adequate sedation is crucial in anesthesia for surgery. Depth of anesthesia used to be 
measured using the Bispectral Index (BIS).118 The BIS is validated for children >1 year 
and is non-invasive. However, the BIS has only been validated for deep sedation and only 
measures frontal lobe EEG. Validation for conscious sedation, which is the preferable state 
of sedation in the ICU, has proven more difficult as clear cut-off values have not been 
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established.129-131 The use of BIS for sedation assessment will probably not be an option, 
as it is no longer the standard of practice for anesthesia and physiologic parameters such 
as blood pressure and heart rate provide enough information.
Other methods to assess sedation depth do not yet exist. Physiologic measures such as heart 
rate, respiratory rate and blood pressure are not primarily used in the PICU as they can 
be influenced by factors such as raising the inspiratory O2 fraction, fluid resuscitation and 
the use of inotropic/vasopressor drugs. Yet, behavioral observational tools may also miss 
the presence of distress – indicative of inadequate sedation – if a patient is not able to 
express distress, for example when a patient is on paralyzing medication.
In the light of patient-centered outcome measures, it would be interesting to know more 
about the relationship between the level of sedation and the memories a patient keeps after 
ICU admission. It is known that patients may recall certain events during ICU admission even 
if they were deeply sedated.132,133 Studies investigating sedative drugs should therefore 
include a follow-up visit with a recall assessment, linked to the overall level of sedation. 
Other challenges of outcome measures
A major issue of analgosedative outcome measures is the overlap in symptoms between 
pain, distress, undersedation134 and other clinical states such as delirium and withdrawal 
syndrome.135 Several studies have addressed this overlap using different techniques, such as 
applying the Item Response Theory to behavioral scales136 or constructing a scale than can 
detect two clinical states with overlapping symptoms, such as the SOS-PD scale to detect 
pediatric delirium and iatrogenic withdrawal syndrome.137 
Other clinical conditions may occur which go unrecognized. We addressed such a pre-
viously unrecognized condition in the study presented in chapter 5, the anticholinergic 
toxidrome. This toxidrome is caused by the use of anticholinergic drugs or other substances 
such as the Angel’s Trumpet (Brugmansia sp.), Jimson weed (Datura stramonium), Deadly 
nightshade (Atropa Belladonna) or muscarinic mushrooms. These agents block the muscarinic 
acetylcholine receptors, both in the peripheral nervous system and in the central nervous 
system. Typically, this leads to a clinical presentation as ‘dry as a bone, blind as a bat, red 
as a beet, hot as a hare and mad as a hatter’.138,139 Table 4 shows the symptoms of this 
toxidrome, broken down into central and peripheral symptoms.
We found a higher anticholinergic burden in patients with symptoms of delirium and/or with-
drawal syndrome in this study but were not able to correct for disease severity and other risk 
factors for delirium and/or withdrawal syndrome. Moreover, we do not know whether such a 
burden would be enough to cause an anticholinergic toxidrome. I would recommend a prospec-
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tive observational study in all children admitted to the PICU, and determining their anticholinergic 
burden on a daily basis and actively screening for anticholinergic symptoms. This could inform 
us on whether the anticholinergic toxidrome is a real problem in our PICU population.
Table 4. Central and peripheral symptoms of the anticholinergic toxidrome.139 
Central anticholinergic symptoms
Delirium
Mydriasis
Amnesia
Hallucinations
Seizures
Coma
Peripheral anticholinergic symptoms
Tachycardia
Hyperthermia
Dry skin
Functional ileus
Urinary retention
Hypertension
Another major issue is the influence of environmental factors on a patient’s level of sedation. 
It has been shown that environmental factors may affect the level of pain.134 Much research 
is focused on the pharmacological management of sedation, but trials on non-pharmacologic 
interventions are few. The earplug study, mentioned above, is a good example of a relatively 
easy intervention which, by reducing noise exposure, could markedly improve a child’s seda-
tion state. In addition, early mobilization strategies may also enhance the child’s comfort.140-142 
In the Netherlands, two newly built pediatric ICUs make use of single bed-rooms. It would be 
enlightening to perform a prospective trial comparing units with and without single-bed rooms, 
with end points such as cumulative sedative consumption, COMFORT-B scores, pain scores, length 
of stay and duration of mechanical ventilation. Moreover, older children should be interviewed 
on discharge on how comfortable they were during their stay. Results of such trials can convince 
architects and executive boards to provide single-bed PICUs in all new children’s hospitals. 
Also, parents may want to be more involved in the child’s bedside care. The concept of 
Patient and Family Centered Care is the new approach to hospital care, in which parental 
participation in care is indispensable. Parents, if they are up to it in view of the stressful 
situation, can be instructed to apply a pain scale, as in the ‘Together less Pain’ initiative in 
our hospital. Open discussion between parents and healthcare professionals may improve 
mutual understanding – and thereby the care for the critically ill child. 
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FUTURE PERSPECTIVES
A recent publication on the global research agenda in pediatric critical care identified 
‘Comfort’ of children as one of the areas deserving scientific attention, particularly the 
long-term effects of analgesics and sedatives.143 It is recommended by the authors to 
study on which age drug-induced neuro-apoptosis exerts the most damage. Also, the 
sedation paradigm is changing from unconscious sedation towards conscious sedation. To 
illustrate this: ten years ago, a patient on ECMO was heavily sedated and received high 
doses of opioids or even sometimes neuromuscular blocking agents to prevent the acciden-
tal removal of cannulas. Nowadays, children on ECMO, if clinically stable, may watch TV. 
A second focus area is the rethinking of the RCT as golden standard for evidence-based 
medicine. Intensive care no longer focuses on life-saving procedures and medically sta-
bilizing the patient, but also on adverse events reduction and good long-term outcome. 
The PICU patient population is changing as the life-expectancy of children with complex 
co-morbidity increases on the one hand, but their vulnerability necessitates frequent re-ad-
missions.144 Moreover, children who have been withheld life support therapy, such as those 
with trisomy 13/18; Rett syndrome or SMA type 1, will nowadays be treated in the PICU 
in some countries. Carrying out a ‘classical’ RCT runs the risk that these complex patients 
will meet an exclusion criterion. 
Yet, there is still a long way to go and it seems that current ethical, regulatory and 
patient factors impede clinical trials in the PICU. Nevertheless, alternative trial designs 
may enhance both patient accrual and external validity and can guide the design of 
future trials.
So far, pain and sedation management mainly relies on surrogate end points. Future 
research should focus on the development of more objective and specific measurements as 
current end points are frequently influenced by external factors, in particular stress. The 
development of the EEG-derived nociceptive brain activity method may pave the way for 
future analgesic trials and may serve as a basis for other pain and sedation assessment 
methods that could also be EEG-based. 
Third, pharmacometric advances such as PBPK modeling and in silico trial simulation gener-
ate a wealth of new information that helps us understand what is going on in the developing, 
critically ill child regarding pharmacokinetics and pharmacodynamics.
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And fourth, I have found that the paradox ‘expect the unexpected’ is certainly applicable 
to science. As the authors of the SLEEPS-study encountered unexpected early extubation 
strategies in cardiac surgery, the investigators of the CloSed trial were ‘surprised’ by neo-
nates who did well without sedatives. 
Besides improving pain and sedation management, new clinical strategies can also lead 
to improved sedation and analgesia in the PICU. In the first paragraph of this discussion, 
I addressed the complex pharmacology that should be dealt with. It is therefore essential 
that a dedicated hospital pharmacist is appointed to the PICU. A few reports support 
the presence of a dedicated pediatric pharmacist present during rounds and medication 
prescription.145-147 In Erasmus MC, a pharmacist is present on the adult ICU, but in the PICU 
only PICU orders are reviewed and possible drug-drug interactions are screened for by 
a pharmacist. Focused review strategies can be the first step for hospitals with budget 
shortage,148 although the presence of a pharmacist in one study resulted in an annual cost 
saving of $ 120,000 by lowering adverse event rates.147 An alternative option is to have 
a clinician/clinical pharmacologists in place, which is the current situation in our center. Yet, 
regular clinical work may stand in the way of dedication to clinical pharmacology and 
therefore it is essential to appoint a dedicated pharmacist. 
In conclusion, the ‘war against suboptimal pain and sedation management’ will continue and 
thus I conclude that it is certainly not quiet at the bedside front.
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SUMMARY
Pain and sedation management are crucial elements in pediatric critical care. Despite the 
major advances that have been made over the last decades, we still have a long way to go 
to reach optimal analgesia and sedation in children. One of the major obstacles in optimi-
zation of pain and sedation management is the lack of evidence-based pharmacotherapy. 
This thesis analyses the challenges in the development of evidence-based pain and sedation 
pharmacotherapy on multiple levels.
Part I contains an overview of the literature of pediatric pain and sedation research with 
the aim of looking for lessons learned from the past. 
In chapter 2 we provide an overview of currently used drugs for the sedation of critically ill 
children with their pharmacological properties. This chapter provides the current available 
evidence for the use in the PICU, as well as an overview of ongoing studies providing more 
information on the pharmacokinetics and pharmacodynamics of these sedatives. We show 
that little evidence is available for the PICU population, but that for most agents new phar-
macokinetic and pharmacodynamic data are on the way. These studies often use advanced 
population modeling techniques and laboratory assessment methods. 
Chapter 3 is a general overview of pain research in infants and neonates. We identified 
multiple important challenges that pain researches face when performing an analgesic 
trial in this population. These challenges include the definition of pain, the multimodality 
and different types of pain, lack of objective and validated end points, lack of knowledge 
on PK and PD, unknown long-term side effects of analgesics and the heterogeneity of the 
population. Based on this literature review, we recommend to focus on the development 
of objective outcome measures, the use of ‘new’ analgesics in this population and ways of 
studying long-term effects in future research.
In part II, we focus deeper into specific challenges that pain and sedation researchers may 
encounter in the PICU. 
Chapter 4 is a clinical study protocol paper describing the design of the CloSed trial. The 
CloSed trial is a multi-center randomized controlled non-inferiority trial comparing clonidine 
with midazolam for the sedation of mechanically ventilated patients. This project faced 
several challenges which are being discussed, such as patient recruitment problems due to 
extensive exclusion criteria and changes in clinical practice which have not been foreseen. 
We therefore recommend to perform a thorough pilot study before the initiation of any 
pediatric critical care trial.
208 Chapter 9
In chapter 5, we explore a possible new challenge that could interfere with pediatric crit-
ical care research: the anticholinergic toxidrome. The anticholinergic toxidrome has similar 
symptoms as pediatric delirium (PD) and iatrogenic withdrawal syndrome (IWS), impairing 
the screening for and diagnosis of these phenomena. This toxidrome may be the result of 
multiple drugs with anticholinergic properties which are often used in the PICU. This study 
describes the anticholinergic burden of patients with a positive screening for PD and/or 
IWS. We found a higher anticholinergic drug burden in patients with pediatric delirium 
and/or iatrogenic withdrawal syndrome, which raises awareness for the anticholinergic 
drug burden in patients with symptoms of PD and/or IWS.
Part III bridges the clinical trial setting to the daily clinical practice. 
In chapter 6, we report on the number of painful and stressful procedures which patients in 
the PICU need to undergo on a daily basis. This study aims to explore the need for anal-
gesic and sedative management of procedures in the PICU by determining the amount of 
procedures, but also which procedures are ranked most painful by healthcare professionals. 
Endotracheal suctioning was by far the most frequent procedure, followed by oral and 
nasal suctioning. Skin-breaking procedures such as arterial and lumbar puncture, IV cannula 
insertion and venipuncture have been ranked most painful according to a nurse survey.
Chapter 7 show the results of an implementation study of IV paracetamol for postoperative 
analgesia in infants. In a previous randomized controlled trial, a morphine consumption 
reduction of 66% was found when IV paracetamol was used as primary analgesic. After 
implementation of a new postoperative pain management protocol for infants in our PICU, 
with IV paracetamol as primary analgesic, we compared the morphine consumption in post-
operative infants in daily practice to that of the RCT. We found equal morphine consumption 
to the RCT, and thus a successful implementation of IV paracetamol as primary analgesic.
Chapter 8 is a reflection on the results of the studies performed and provides and integra-
tive discussion of these results. We conclude that there is a lack of sound evidence for current 
pain and sedation management in the PICU and we have identified some major challenges 
that pediatric pain and sedation research will encounter. We propose a research agenda 
for the coming years, specifically aiming at the development of clinical end points and the 
safety of drugs administered to very young children. 
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Adequate pijnbestrijding en sedatie zijn cruciale onderdelen van de zorg voor kritisch 
zieke kinderen. Ondanks de grote vooruitgang die is geboekt over de afgelopen decen-
nia, hebben we nog een lange weg te gaan naar optimale pijnbestrijding en sedatie voor 
kinderen. Eén van de grootste obstakels in het optimaliseren van pijnbestrijding en sedatie 
is het gebrek aan wetenschappelijk onderbouwde farmacotherapie. Dit proefschrift onder-
zoekt de uitdagingen die liggen in het ontwikkelen van wetenschappelijk onderbouwde 
farmacotherapie voor pijn en sedatie op verschillende niveaus.
Deel I bevat een overzicht van beschikbare wetenschappelijke literatuur over pijnbestrij-
ding en sedatie bij kinderen met als doel om te zoeken naar lessen die we uit het verleden 
kunnen trekken.
In hoofdstuk 2 wordt een overzicht gegeven van medicijnen die op dit moment worden 
gebruikt voor sedatie van kritisch zieke kinderen, inclusief de farmacologische eigenschappen 
van deze medicijnen. Dit hoofdstuk presenteert het huidige beschikbare wetenschappelijke 
bewijs voor gebruik in de kinder-IC, evenals een overzicht van onderzoeken die op dit 
moment lopen en die meer informatie zullen opleveren over de farmacokinetiek en farma-
codynamiek van deze sedativa. We laten zien dat er weinig bewijs is voor de populatie 
op de kinder-IC, maar dat er voor de meeste sedativa nieuwe farmacokinetische en/of 
farmacodynamische gegevens onderweg zijn. Deze onderzoeken gebruiken vaak geavan-
ceerde populatie-modeltechnieken en laboratoriummethodes.
Hoofdstuk 3 is een algemeen overzicht van pijnonderzoek bij zuigelingen en pasgebo-
renen. We identificeerden meerdere belangrijke uitdagingen die pijnonderzoekers tegen 
kunnen komen als zij een pijnstiller onderzoeken in deze groep patiënten. Deze uitdagingen 
omvatten onder andere de definitie van pijn, de multimodaliteit en verschillende typen 
van pijn, het gebrek aan objectieve en gevalideerde uitkomstmaten, gebrek aan kennis 
over PK en PD, onbekende langetermijneffecten van analgetica en de grote onderlinge 
verschillen binnen deze populatie. Op basis van dit literatuuronderzoek bevelen we aan 
om te focussen op de ontwikkeling van objectieve uitkomstmaten, het gebruik van ‘nieuwe’ 
analgetica in deze patiëntengroep en manieren om langetermijneffecten te bestuderen in 
toekomstig onderzoek.
In deel II gaan we dieper in op speficieke uitdagingen die pijn- en sedatieonderzoekers 
tegen kunnen komen op de kinder-IC. 
214 Chapter 10
Hoofdstuk 4 is een beschrijving van een protocol van een klinische trial, de CloSed trial. 
De CloSed trial is een multicenter, gerandomiseerde, dubbelblinde gecontroleerde non-in-
feriority-trial die clonidine met midazolam vergelijkt voor de sedatie van kunstmatig 
beademende kinderen. Dit project is meerdere problemen tegengekomen die worden 
beschreven, zoals patiëntenwervingsproblemen door uitgebreide exclusiecriteria en ver-
anderingen in de klinische praktijk die aanvankelijk niet zijn voorzien. Daarom bevelen we 
aan om een degelijk proefonderzoek uit te voren vóór het starten van een wetenschappelijk 
onderzoek bij kritisch zieke kinderen.
In hoofdstuk 5 verkennen we een mogelijke nieuwe uitdaging die kan interfereren met 
onderzoek op de kinder-IC: het anticholinerg toxidroom. Het anticholinerg toxidroom 
heeft vergelijkbare symptomen met delirium op de kinderleeftijd (PD) en iatrogeen ont-
rekkingssyndroom (IWS), welke het screenen op en diagnosticeren van deze fenomenen 
bemoeilijkt. Dit toxidroom kan het resultaat zijn van verschillende medicijnen met anticholi-
nerge eigenschappen welke vaak worden gebruikt op de kinder-IC. Dit onderzoek beschrijft 
de anticholinerge-medicatie’last’ van patiënten met PD en/of IWS. We vonden een hogere 
anticholinerge-medicatielast bij patiënten met PD en/of IWS, wat aandacht vraagt voor 
deze last bij patiënten met symptomen van PD en/of IWS.
Deel III slaat een brug van de onderzoekssetting naar de dagelijkse klinische praktijk.
In hoofdstuk 6 rapporteren we het aantal pijnlijke en stressvolle handelingen die kinderen 
op de IC dagelijks moeten ondergaan. Dit onderzoek richt zich op het verkennen van de 
noodzaak tot pijnstiller- en sedativagebruik tijdens procedures door het aantal handelingen 
vast te stellen, maar ook door welke handelingen als meest pijnlijk worden ervaren door 
de zorgverlener. Endotracheaal uitzuigen was verreweg de meest frequent uitgevoerde 
handeling, gevolgd door oraal en nasaal uitzuigen. Procedures waarbij de huid doorbroken 
moet worden zoals lumbaal-, arterie- en venapunctie en infuus prikken werden als meest 
pijnlijk gescoord in een verpleegkundigenenquête.
Hoofstuk 7 geeft de resultaten van een implementatieonderzoek van paracetamol IV voor 
postoperatieve pijnbestrijding bij zuigelingen. In een vorige gerandomiseerde gecontro-
leerde studie (RCT) werd een reductie van 66% in het gebruik van morfine gevonden als 
paracetamol IV als eerstekeus pijnstiller wordt gebruikt. Na implementatie van een nieuw 
postoperatief pijnbestrijdingsprotocol voor zuigelingen op onze kinder-IC, met parace-
tamol IV als eerstekeus pijnstiller, vergeleken we het morfinegebruik van postoperatieve 
zuigelingen in de dagelijkse praktijk met die van de RCT. We vonden een even grote mor-
fineconsumptie als in de RCT en zodoende een succesvolle implementatie van paracetamol 
IV als eerstekeus pijnstiller.
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Hoofdstuk 8 is een reflectie op de resultaten van de uitgevoerde onderzoeken en bespreekt 
een integratieve discussie van de resultaten. We concluderen dat er een gebrek is aan 
solide wetenschappelijk bewijs voor het huidige pijnbestrijdings- en sedatiebeleid op de 
kinder-IC en we hebben enkele grote uitdagingen geïdentificeerd waarmee pijn- en seda-
tieonderzoek kan worden geconfronteerd. We stellen een onderzoeksagenda op voor de 
komende jaren, met name gericht op het ontwikkelen van klinische uitkomstmaten en de 
veiligheid van medicijnen die aan zeer jonge kinderen worden gegeven.
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LIST OF ABBREVIATIONS
ABC  Airway, Breathing, Circulation
ACBS  Anticholinergic Cognitive Burden Score
ADS  Anticholinergic Drug Scale
AE  Adverse Event
aEEG  Amplitude-integrated electroencephalography
AICU  Adult Intensive Care Unit
ANOVA  Analysis of Variance
BBB  Blood-Brain Barrier
BDE  Bodyweight-Dependent Exponent
BIS  Bispectral Index
BPCA  Best Pharmaceutical’s for Children’s Act
BSID-III  Bayley Scales of Infant and Toddler Development-III 
CH  Chloral Hydrate
CNS  Central Nervous System
CRF  Case Record Form
CSF  Cerebrospinal Fluid
CT  Computed Tomography
CVC  Central Venous Catheter
DSI  Daily Sedation Interruption
ECMO  Extracorporeal Membrane Oxygenation
EEG  Electroencephalography
EMA  European Medicines Agency
EMLA  Eutectic Mixture of Local Anesthetics
EU  European Union
FAS  Full Analysis Set
FDA  Food and Drug Administration
FLACC  Face, Legs, Activity, Cry and Consolability scale
GABA  Gamma-Amino Butyric Acid
GCP  Good Clinical Practice
HIE  Hypoxic-Ischemic Encephalopathy
HRV  Heart Rate Variability
IASP  International Association for the Study of Pain
IM  Intramuscular
IMP  Investigational Medicinal Product
IMPD  Investigational Medicinal Product Dossier
IQR  Interquartile Range
ITT  Intention To Treat
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IV  Intravenous
IWS  Iatrogenic Withdrawal Syndrome
LCMS/MS Liquid Chromatography Mass Spectometry/Mass Spectrometry
LOS  Length of Stay
MDZ  Midazolam
MRI  Magnetic Resonance Imaging
MV  Mechanical Ventilation
NEC  Necrotizing Enterocolitis
NICU  Neonatal Intensive Care Unit
NIRS  Near-Infrared Spectroscopy
NISS  Nurses Interpretation of Sedation Score
NMDA  N-methyl-D-aspartate
NONMEM Non-linear Mixed Effects Modeling
NRS  Numerical Rating Scale
OIH  Opioid-Induced Hyperalgesia
OR  Odds Ratio
PBPK  Physiology-Based Pharmacokinetics
PCM  Paracetamol
PD  Pharmacodynamics; OR Pediatric Delirium
PICU  Pediatric Intensive Care Unit
PIM-2  Pediatric Index of Mortality
PIPP  Premature Infant Pain Profile
PK  Pharmacokinetics
PO  Per Os
PRD  Pupillary Reflex Dilation
PRIS  Propofol Infusion Syndrome
PRISM-III  Pediatric Risk of Mortality-III
PUMA  Paediatric Use Marketing Authorisation
RASS  Richmond Agitation-Sedation Scale
RCT   Randomized Controlled Trial
SAA  Serum Anticholinergic Activity
SAE  Serious Adverse Event
SBS  State Behavioral Scale
SC  Subcutaneous
SES  Safety Evaluation Set
SNP  Single Nucleotide Polymorphism
SOS  Sophia Observation withdrawal Symptoms
SOS-PD  Sophia Observation withdrawal Symptoms-Pediatric Delirium
SPC  Summary of Product Characteristics
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SSEP  Somatosensory Evoked Potentials
SUSAR  Suspected Unexpected Serious Adverse Reaction
TCA  Trichloroacetic acid
TCE  Trichloroethanol
UMSS  University of Michigan Sedation Scale 
WAT-1  Withdrawal Assessment Tool 1
WPPSI-III Wechsler Preschool and Primary Scale of Intelligence Third Edition 
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DANKWOORD
Eigenlijk zou de omslag van dit proefschrift moeten zijn volgeschreven met namen van 
mensen die bij hebben gedragen aan dit proefschrift. Vier jaar werk, maar geen vier jaar 
one-man-show: Mijn dank is groot aan allen die mee hebben gewerkt aan de totstandko-
ming van hetgeen voor u ligt!
Allereerst wil ik de patiënten en hun ouders bedanken die direct of indirect hebben bijge-
dragen aan dit proefschrift. De gegevens die door jullie beschikbaar zijn gesteld, maken 
het mogelijk dat we in de toekomst de zorg beter kunnen maken.
Prof.dr. D. Tibboel, beste Dick, allereerst veel dank voor het vertrouwen dat ik heb gekre-
gen met een baan als deze waarin we zouden beginnen aan een groot Europees avontuur. 
Hoewel dit avontuur uiteindelijk niet heeft gebracht wat we hoopten, heeft het mij in ieder 
geval veel geleerd en heb ik ook veel van je kunnen leren als het gaat om politieke ver-
houdingen en strategisch inzicht. Veel dank ook voor alle motivatie die je me hebt kunnen 
geven ondanks alle tegenslagen, het resultaat ligt hier!
Prof.dr. M. van Dijk, beste Monique, jouw wetenschappelijke inzicht en kritische blik hebben 
me elke keer weer laten groeien. Dank voor al jouw briljante ideeën en voorstellen, het 
is meer dan logisch dat je uiteindelijk hoogleraar bent geworden! Naast alle inzichten en 
leerzame sessies ook veel dank voor alle gezelligheid en betrokkenheid!
Prof.dr. M. de Hoog en prof.dr. J.B. van Woensel, veel dank voor het nemen van de moeite 
om dit manuscript te beoordelen.
Prof. dr. T. van Gelder, beste Teun, dank voor het beoordelen van mijn proefschrift én veel 
dank voor het feit dat ik mijn opleiding tot klinisch farmacoloog succesvol en met veel 
plezier heb mogen afronden.
Veel dank aan alle commissieleden die zitting hebben genomen in de grote commissie.
Dr. E. Ista, beste Erwin, we hebben een aantal stukken samen mogen schrijven, dank voor 
alle waardevolle bijdrages en inzichten! 
Prof. dr. K. Allegaert, beste Karel, er bestaat geen paper die je niet hebt gelezen, dank 
voor alle suggesties en ook voor een flinke dosis Vlaamse humor!
Prof. dr. J. van den Anker, beste John, veel dank voor alle suggesties en inspirerende pre-
sentaties aan het begin van mijn promotietraject in Praag.
Prof. dr. S.N. de Wildt, beste Saskia, zeer veel dank voor alle verbeteringen en nauwkeu-
righeid die je me hebt meegegeven.
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Prof. dr. C.A.J. Knibbe, beste Catherijne, dank voor alle inzichten in de wondere wereld 
van PK-PD-modelling. 
Dr. S. Simons, beste Sinno, veel dank voor je relativerende inzichten.
Dr. J. van Rosmalen, beste Joost, dank voor alle goede uitleg over statistiek: van een blinde 
vlek naar een begrijpelijke wereld.
Dr. T. de Leeuw, beste Tom, dank voor je waardevolle bijdrage als anesthesioloog aan dit 
boekje.
I would also like to thank all members of the CloSed consortium who have helped me on my 
way during the CloSed trial. This trial has learned me a lot about performing clinical studies!
Aan alle begeleiding tijdens mijn opleiding tot klinisch farmacoloog: Prof. dr. Ron van 
Schaik, prof. dr. Ron Matthijsen, prof. dr. Patricia v/d Bemt, dr. Birgit Koch, dr. Heleen van 
der Sijs, dr. Lidwien Hanff, dr. Nicole Hunfeld, en alle anderen die mij hebben begeleid. 
Ook mijn farmacologie-maatjes Jorie, Eric, Louise, Linda, Sanne, Annette en Maja, veel dank 
voor de gezelligheid tijdens de leerzame sessies van ‘opa’ Giacoia.
Mijn promotietraject begon fantastisch op Na-1723, en heeft zich vervolgens even fan-
tastisch voortgezet op Sp-2430. Jullie als collega’s hebben mijn promotietraject tot ruim 3 
inspirerende en gezellige jaren gemaakt!
Aukje: accepteren kan je leren; een gevleugelde uitspraak die ik op de kinder-IC nog 
regelmatig gebruik! Bram: stipt 12 uur lunch: een traditie die ik met plezier heb doorgezet! 
Jennifer: van ‘jonge’ flapuit tot bijna doctor! Ries: altijd scherp, zelfs op maandagochtend! 
Janneke en Thijs: wat zat er toch een wijsheid achter in de hoek!
Jonathan, Everlien en Sven: gezelligheid kent geen (studenten)tijd!
En Sp-2430: Miriam, Alexandra, Nienke: ik heb jullie maar kort meegemaakt maar veel 
dank voor alle wegwijs! Kitty: ondanks je harde werken altijd tijd voor een lunch of kopje 
koffie! Dorian: Wanneer maken we Vilnius weer onveilig? Lisette: proost op een mooi assi-
stentenfeestje in de Onderwijsruimte. Marlous: altijd betrokken en bevlogen. Annelieke: zo 
onbeschreven begonnen, zo ervaren het pand straks verlaten! Raisa: een supercarrière is 
begonnen! Willem: altijd wat te klagen maar ook altijd zo gezellig! Tanja: regelt alles tot 
in de puntjes. Evelien: kort maar krachtig! Esther en Renate: no panic for PePANIC: met jullie 
komt die follow-up wel goed! Frank: dank voor de extra en ongenuanceerde mannelijke 
input in het kippenhok. 
En dan zijn me gelukkig een hoop weekenden en geregel in vakanties bespaard gebleven 
dankzij de tomeloze inzet van mijn lieve poulegenoten: Paola, graag nog een paraceta-
mol tegen de hoofdpijn! Özge: jouw zorgvuldigheid verdient een pluim! Gerdien: kritisch 
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en geleerd, maar bovenal gewaardeerd! Nienke: dank voor je betrokkenheid. Shelley: 
variërend van getier en gevloek tot een grote glimlach en een dosis humor: dank je wel!
En zeker ook Joke Dunk niet te vergeten: dank voor al jouw ondersteuning bij CloSed en 
jouw gave om de hele poule-boel in het gareel te houden!
Zo kon ik voor hulp ook altijd terecht bij Annemarie Illsley, Judith Visser, Chantal Strik en 
Marja van Engelen: dank voor alle hulp en geregel! Ko Hagoort: dankzij jou is dit proef-
schrift tot een verhaal geworden, veel dank voor alle tips en tricks! ICK-verpleegkundigen: 
veel dank voor de extra inzet die van jullie werd gevraagd.
Naast het organiseren van mijn eigen promotie heb ik me met veel plezier beziggehouden 
met de Erasmus Tour binnen de onderwijscommissie: veel dank allemaal voor de mooie tijd 
en het succesvolle programma wat we hebben opgezet!
Sharan Jhingoer en Ela Hutten, heel veel dank voor jullie werk tijdens jullie wetenschap-
pelijke stage, er zijn mooie hoofdstukken uit voortgekomen! Het ga jullie goed tijdens jullie 
carrière.
Ook veel dank aan mijn coachingstudenten Tobias, Ibtissam, Babette en Anne voor alle 
leuke coachinggesprekken en betrokkenheid.
Promoveren valt te leren: maar het meeste heb ik nog geleerd van mijn IC-opname, en 
daarom wil ik ook alle zorgverleners, in het bijzonder de IC-verpleegkundigen van het UMC 
Utrecht bedanken voor de goede zorgen rondom mijn IC-opname. Henk en Annet: als vast 
duo hebben jullie in deze onverwachte heftige tijd veel voor mij en mijn vrouw betekend!
Mijn promotie heeft me uiteraard niet alleen binnen de muren van het ziekenhuis bezig 
gehouden, maar ook zeker daarbuiten! Daarom wil ik mijn vrienden en familie ook enorm 
bedanken: alle Springbokkies (Tom, Mirte, Jaap, Sabrine, Kaitlyn, Detmar, Anieke, Maar-
ten, Robin en Roderick) voor alle gezelligheid en inspiratie op onze borrelavonden. Wijn 
is een groot goed!
Ook alle Hemo-gangsters (Arnoud, Anne-Jet, Evelyn, Minette, Michael, Sarah en Stephan): 
onze weekenden weg en spelletjesavonden waren een welkome verademing tussen het 
werken door! 
Bloedverwanten (Minette, Evelyn, Manon, Robbert-Jan, Jeshua, Fred, Stephan en het duo 
Chris/Ad): De race naar de top in Stavanger was een hoogtepunt tijdens mijn promotie en 
heeft me aan het sporten gebracht!
De mensen van de ‘oude’ kring (Arie, Esther, Gert-Jan, Carolien, Laura, Arco en Marion) en 
de mensen van de ‘nieuwe’ kring (Emma, Rick, Jesse, Debbie en Kim): goed om over andere 
dingen dan alleen werk te praten!
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En alle andere lieve ‘losse’ vrienden: Nina en Martijn, Lilian, Josta, Lennart en Patricia, 
Jolanda en Fritz, Céline, Douwe en Iris, Veronica, Jurjen en Joy, Annelous en René, Maarten 
en Judith, Rinske en Sicelo, Hiske en Eelke: Dank voor alle steun, vertrouwen en gezelligheid!
Bianca en Robin: Tijdens mijn promotie zaten jullie aan mijn zijde, en nu als paranimfen 
staan jullie aan mijn zijde! Dank voor de topjaren, beter een goede buur dan een verre 
vriend! Bianca: altijd keten en lachen, maar ook altijd superbetrokken! Dank je wel! Robin: 
naast jouw scherpte en inzicht altijd vol verrassingen: zo was je ineens mijn buurvrouw op 
dag 1 en zo stond ik ineens een tekst voor te lezen op jouw bruiloft. 
Niek, Annemarie, Hilbert en Ingeborg: Dank voor jullie support als schoonfamilie!
Lieve Maria, Jan, Julia en Renate, we hebben altijd een hoop lol gehad en ik ben dankbaar 
voor jullie als mijn broer en zussen! Mami, Andrés en Sara: muchos gracias para tan mucho 
amor, espero mucho que podemos encontrarnos rápido! 
Pa, de nieuwsgierigheid en leergierigheid die ik nodig had voor dit promotietraject heb ik 
grotendeels aan jou te danken! Ma: je staat altijd voor ons klaar en hebt me geleerd dicht 
bij mezelf te blijven. Dank jullie wel!
Lieve Jeshua, jouw komst in mijn leven vervult mijn hele wezen met dankbaarheid. Je bent 
zo’n ongelofelijk prachtig mannetje! Ik ben enorm trots op je en hou onbeschrijflijk veel 
van je. 
Lieve dochter, die nu nog heerlijk bij mama in de buik groeit en bloeit: ik kan niet wachten 
om je in mijn armen te sluiten!
Hannelise, voor ons samen is de tijd van dit promotietraject een ongelofelijke rollercoaster 
geweest: van verhuizen naar trouwen naar een kindje krijgen, maar ook tot je schrik horen 
dat ik op de IC lig na een operatie! Wat hebben we veel meegemaakt en wat hebben we 
veel van elkaar geleerd! Maar alles ten goede en wat ben ik dankbaar met jou als vrouw 
aan mijn zijde! Ik hou oneindig veel van je! 
Manuel
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